Renal cell carcinoma

Nature Reviews Disease Primers
3, 17009
DOI: 10.1038/nrdp.2017.9

Citation Report

#	Article	IF	Citations
1	Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection. Nature Communications, 2017, 8, 15165.	5.8	61
2	The Efficacy of Lenvatinib and Everolimus in Chromophobe-type Nonâ€“Clear-Cell Renal Cell Carcinoma: A Case Report and Literature Review. Clinical Genitourinary Cancer, 2017, 15, e903-e906.	0.9	2
3	Potential abscopal response to dual checkpoint blockade in RCC after reirradiation using dose-painting SBRT. Practical Radiation Oncology, 2017, 7, 396-399.	1.1	13
4	SPP1, analyzed by bioinformatics methods, promotes the metastasis in colorectal cancer by activating EMT pathway. Biomedicine and Pharmacotherapy, 2017, 91, 1167-1177.	2.5	88
5	Potential protective role of Grainyheadâ€like genes in the development of clear cell renal cell carcinoma. Molecular Carcinogenesis, 2017, 56, 2414-2423.	1.3	11
6	Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice. Nature Medicine, 2017, 23, 869-877.	15.2	101
7	The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma. Cell Reports, 2017, 18, 2893-2906.	2.9	153
8	The current status of adjuvant treatment for high-risk renal cell carcinoma. Future Oncology, 2017, 13, 2017-2020.	1.1	0
9	MicroRNA-590-5p regulates cell viability, apoptosis, migration and invasion of renal cell carcinoma cell lines through targeting ARHGAP24. Molecular BioSystems, 2017, 13, 2564-2573.	2.9	16
10	Complexity of the genomic landscape of renal cell carcinoma: Implications for targeted therapy and precision immuno-oncology. Critical Reviews in Oncology/Hematology, 2017, 119, 23-28.	2.0	17
11	Genetic association of polymorphisms in AXIN1 gene with clear cell renal cell carcinoma in a Chinese population. Biomarkers in Medicine, 2017, 11, 947-955.	0.6	6
12	Regulation of spindle and kinetochoreâ€associated protein 1 by antitumor miRâ€10aâ€5p in renal cell carcinoma. Cancer Science, 2017, 108, 2088-2101.	1.7	49
13	Clinical correlates and prognostic value of different metastatic sites in metastatic renal cell carcinoma. Future Oncology, 2017, 13, 1967-1980.	1.1	36
14	Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. OncoImmunology, 2017, 6, e1371896.	2.1	36
15	Metastatic renal cell carcinoma: Patterns and predictors of metastasesâ€”A contemporary population-based series. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 661.e7-661.e14.	0.8	76
16	Pan-urologic cancer genomic subtypes that transcend tissue of origin. Nature Communications, 2017, 8, 199.	5.8	49
17	Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis. European Urology, 2017, 72, 1027-1028.	0.9	2
18	Preservation of truncal genomic alterations in clear cell and papillary renal cell carcinomas with sarcomatoid features: An intraâ€and intertumoral, multifocal fluorescence in situ hybridization analysis reveals limited genetic heterogeneity. Molecular Carcinogenesis, 2017, 56, 2527-2537.	1.3	5

#	Article	IF	Citations
19	Bap1 and Pbrm1: Determinants of Tumor Grade and mTOR Activation in VHL-Deficient Mouse Models of Renal Cell Carcinoma. Cancer Discovery, 2017, 7, 802-804.	7.7	8
20	Upregulation of long noncoding RNA PVT1 predicts unfavorable prognosis in patients with clear cell renal cell carcinoma. Cancer Biomarkers, 2017, 21, 55-63.	0.8	32
21	A novel machine learning approach reveals latent vascular phenotypes predictive of renal cancer outcome. Scientific Reports, 2017, 7, 13190.	1.6	28
22	SWI/SNF tumor suppressor gene PBRM1/BAF180 in human clear cell kidney cancer. Molecular and Cellular Oncology, 2017, 4, e1342747.	0.3	10
23	Targeted therapies for renal cell carcinoma. Nature Reviews Nephrology, 2017, 13, 496-511.	4.1	185
24	MicroRNAâ€'191â€'5p exerts a tumor suppressive role in renal cell carcinoma. Experimental and Therapeutic Medicine, 2017, 15, 1686-1693.	0.8	15
25	Co-expression network analysis identified FCER1G in association with progression and prognosis in human clear cell renal cell carcinoma. International Journal of Biological Sciences, 2017, 13, 1361-1372.	2.6	123
26	Renal Cell Tumors: Understanding Their Molecular Pathological Epidemiology and the 2016 WHO Classification. International Journal of Molecular Sciences, 2017, 18, 2195.	1.8	116
27	Peritoneal Dialysis and Retroperitoneal Laparoscopic Radical Nephrectomy: A Favorable Experience With a Patient Complicated by Renal Cell Carcinoma. Clinical Medicine Insights: Case Reports, 2017, 10, 117954761774636.	0.3	2
28	The Cytokine Flt3-Ligand in Normal and Malignant Hematopoiesis. International Journal of Molecular Sciences, 2017, 18, 1115.	1.8	91
29	Incidental Eosinophilic Chromophobe Renal Cell Carcinoma in Renal Allograft. Case Reports in Transplantation, 2017, 2017, 1-6.	0.1	5
30	Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma. International Journal of Molecular Sciences, 2017, 18, 1736.	1.8	21
31	Molecular Classification of Renal Cell Carcinoma and Its Implication in Future Clinical Practice. Kidney Cancer, 2017, 1, 3-13.	0.2	40
32	Past, Present, and Future: Development of Theranostic Agents Targeting Carbonic Anhydrase IX. Theranostics, 2017, 7, 4322-4339.	4.6	59
33	Expression of minichromosome maintenance genes in renal cell carcinoma. Cancer Management and Research, 2017, Volume 9, 637-647.	0.9	28
34	A brain proteomic investigation of rapamycin effects in the Tsc1 +/â^' mouse model. Molecular Autism, 2017, 8, 41.	2.6	19
35	HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma. OncoTargets and Therapy, 2017, Volume 10, 4635-4643.	1.0	10
36	Overexpression of CKAP4 is Associated with Poor Prognosis in Clear Cell Renal Cell Carcinoma and Functions via Cyclin B Signaling. Journal of Cancer, 2017, 8, 4018-4026.	1.2	11

#	Article	IF	Citations
37	Renal Medullary Carcinoma. Journal of Oncology Practice, 2017, 13, 422-423.	2.5	2
38	Molecular and Metabolic Basis of Clear Cell Carcinoma of the Kidney. Advances in Anatomic Pathology, 2018, 25, 189-196.	2.4	24
39	Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 311.e15-311.e25.	0.8	21
40	Alternative splice variants of DCLK1 mark cancer stem cells, promote selfâ€renewal and drugâ€resistance, and can be targeted to inhibit tumorigenesis in kidney cancer. International Journal of Cancer, 2018, 143, 1162-1175.	2.3	52
41	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports, 2018, 23, 313-326.e5.	2.9	523
42	Generation of autochthonous mouse models of clear cell renal cell carcinoma: mouse models of renal cell carcinoma. Experimental and Molecular Medicine, 2018, 50, 1-10.	3.2	14
43	Capn4 contributes to tumor invasion and metastasis in clear cell renal cell carcinoma cells via modulating talin–focal adhesion kinase signaling pathway. Acta Biochimica Et Biophysica Sinica, 2018, 50, 465-472.	0.9	9
44	Molecular Characterization of Renal Cell Carcinoma: A Potential Three-MicroRNA Prognostic Signature. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 464-472.	1.1	43
45	miRNAs as potential regulators of mTOR pathway in renal cell carcinoma. Pharmacogenomics, 2018, 19, 249-260.	0.6	9
46	Rapid intraâ€operative diagnosis of kidney cancer by attenuated total reflection infrared spectroscopy of tissue smears. Journal of Biophotonics, 2018, 11, e201700260.	1.1	7
47	Identification of a novel lncRNA induced by the nephrotoxin ochratoxin A and expressed in human renal tumor tissue. Cellular and Molecular Life Sciences, 2018, 75, 2241-2256.	2.4	24
48	Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with panâ€omics precision. Journal of Pathology, 2018, 244, 525-537.	2.1	93
49	Sarcomatoid renal cell carcinoma: a case report and literature review. BMC Nephrology, 2018, 19, 84.	0.8	7
50	Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma. Cancer Cell International, 2018, 18, 31.	1.8	63
52	Prognostic significance of the combination of preoperative hemoglobin and albumin levels and lymphocyte and platelet counts (HALP) in patients with renal cell carcinoma after nephrectomy. BMC Urology, 2018, 18, 20.	0.6	54
53	Personalised drug repositioning for Clear Cell Renal Cell Carcinoma using gene expression. Scientific Reports, 2018, 8, 5250.	1.6	14
54	Tumor suppressor microRNAâ€'136â€'5p regulates the cellular function of renal cell carcinoma. Oncology Letters, 2018, 15, 5995-6002.	0.8	28
55	Up-regulation of miR-181a in clear cell renal cell carcinoma is associated with lower KLF6 expression, enhanced cell proliferation, accelerated cell cycle transition, and diminished apoptosis. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 93.e23-93.e37.	0.8	36

#	Article	IF	Citations
56	Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. European Urology Focus, 2018, 4, 986-994.	1.6	29
57	TGF-Î²1 targets a microRNA network that regulates cellular adhesion and migration in renal cancer. Cancer Letters, 2018, 412, 155-169.	3.2	47
58	Are We Ready for Adjuvant Sunitinib in High-risk Renal Cell Carcinoma?. European Urology, 2018, 73, 69-70.	0.9	2
59	Antiangiogenic compounds: well-established drugs versus emerging natural molecules. Cancer Letters, 2018, 415, 86-105.	3.2	21
60	Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting. Clinical Genitourinary Cancer, 2018, 16, e605-e612.	0.9	37
61	Enhanced anticancer effect of fabricated gallic acid/CdS on the rGO nanosheets on human glomerular mesangial (IP15) and epithelial proximal (HK2) kidney cell lines - Cytotoxicity investigations. Journal of Photochemistry and Photobiology B: Biology, 2018, 178, 243-248.	1.7	15
62	microRNAâ€'181aâ€'5p functions as an oncogene in renal cell carcinoma. Molecular Medicine Reports, 2018, 17, 8510-8517.	1.1	5
63	Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. Journal of Clinical Oncology, 2018, 36, 3553-3559.	0.8	49
64	Chromosome 3p Lossâ€"Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology, 2018, 36, 3533-3539.	0.8	99
65	Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma. Journal of Clinical Oncology, 2018, 36, 3615-3623.	0.8	65
66	Early tumor shrinkage as a predictive factor of metastatic renal cell carcinoma in molecular targeted therapy: A single institutional study. Molecular and Clinical Oncology, 2018, 10, 125-131.	0.4	3
67	Histological complete response with nivolumab for renal cell carcinoma with multiple metastases: A case report. Molecular and Clinical Oncology, 2019, 10, 244-248.	0.4	15
68	miRNA-182-5p, via HIF2Î±, contributes to arsenic carcinogenesis: evidence from human renal epithelial cells. Metallomics, 2018, 10, 1607-1617.	1.0	18
69	The landscape of miRNA-related ceRNA networks for marking different renal cell carcinoma subtypes. Briefings in Bioinformatics, 2018, , .	3.2	5
70	CIP2A Promotes Proliferation, Invasion and Chemoresistance to Cisplatin in Renal Cell Carcinoma. Journal of Cancer, 2018, 9, 4029-4038.	1.2	23
71	MiR-337-3p suppresses the proliferation and metastasis of clear cell renal cell carcinoma cells via modulating Capn4. Cancer Biomarkers, 2018, 23, 515-525.	0.8	20
72	Renal cell carcinoma presenting as nonspecific gastrointestinal symptoms: a case report. International Medical Case Reports Journal, 2018, Volume 11, 345-348.	0.3	2
73	Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma. BMC Pharmacology & Toxicology, 2018, 19, 77.	1.0	19

#	Article	IF	Citations
74	The Impact of Tumor Eco-Evolution in Renal Cell Carcinoma Sampling. Cancers, 2018, 10, 485.	1.7	9
75	Bexarotene â€“ a novel modulator of AURKA and the primary cilium in VHL-deficient cells. Journal of Cell Science, 2018, 131, .	1.2	5
76	Renal Cell Carcinoma Is Abrogated by p53 Stabilization through Transglutaminase 2 Inhibition. Cancers, 2018, 10, 455.	1.7	19
77	Metabolic Footprinting of a Clear Cell Renal Cell Carcinoma in Vitro Model for Human Kidney Cancer Detection. Journal of Proteome Research, 2018, 17, 3877-3888.	1.8	19
78	Renal cell carcinoma: a review of biology and pathophysiology. F1000Research, 2018, 7, 307.	0.8	105
79	A minority-group of renal cell cancer patients with high infiltration of CD20+B-cells is associated with poor prognosis. British Journal of Cancer, 2018, 119, 840-846.	2.9	42
80	Expression and significance of Cystatin-C in clear cell renal cell carcinoma. Biomedicine and Pharmacotherapy, 2018, 107, 1237-1245.	2.5	14
81	Circulating Tumor Cells for the Management of Renal Cell Carcinoma. Diagnostics, 2018, 8, 63.	1.3	9
82	Global and Targeted miRNA Expression Profiling in Clear Cell Renal Cell Carcinoma Tissues Potentially Links miR-155-5p and miR-210-3p to both Tumorigenesis and Recurrence. American Journal of Pathology, 2018, 188, 2487-2496.	1.9	34
83	Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages. Biomaterials, 2018, 183, 280-294.	5.7	57
84	The Role of DNA Methylation in Renal Cell Carcinoma. Molecular Diagnosis and Therapy, 2018, 22, 431-442.	1.6	46
85	Identification of potential pathogenic biomarkers in clear cell renal cell carcinoma. Oncology Letters, 2018, 15, 8491-8499.	0.8	8
86	RASSF6-mediated inhibition of Mcl-1 through JNK activation improves the anti-tumor effects of sorafenib in renal cell carcinoma. Cancer Letters, 2018, 432, 75-83.	3.2	12
87	Phospholipase D2 promotes disease progression of renal cell carcinoma through the induction of angiogenin. Cancer Science, 2018, 109, 1865-1875.	1.7	20
88	Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma. European Urology Oncology, 2018, 1, 364-377.	2.6	21
89	Cabozantinib-induced serum creatine kinase elevation and musculoskeletal complaints. Investigational New Drugs, 2018, 36, 1143-1146.	1.2	4
90	Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study. European Journal of Cancer, 2018, 100, 1-7.	1.3	31
91	A Rare Case of Metastasis to the Thyroid Gland from Renal Clear Cell Carcinoma 11 Years after Nephrectomy and Concurrent Primary Esophageal Carcinoma. Case Reports in Oncological Medicine, 2018, 2018, 1-4.	0.2	4

#	Article	IF	Citations
92	Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial. Clinical Cancer Research, 2018, 24, 5534-5542.	3.2	15
93	HILIC/ESI-MS determination of gangliosides and other polar lipid classes in renal cell carcinoma and surrounding normal tissues. Analytical and Bioanalytical Chemistry, 2018, 410, 6585-6594.	1.9	31
94	UCA1 promotes cell proliferation and invasion and inhibits apoptosis through regulation of the miR129–SOX4 pathway in renal cell carcinoma. OncoTargets and Therapy, 2018, Volume 11, 2475-2487.	1.0	24
95	Anesthesia for Nephrectomy with Vena Cava Thrombectomy. , 2018, , 635-644.		0
96	miRâ€'199bâ€'5p serves as a tumor suppressor in renal cell carcinoma. Experimental and Therapeutic Medicine, 2018, 16, 436-444.	0.8	15
97	Hypoxia-Inducible Factor 2-Dependent Pathways Driving Von Hippelâ€"Lindau-Deficient Renal Cancer. Frontiers in Oncology, 2018, 8, 214.	1.3	46
98	Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma. BMC Medicine, 2018, 16, 108.	2.3	11
99	VHL and Hypoxia Signaling: Beyond HIF in Cancer. Biomedicines, 2018, 6, 35.	1.4	80
100	Targeting mitochondria by anthelmintic drug atovaquone sensitizes renal cell carcinoma to chemotherapy and immunotherapy. Journal of Biochemical and Molecular Toxicology, 2018, 32, e22195.	1.4	22
101	VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science, 2018, 361, 290-295.	6.0	134
102	The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Nonâ€"Clear Cell Renal Cell Carcinoma. Cancer Immunology Research, 2018, 6, 758-765.	1.6	89
103	Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation InÂVivo. Cell Metabolism, 2018, 28, 793-800.e2.	7.2	193
104	Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma. European Urology, 2018, 74, 756-763.	0.9	144
105	CLEC3B is downregulated and inhibits proliferation in clear cell renal cell carcinoma. Oncology Reports, 2018, 40, 2023-2035.	1.2	23
106	A Multicenter Phase II Trial of Axitinib in Patients With Recurrent or Metastatic Nonâ€"clear-cell Renal Cell Carcinoma Who Had Failed Prior Treatment With Temsirolimus. Clinical Genitourinary Cancer, 2018, 16, e997-e1002.	0.9	25
107	Tracing Renal Cell Carcinomas back to the Nephron. Trends in Cancer, 2018, 4, 472-484.	3.8	17
109	Challenges and opportunities in the proteomic characterization of clear cell renal cell carcinoma (ccRCC): A critical step towards the personalized care of renal cancers. Seminars in Cancer Biology, 2019, 55, 8-15.	4.3	55
111	PAX8 activates metabolic genes via enhancer elements in Renal Cell Carcinoma. Nature Communications, 2019, 10, 3739.	5.8	49

#	Article	IF	Citations
112	BAP1 in solid tumors. Future Oncology, 2019, 15, 2151-2162.	1.1	20
113	Toward a genome-based treatment landscape for renal cell carcinoma. Critical Reviews in Oncology/Hematology, 2019, 142, 141-152.	2.0	15
114	TFEB Mediates Immune Evasion and Resistance to mTOR Inhibition of Renal Cell Carcinoma via Induction of PD-L1. Clinical Cancer Research, 2019, 25, 6827-6838.	3.2	47
115	NR1B2 suppress kidney renal clear cell carcinoma (KIRC) progression by regulation of LATS 1/2-YAP signaling. Journal of Experimental and Clinical Cancer Research, 2019, 38, 343.	3.5	37
116	VHLSynthetic Lethality Signatures Uncovered by Genotype-Specific CRISPR-Cas9 Screens. CRISPR Journal, 2019, 2, 230-245.	1.4	8
117	Everolimus resistance in clear cell renal cell carcinoma: miRNA-101 and HIF-2Î± as molecular triggers?. Future Oncology, 2019, 15, 2361-2370.	1.1	11
118	UBE2T promotes proliferation and regulates PI3K/Akt signaling in renal cell carcinoma. Molecular Medicine Reports, 2019, 20, 1212-1220.	1.1	28
119	Long noncoding RNA LINC-PINT promotes proliferation through EZH2 and predicts poor prognosis in clear cell renal cell carcinoma . OncoTargets and Therapy, 2019, Volume 12, 4729-4740.	1.0	19
120	MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma. Oncogene, 2019, 38, 6211-6225.	2.6	78
121	Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma?. Clinical and Translational Radiation Oncology, 2019, 18, 104-112.	0.9	30
122	Renal Cell Carcinoma in the Canadian Indigenous Population. Current Oncology, 2019, 26, 367-371.	0.9	3
123	Tr-KIT/c-KIT ratio in renal cell carcinoma. Molecular Biology Reports, 2019, 46, 5287-5294.	1.0	8
124	DNA methylation-based classification and identification of renal cell carcinoma prognosis-subgroups. Cancer Cell International, 2019, 19, 185.	1.8	39
125	Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series. Clinical Genitourinary Cancer, 2019, 17, 373-379.e4.	0.9	33
126	miR-130b Promotes Sunitinib Resistance through Regulation of PTEN in Renal Cell Carcinoma. Oncology, 2019, 97, 164-172.	0.9	23
127	Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clearâ€'cell renal cell carcinoma treated with sunitinib as firstâ€'line treatment. International Journal of Oncology, 2019, 55, 371-390.	1.4	24
128	The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications. Nature Reviews Urology, 2019, 16, 539-552.	1.9	357
129	Circ-AKT3 inhibits clear cell renal cell carcinoma metastasis via altering miR-296-3p/E-cadherin signals. Molecular Cancer, 2019, 18, 151.	7.9	122

#	Article	IF	Citations
130	Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell, 2019, 179, 964-983.e31.	13.5	430
131	Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study. Cancer Communications, 2019, 39, 1-4.	3.7	14
132	Identification of Prognostic and Metastatic Alternative Splicing Signatures in Kidney Renal Clear Cell Carcinoma. Frontiers in Bioengineering and Biotechnology, 2019, 7, 270.	2.0	55
133	Three novel hub genes and their clinical significance in clear cell renal cell carcinoma. Journal of Cancer, 2019, 10, 6779-6791.	1.2	21
134	Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. Immunotherapy, 2019, 11, 1507-1521.	1.0	17
135	Overexpression of P4HB is correlated with poor prognosis in human clear cell renal cell carcinoma. Cancer Biomarkers, 2019, 26, 431-439.	0.8	22
136	Vascular endothelial growth factor and programmed deathâ€1 pathway inhibitors in renal cell carcinoma. Cancer, 2019, 125, 4148-4157.	2.0	21
137	Mitochondrial E3 ubiquitin ligase 1 promotes autophagy flux to suppress the development of clear cell renal cell carcinomas. Cancer Science, 2019, 110, 3533-3542.	1.7	17
138	A Hypoxia-Inducible HIF1â€“GAL3ST1-Sulfatide Axis Enhances ccRCC Immune Evasion via Increased Tumor Cellâ€“Platelet Binding. Molecular Cancer Research, 2019, 17, 2306-2314.	1.5	19
139	A Renal Cell Carcinoma with Biallelic Somatic TSC2 Mutation: Clinical Study and Literature Review. Urology, 2019, 133, 96-102.	0.5	5
140	SETD2 loss sensitizes cells to PI3KÎ² and AKT inhibition. Oncotarget, 2019, 10, 647-659.	0.8	7
141	Diagnosis of uncommon renal epithelial neoplasms: performances of fluorescence in situ hybridization. Human Pathology, 2019, 92, 81-90.	1.1	6
142	Relationship of B7-H3 expression in tumor cells and tumor vasculature with FOXP3+ regulatory T cells in renal cell carcinoma . Cancer Management and Research, 2019, Volume 11, 7021-7030.	0.9	26
143	Vimentin Overexpressions Induced by Cell Hypoxia Promote Vasculogenic Mimicry by Renal Cell Carcinoma Cells. BioMed Research International, 2019, 2019, 1-12.	0.9	7
144	Cell death-related molecules and biomarkers for renal cell carcinoma targeted therapy. Cancer Cell International, 2019, 19, 221.	1.8	25
145	The Hippo Pathway Effector TAZ Regulates Ferroptosis in Renal Cell Carcinoma. Cell Reports, 2019, 28, 2501-2508.e4.	2.9	290
146	The interaction of YBX1 with G3BP1 promotes renal cell carcinoma cell metastasis via YBX1/G3BP1-SPP1-NF-ÎºB signaling axis. Journal of Experimental and Clinical Cancer Research, 2019, 38, 386.	3.5	51
147	The Prognostic Significance of Protein Expression of CASZ1 in Clear Cell Renal Cell Carcinoma. Disease Markers, 2019, 2019, 1-6.	0.6	7

#	Article	IF	Citations
148	Towards an Interpretable Radiomics Model for Classifying Renal Cell Carcinomas Subtypes: A Radiogenomics Assessment. , 2019, , .		1
149	Inhibition of AKT enhances the anti-cancer effects of Artemisinin in clear cell renal cell carcinoma. Biomedicine and Pharmacotherapy, 2019, 118, 109383.	2.5	21
150	Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience. Advances in Chronic Kidney Disease, 2019, 26, 253-266.	0.6	135
151	Connecting Histopathology Imaging and Proteomics in Kidney Cancer through Machine Learning. Journal of Clinical Medicine, 2019, 8, 1535.	1.0	27
152	SPTLC1 inhibits cell growth via modulating Akt/FOXO1 pathway in renal cell carcinoma cells. Biochemical and Biophysical Research Communications, 2019, 520, 1-7.	1.0	2
153	Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and) Tj ETQq1 1 0.784314 rgBT /Overlo 4712.	1.8	48
154	LINC00461 affects the survival of patients with renal cell carcinoma by acting as a competing endogenous RNA for microRNAâ€‘942. Oncology Reports, 2019, 42, 1924-1934.	1.2	19
155	Allosteric inhibition of HIF-2Î± as a novel therapy for clear cell renal cell carcinoma. Drug Discovery Today, 2019, 24, 2332-2340.	3.2	39
156	Targeting angiogenesis in metastatic renal cell carcinoma. Expert Review of Anticancer Therapy, 2019, 19, 245-257.	1.1	12
157	Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma. Clinical Genitourinary Cancer, 2019, 17, e454-e460.	0.9	14
158	miR-22 Regulates Invasion, Gene Expression and Predicts Overall Survival in Patients with Clear Cell Renal Cell Carcinoma. Kidney Cancer, 2019, 3, 119-132.	0.2	9
159	CT texture analysis in the differentiation of major renal cell carcinoma subtypes and correlation with Fuhrman grade. European Radiology, 2019, 29, 6922-6929.	2.3	58
160	Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. Cancers, 2019, 11, 830.	1.7	29
161	Unusual metastasis of papillary renal cell carcinoma to the pyriform sinus: Case report. Clinical Case Reports (discontinued), 2019, 7, 1222-1225.	0.2	3
162	Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors. Clinical Genitourinary Cancer, 2019, 17, e981-e994.	0.9	34
163	Personalized approach to systemic therapy of renal cancer. Expert Review of Precision Medicine and Drug Development, 2019, 4, 179-188.	0.4	0
164	HAO2 inhibits malignancy of clear cell renal cell carcinoma by promoting lipid catabolic process. Journal of Cellular Physiology, 2019, 234, 23005-23016.	2.0	36
165	DNA methylation of CRB3 is a prognostic biomarker in clear cell renal cell carcinoma. Molecular Biology Reports, 2019, 46, 4377-4383.	1.0	6

#	Article	IF	Citations
166	Nobiletin Inhibits Cell Viability via the SRC/AKT/STAT3/YY1AP1 Pathway in Human Renal Carcinoma Cells. Frontiers in Pharmacology, 2019, 10, 690.	1.6	32
167	Reduction in H3K4me patterns due to aberrant expression of methyltransferases and demethylases in renal cell carcinoma: prognostic and therapeutic implications. Scientific Reports, 2019, 9, 8189.	1.6	21
168	Long non-coding RNAs in genitourinary malignancies: a whole new world. Nature Reviews Urology, 2019, 16, 484-504.	1.9	80
169	Early Changes in CT Perfusion Parameters: Primary Renal Carcinoma Versus Metastases After Treatment with Targeted Therapy. Cancers, 2019, 11, 608.	1.7	5
170	Associations of high expression of miR-106b-5p detected from FFPE sample with poor prognosis of RCC patients. Pathology Research and Practice, 2019, 215, 152391.	1.0	6
171	PPARG Negatively Modulates Six2 in Tumor Formation of Clear Cell Renal Cell Carcinoma. DNA and Cell Biology, 2019, 38, 700-707.	0.9	13
172	Targeting Tyrosine kinases in Renal Cell Carcinoma: â€œNew Bullets against Old Guysâ€• International Journal of Molecular Sciences, 2019, 20, 1901.	1.8	41
173	miR-19 promotes the proliferation of clear cell renal cell carcinoma by targeting the FRK–PTEN axis . OncoTargets and Therapy, 2019, Volume 12, 2713-2727.	1.0	16
174	Brain Complete Response to Cabozantinib prior to Radiation Therapy in Metastatic Renal Cell Carcinoma. Case Reports in Urology, 2019, 2019, 1-4.	0.1	17
175	Chemoimmunotherapy in Advanced Renal Cell Carcinoma: A Case Report of a Long-Term Survivor Adjunctly Treated with Viscum album Extracts. Complementary Medicine Research, 2019, 26, 276-279.	0.5	3
176	In silico repurposing the Rac1 inhibitor NSC23766 for treating PTTG1-high expressing clear cell renal carcinoma. Pathology Research and Practice, 2019, 215, 152373.	1.0	4
177	Identification of key genes involved in the metastasis of clear cell renal cell carcinoma. Oncology Letters, 2019, 17, 4321-4328.	0.8	56
178	Overexpression of FZD1 is Associated with a Good Prognosis and Resistance of Sunitinib in Clear Cell Renal Cell Carcinoma. Journal of Cancer, 2019, 10, 1237-1251.	1.2	20
179	Comprehensive Analysis of Driver Genes in Personal Genomes of Clear Cell Renal Cell Carcinoma. Technology in Cancer Research and Treatment, 2019, 18, 153303381983096.	0.8	3
180	Linking Binary Gene Relationships to Drivers of Renal Cell Carcinoma Reveals Convergent Function in Alternate Tumor Progression Paths. Scientific Reports, 2019, 9, 2899.	1.6	13
181	Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. Journal of Hematology and Oncology, 2019, 12, 27.	6.9	211
182	Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5. Theranostics, 2019, 9, 1181-1199.	4.6	20
183	IL-6-producing Renal Cell Carcinoma Causing Renal and Endocrine Paraneoplastic Syndromes. Internal Medicine, 2019, 58, 1953-1960.	0.3	3

#	Article	IF	Citations
184	Metformin Induces Different Responses in Clear Cell Renal Cell Carcinoma Caki Cell Lines. Biomolecules, 2019, 9, 113.	1.8	12
185	The impact of estimated tumour purity on gene expression-based drug repositioning of Clear Cell Renal Cell Carcinoma samples. Scientific Reports, 2019, 9, 2495.	1.6	7
186	KIF20B promotes the progression of clear cell renal cell carcinoma by stimulating cell proliferation. Journal of Cellular Physiology, 2019, 234, 16517-16525.	2.0	15
187	Myocardial Dysfunction Associated with Cancer Therapy. Cardiovascular Medicine, 2019, , 71-79.	0.0	0
188	Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension. Cardiovascular Research, 2019, 115, 904-914.	1.8	63
189	Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy. Cancers, 2019, 11, 196.	1.7	23
190	Overexpression of COL5A1 promotes tumor progression and metastasis and correlates with poor survival of patients with clear cell renal cell carcinoma . Cancer Management and Research, 2019, Volume 11, 1263-1274.	0.9	36
191	Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2019, 30, 706-720.	0.6	750
192	Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus. Cancer Immunology, Immunotherapy, 2019, 68, 787-798.	2.0	2
193	Long intergenic non-coding RNA, regulator of reprogramming (LINC-ROR) over-expression predicts poor prognosis in renal cell carcinoma. Archives of Medical Science, 2019, 17, 1016-1027.	0.4	5
194	A Novel Preoperative Nomogram for Predicting Lymph Node Invasion in Renal Cell Carcinoma Patients Without Metastasis . Cancer Management and Research, 2019, Volume 11, 9961-9967.	0.9	7
195	An Effective Radiomics Model for Noninvasive Discrimination of Fat-poor Angiomyolipoma from Clear Cell Renal Cell Carcinoma. , 2019, , .		2
196	The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma. Oncologist, 2019, 24, 338-348.	1.9	34
197	MiR-935 Promotes Clear Cell Renal Cell Carcinoma Migration and Invasion by Targeting IREB2 . Cancer Management and Research, 2019, Volume 11, 10891-10900.	0.9	12
198	Exceptional Response of Metastatic Chromophobe Renal Cell Carcinoma to Vascular Endothelial Growth Factor (VEGF) Inhibitors: Should Increased VEGF-C Expression Be Used to Guide Treatment?. Case Reports in Urology, 2019, 2019, 1-6.	0.1	0
199	Polycythemia with Renal Cell Carcinoma and Normal Erythropoietin Level. Case Reports in Urology, 2019, 2019, 1-5.	0.1	2
200	A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with metastatic and unresectable renal cell carcinoma. BMJ Open, 2019, 9, e030522.	0.8	2
201	Mouse- and patient-derived CAM xenografts for studying metastatic renal cell carcinoma. The Enzymes, 2019, 46, 59-80.	0.7	4

#	Article	IF	Citations
202	Integrating multi-platform genomic datasets for kidney renal clear cell carcinoma subtyping using stacked denoising autoencoders. Scientific Reports, 2019, 9, 16668.	1.6	7
203	Cadmium and Lead Decrease Cellâ€“Cell Aggregation and Increase Migration and Invasion in Renca Mouse Renal Cell Carcinoma Cells. International Journal of Molecular Sciences, 2019, 20, 6315.	1.8	8
204	LncRNA-LET inhibits cell growth of clear cell renal cell carcinoma by regulating miR-373-3p. Cancer Cell International, 2019, 19, 311.	1.8	19
205	MTA2 as a Potential Biomarker and Its Involvement in Metastatic Progression of Human Renal Cancer by miR-133b Targeting MMP-9. Cancers, 2019, 11, 1851.	1.7	16
206	Treatment selection for firstâ€line metastatic renal cell carcinoma in Australia: Impact of new therapy options. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 3-10.	0.7	3
207	Dysregulation of Ketone Body Metabolism Is Associated With Poor Prognosis for Clear Cell Renal Cell Carcinoma Patients. Frontiers in Oncology, 2019, 9, 1422.	1.3	16
208	GSTO1*CC Genotype (rs4925) Predicts Shorter Survival in Clear Cell Renal Cell Carcinoma Male Patients. Cancers, 2019, 11, 2038.	1.7	9
209	MCP-1/MCPIP-1 Signaling Modulates the Effects of IL-1Î² in Renal Cell Carcinoma through ER Stress-Mediated Apoptosis. International Journal of Molecular Sciences, 2019, 20, 6101.	1.8	16
210	Characterization of the role of TMEM45A in cancer cell sensitivity to cisplatin. Cell Death and Disease, 2019, 10, 919.	2.7	11
211	Decreased capillary density in renal cell carcinoma. Medicine (United States), 2019, 98, e16910.	0.4	1
212	Primary Extrarenal Renal Cell Carcinoma: A Unique Diagnosis Performed through Endoscopic Ultrasound. GE Portuguese Journal of Gastroenterology, 2019, 26, 378-380.	0.3	3
213	Validation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series. PLoS ONE, 2019, 14, e0226285.	1.1	12
214	Preparation of AS1411 Aptamer Modified Mn-MoS₂ QDs for Targeted MR Imaging and Fluorescence Labelling of Renal Cell Carcinoma . International Journal of Nanomedicine, 2019, Volume 14, 9513-9524.	3.3	34
215	Honokiol Enhances TRAIL-Mediated Apoptosis through STAMBPL1-Induced Survivin and c-FLIP Degradation. Biomolecules, 2019, 9, 838.	1.8	23
216	Efficacy of sorafenib adjuvant therapy in northwestern Chinese patients with non-metastatic renal-cell carcinoma after nephrectomy. Medicine (United States), 2019, 98, e14237.	0.4	4
218	Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial. Oncologist, 2019, 24, e702-e708.	1.9	70
219	Nobiletin inhibits hypoxiaâ€induced epithelialâ€mesenchymal transition in renal cell carcinoma cells. Journal of Cellular Biochemistry, 2019, 120, 2039-2046.	1.2	15
220	Induction of apoptosis by magnolol via the mitochondrial pathway and cell cycle arrest in renal carcinoma cells. Biochemical and Biophysical Research Communications, 2019, 508, 1271-1278.	1.0	22

#	Article	IF	Citations
221	Emerging oral VEGF inhibitors for the treatment of renal cell carcinoma. Expert Opinion on Investigational Drugs, 2019, 28, 121-130.	1.9	21
222	Gankyrin is a novel biomarker for disease progression and prognosis of patients with renal cell carcinoma. EBioMedicine, 2019, 39, 255-264.	2.7	14
224	Cutaneous Metastasis. Hematology/Oncology Clinics of North America, 2019, 33, 173-197.	0.9	32
225	Prognostic value of a gene signature in clear cell renal cell carcinoma. Journal of Cellular Physiology, 2019, 234, 10324-10335.	2.0	34
226	Hyperpolarized MRI Visualizes Warburg Effects and Predicts Treatment Response to mTOR Inhibitors in Patient-Derived ccRCC Xenograft Models. Cancer Research, 2019, 79, 242-250.	0.4	27
228	A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma. Current Urology Reports, 2019, 20, 1.	1.0	63
229	Predictors of disease aggressiveness influence outcome from immunotherapy treatment in renal clear cell carcinoma. OncoImmunology, 2019, 8, e1500106.	2.1	18
230	Metastatic Lesion From Clear-cell Renal Carcinoma After 40 Years and a Review of the Literature. Clinical Genitourinary Cancer, 2019, 17, e372-e376.	0.9	2
231	Differentiation of clear cell and non-clear cell renal cell carcinomas by all-relevant radiomics features from multiphase CT: a VHL mutation perspective. European Radiology, 2019, 29, 3996-4007.	2.3	78
232	Age-related variations in gene expression patterns of renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 166-175.	0.8	8
233	Preoperative apolipoprotein B/A1 ratio is an independent prognostic factor in metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 184.e9-184.e17.	0.8	13
234	Targeting the RhoGTPase/ROCK pathway for the treatment of VHL/HIF pathway-driven cancers. Small GTPases, 2020, 11, 32-38.	0.7	1
235	Mutations in renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 763-773.	0.8	58
236	Overexpression of BMP1 reflects poor prognosis in clear cell renal cell carcinoma. Cancer Gene Therapy, 2020, 27, 330-340.	2.2	37
237	The role of cancer-associated fibroblasts in renal cell carcinoma. An example of tumor modulation through tumor/non-tumor cell interactions. Journal of Advanced Research, 2020, 21, 103-108.	4.4	40
238	Targeting lysosome function causes selective cytotoxicity in VHL-inactivated renal cell carcinomas. Carcinogenesis, 2020, 41, 828-840.	1.3	7
239	Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy. Oncogene, 2020, 39, 1231-1245.	2.6	31
240	miR-26 suppresses renal cell cancer via down-regulating coronin-3. Molecular and Cellular Biochemistry, 2020, 463, 137-146.	1.4	12

#	Article	IF	Citations
241	Improving diagnosis of genitourinary cancers: Biomarker discovery strategies through mass spectrometry-based metabolomics. Journal of Pharmaceutical and Biomedical Analysis, 2020, 178, 112905.	1.4	13
242	Silencing of tumorâ€suppressive NR_023387 in renal cell carcinoma via promoter hypermethylation and HNF4A deficiency. Journal of Cellular Physiology, 2020, 235, 2113-2128.	2.0	12
243	Papillary vs clear cell renal cell carcinoma. Differentiation and grading by iodine concentration using DECTâ€"correlation with microvascular density. European Radiology, 2020, 30, 1-10.	2.3	57
244	Neoplasms of the Kidney. , 2020, , 83-163.e23.		2
245	Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies. Expert Review of Molecular Diagnostics, 2020, 20, 141-150.	1.5	14
246	Expression of PBRM1 as a prognostic predictor in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitor. International Journal of Clinical Oncology, 2020, 25, 338-346.	1.0	3
247	GATA3 suppresses human fibroblasts-induced metastasis of clear cell renal cell carcinoma via an anti-IL6/STAT3 mechanism. Cancer Gene Therapy, 2020, 27, 726-738.	2.2	6
248	MicroRNAâ€96 is a potential tumor repressor by inhibiting NPTX2 in renal cell carcinoma. Journal of Cellular Biochemistry, 2020, 121, 1504-1513.	1.2	8
249	Usefulness of CT texture analysis in differentiating benign and malignant renal tumours. Clinical Radiology, 2020, 75, 108-115.	0.5	31
250	Glutathione transferase genotypes may serve as determinants of risk and prognosis in renal cell carcinoma. BioFactors, 2020, 46, 229-238.	2.6	5
251	A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects. Cancer Chemotherapy and Pharmacology, 2020, 85, 555-562.	1.1	12
252	SH3BGRL2 inhibits growth and metastasis in clear cell renal cell carcinoma via activating hippo/TEAD1-Twist1 pathway. EBioMedicine, 2020, 51, 102596.	2.7	49
253	A1CF-promoted colony formation and proliferation of RCC depends on DKK1-MEK/ERK signal axis. Gene, 2020, 730, 144299.	1.0	8
254	MiR-765 functions as a tumour suppressor and eliminates lipids in clear cell renal cell carcinoma by downregulating PLP2. EBioMedicine, 2020, 51, 102622.	2.7	59
255	Renal cell cancer. , 2020, , 229-243.e4.		0
256	Emerging role of secreted miR-210-3p as potential biomarker for clear cell Renal Cell Carcinoma metastasis. Cancer Biomarkers, 2020, 27, 181-188.	0.8	24
257	Identification of Therapeutic Targets and Prognostic Biomarkers Among CXC Chemokines in the Renal Cell Carcinoma Microenvironment. Frontiers in Oncology, 2019, 9, 1555.	1.3	72
258	Hypertonicity-Affected Genes Are Differentially Expressed in Clear Cell Renal Cell Carcinoma and Correlate with Cancer-Specific Survival. Cancers, 2020, 12, 6.	1.7	13

#	Article	IF	Citations
259	Highâ€dimensional singleâ€cell proteomics analysis reveals the landscape of immune cells and stemâ€like cells in renal tumors. Journal of Clinical Laboratory Analysis, 2020, 34, e23155.	0.9	13
260	Defining the human kidney Nâ€glycome in normal and cancer tissues using MALDI imaging mass spectrometry. Journal of Mass Spectrometry, 2020, 55, e4490.	0.7	40
261	Characterization of the expression and immunological impact of the transcriptional activator CREB in renal cell carcinoma. Journal of Translational Medicine, 2020, 18, 371.	1.8	7
262	Identification of Immune-Related Cells and Genes in Tumor Microenvironment of Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2020, 10, 1770.	1.3	7
263	Comparison of T2N0M0 and T3aN0M0 in Predicting the Prognosis of Patients With Renal Cell Carcinoma. Frontiers in Oncology, 2020, 10, 564631.	1.3	1
264	Identification of RNA Transcript Makers Associated With Prognosis of Kidney Renal Clear Cell Carcinoma by a Competing Endogenous RNA Network Analysis. Frontiers in Genetics, 2020, 11, 540094.	1.1	18
265	Long Non-coding RNA CCAT1 Acts as an Oncogene and Promotes Sunitinib Resistance in Renal Cell Carcinoma. Frontiers in Oncology, 2020, 10, 516552.	1.3	10
266	CircAKT1 acts as a sponge of miR-338â€“3p to facilitate clear cell renal cell carcinoma progression by up-regulating CAV1. Biochemical and Biophysical Research Communications, 2020, 532, 584-590.	1.0	14
267	Prognostic Value and Potential Biological Functions of CLDN8 in Patients with Clear Cell Renal Cell Carcinoma . OncoTargets and Therapy, 2020, Volume 13, 9135-9145.	1.0	8
268	Expression Profile Analysis of m6A RNA Methylation Regulators Indicates They Are Immune Signature Associated and Can Predict Survival in Kidney Renal Cell Carcinoma. DNA and Cell Biology, 2020, 39, 2194-2211.	0.9	23
269	Tivozanib, a highly potent and selective inhibitor of VEGF receptor tyrosine kinases, for the treatment of metastatic renal cell carcinoma. Future Oncology, 2020, 16, 2147-2164.	1.1	10
270	Identification of a Novel Signature and Construction of a Nomogram Predicting Overall Survival in Clear Cell Renal Cell Carcinoma. Frontiers in Genetics, 2020, 11, 1017.	1.1	6
271	Development of a DNA Methylationâ€“Based Diagnostic Signature to Distinguish Benign Oncocytoma From Renal Cell Carcinoma. JCO Precision Oncology, 2020, 4, 1141-1151.	1.5	10
272	NF-Î°B and pSTAT3 synergistically drive G6PD overexpression and facilitate sensitivity to G6PD inhibition in ccRCC. Cancer Cell International, 2020, 20, 483.	1.8	8
273	Biological functions and prognostic value of RNA Binding Proteins in clear cell Renal Cell Carcinoma. Journal of Cancer, 2020, 11, 6591-6600.	1.2	9
274	Targeting Metabolic Pathways in Kidney Cancer. Cancer Journal (Sudbury, Mass), 2020, 26, 407-418.	1.0	6
275	Preclinical evidence that MNK/eIF4E inhibition by cercosporamide enhances the response to antiangiogenic TKI and mTOR inhibitor in renal cell carcinoma. Biochemical and Biophysical Research Communications, 2020, 530, 142-148.	1.0	9
276	The Gender Issue. Clinical Genitourinary Cancer, 2020, 18, 77.	0.9	0

#	Article	IF	Citations
277	Development and validation of an integrative methylation signature and nomogram for predicting survival in clear cell renal cell carcinoma. Translational Andrology and Urology, 2020, 9, 1082-1098.	0.6	8
278	Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma. PLoS ONE, 2020, 15, e0236119.	1.1	20
279	A Three-Metabolic-Genes Risk Score Model Predicts Overall Survival in Clear Cell Renal Cell Carcinoma Patients. Frontiers in Oncology, 2020, 10, 570281.	1.3	10
280	ID1 As a Prognostic Biomarker and Promising Drug Target Plays a Pivotal Role in Deterioration of Clear Cell Renal Cell Carcinoma. BioMed Research International, 2020, 2020, 1-13.	0.9	1
282	The Roles of Base Modifications in Kidney Cancer. Frontiers in Oncology, 2020, 10, 580018.	1.3	2
283	Cytotoxic Effect of Silver Nanoparticles Synthesized by Green Methods in Cancer. Journal of Medicinal Chemistry, 2020, 63, 14308-14335.	2.9	44
284	Role of the KEAP1-NRF2 Axis in Renal Cell Carcinoma. Cancers, 2020, 12, 3458.	1.7	17
285	Tumor promoting effects of circRNA_001287 on renal cell carcinoma through miR-144-targeted CEP55. Journal of Experimental and Clinical Cancer Research, 2020, 39, 269.	3.5	16
286	Mitophagy-associated genes PINK1 and PARK2 are independent prognostic markers of survival in papillary renal cell carcinoma and associated with aggressive tumor behavior. Scientific Reports, 2020, 10, 18857.	1.6	5
287	Liquid Biopsies in Renal Cell Carcinomaâ€"Recent Advances and Promising New Technologies for the Early Detection of Metastatic Disease. Frontiers in Oncology, 2020, 10, 582843.	1.3	16
288	Tubulocystic Renal Cell Carcinoma of the Native Kidney in a Renal Transplant Recipient: A Rare Case Report. Case Reports in Nephrology, 2020, 2020, 1-5.	0.2	0
289	HSPA12A unstabilizes CD147 to inhibit lactate export and migration in human renal cell carcinoma. Theranostics, 2020, 10, 8573-8590.	4.6	19
290	Genetic Alterations in Renal Cancers: Identification of The Mechanisms Underlying Cancer Initiation and Progression and of Therapeutic Targets. Medicines (Basel, Switzerland), 2020, 7, 44.	0.7	13
291	Circular RNA circ_001842 plays an oncogenic role in renal cell carcinoma by disrupting microRNAâ€502â€5pâ€mediated inhibition of SLC39A14. Journal of Cellular and Molecular Medicine, 2020, 24, 9712-9725.	1.6	21
292	Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs. Frontiers in Cell and Developmental Biology, 2020, 8, 584.	1.8	40
293	FLCN Regulates HIF2Î± Nuclear Import and Proliferation of Clear Cell Renal Cell Carcinoma. Frontiers in Molecular Biosciences, 2020, 7, 121.	1.6	4
294	The immunology of renal cell carcinoma. Nature Reviews Nephrology, 2020, 16, 721-735.	4.1	229
295	High-dimensional Cytometry (ExCYT) and Mass Spectrometry of Myeloid Infiltrate in Clinically Localized Clear Cell Renal Cell Carcinoma Identifies Novel Potential Myeloid Targets for Immunotherapy. Molecular and Cellular Proteomics, 2020, 19, 1850-1859.	2.5	2

#	Article	IF	Citations
296	Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma. Current Medical Research and Opinion, 2020, 36, 1507-1517.	0.9	11
297	Identification and Comprehensive Validation of a DNA Methylation-Driven Gene-Based Prognostic Model for Clear Cell Renal Cell Carcinoma. DNA and Cell Biology, 2020, 39, 1799-1812.	0.9	11
298	The 2020 Kidney Cancer Treatment Sequence Issue. Clinical Genitourinary Cancer, 2020, 18, 241-243.	0.9	3
299	Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance. Cancers, 2020, 12, 3172.	1.7	17
300	MBD2 Correlates with a Poor Prognosis and Tumor Progression in Renal Cell Carcinoma . OncoTargets and Therapy, 2020, Volume 13, 10001-10012.	1.0	7
301	Genetic Analysis Identifies the Role of HLF in Renal Cell Carcinoma. Cancer Genomics and Proteomics, 2020, 17, 827-833.	1.0	5
302	Core regulatory circuitries in defining cancer cell identity across the malignant spectrum. Open Biology, 2020, 10, 200121.	1.5	10
303	Clinical Studies Applying Cytokine-Induced Killer Cells for the Treatment of Renal Cell Carcinoma. Cancers, 2020, 12, 2471.	1.7	20
304	Potential biomarkers and risk assessment models to enhance the tumor-node-metastasis (TNM) staging classification of urologic cancers. Expert Review of Molecular Diagnostics, 2020, 20, 921-932.	1.5	2
305	An immune scores-based nomogram for predicting overall survival in patients with clear cell renal cell carcinoma. Medicine (United States), 2020, 99, e21693.	0.4	4
306	Identification of 12 immune-related lncRNAs and molecular subtypes for the clear cell renal cell carcinoma based on RNA sequencing data. Scientific Reports, 2020, 10, 14412.	1.6	8
307	A seven-gene signature model predicts overall survival in kidney renal clear cell carcinoma. Hereditas, 2020, 157, 38.	0.5	16
308	Comprehensive analysis on the expression levels and prognostic values of LOX family genes in kidney renal clear cell carcinoma. Cancer Medicine, 2020, 9, 8624-8638.	1.3	15
309	Overexpression of Spondin-2 Is Associated with Recurrence-Free Survival in Patients with Localized Clear Cell Renal Cell Carcinoma. Disease Markers, 2020, 2020, 1-11.	0.6	3
310	Identification of KIF18B as a Hub Candidate Gene in the Metastasis of Clear Cell Renal Cell Carcinoma by Weighted Gene Co-expression Network Analysis. Frontiers in Genetics, 2020, 11, 905.	1.1	10
311	Cell Polarity Protein Pals1-Associated Tight Junction Expression Is a Favorable Prognostic Marker in Clear Cell Renal Cell Carcinoma. Frontiers in Genetics, 2020, 11, 931.	1.1	6
312	Co-expression Network Analysis Identifies Fourteen Hub Genes Associated with Prognosis in Clear Cell Renal Cell Carcinoma. Current Medical Science, 2020, 40, 773-785.	0.7	3
313	Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinoma. Scandinavian Journal of Urology, 2020, 54, 493-499.	0.6	12

#	Article	IF	Citations
314	Treatment patterns, outcomes and clinical characteristics in advanced renal cell carcinoma: a real-world US study. Future Oncology, 2020, 16, 3045-3060.	1.1	7
315	Long Non-coding RNA IRAIN Inhibits VEGFA Expression via Enhancing Its DNA Methylation Leading to Tumor Suppression in Renal Carcinoma. Frontiers in Oncology, 2020, 10, 1082.	1.3	9
316	A Study on the Immunohistochemical Expressions of Leptin and Leptin Receptor in Clear Cell Renal Cell Carcinoma. BioMed Research International, 2020, 2020, 1-10.	0.9	7
317	ApoC1 promotes the metastasis of clear cell renal cell carcinoma via activation of STAT3. Oncogene, 2020, 39, 6203-6217.	2.6	45
318	Ultrasound-Based Microvascular Parameters for Classification of Anti-Angiogenic Tumor Treatment Response: A Scalable Preclinical Approach. , 2020, , .		2
319	The highest Fuhrman and WHO/ISUP grade influences the Kiâ€67 labeling index of those of grades 1 and 2 in clear cell renal cell carcinoma. Pathology International, 2020, 70, 984-991.	0.6	3
320	Epigenetic signature predicts overall survival clear cell renal cell carcinoma. Cancer Cell International, 2020, 20, 564.	1.8	4
321	Development and validation of a VHL-associated immune prognostic signature for clear cell renal cell carcinoma. Cancer Cell International, 2020, 20, 584.	1.8	9
322	Prognostic Significance of Sarcomatoid Differentiation in Patients With Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2020, 10, 591001.	1.3	4
323	Dopamine D1 Receptor in Cancer. Cancers, 2020, 12, 3232.	1.7	20
324	Prognostic Value of Histologic Subtype and Treatment Modality for T1a Kidney Cancers1. Kidney Cancer, 2020, 4, 49-58.	0.2	2
325	MicroRNAâ€100 Enhances Autophagy and Suppresses Migration and Invasion of Renal Cell Carcinoma Cells via Disruption of NOX4â€Dependent mTOR Pathway. Clinical and Translational Science, 2022, 15, 567-575.	1.5	15
326	Efficacy of Nivolumab Plus Ipilimumab in a Patient With Renal Cell Carcinoma Concomitant With Cardiac Metastasis: A Case Report. In Vivo, 2020, 34, 1475-1480.	0.6	4
327	The level of zinc finger of the cerebellum 2 is predictive of overall survival in clear cell renal cell carcinoma. Translational Andrology and Urology, 2020, 9, 614-620.	0.6	5
328	CircUBAP2 Inhibits Proliferation and Metastasis of Clear Cell Renal Cell Carcinoma via Targeting miR-148a-3p/FOXK2 Pathway. Cell Transplantation, 2020, 29, 096368972092575.	1.2	21
329	Identification of significant genes with prognostic influence in clear cell renal cell carcinoma via bioinformatics analysis. Translational Andrology and Urology, 2020, 9, 452-461.	0.6	7
330	Molecular targeting of renal cell carcinoma by an oral combination. Oncogenesis, 2020, 9, 52.	2.1	8
331	Construction and Validation of an Autophagy-Related Prognostic Risk Signature for Survival Predicting in Clear Cell Renal Cell Carcinoma Patients. Frontiers in Oncology, 2020, 10, 707.	1.3	12

#	Article	IF	Citations
332	Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma. Future Oncology, 2020, 16, 1199-1210.	1.1	4
333	MUC15 inhibits cancer metastasis via PI3K/AKT signaling in renal cell carcinoma. Cell Death and Disease, 2020, 11, 336.	2.7	24
334	Methylationâ€mediated miRâ€214 regulates proliferation and drug sensitivity of renal cell carcinoma cells through targeting LIVIN. Journal of Cellular and Molecular Medicine, 2020, 24, 6410-6425.	1.6	13
335	Elective Cytoreductive Nephrectomy After Checkpoint Inhibitor Immunotherapy in Patients With Initially Unresectable Metastatic Clear Cell Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, 361-366.	0.9	13
336	Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma. European Urology Oncology, 2020, 3, 523-529.	2.6	33
337	Identification of biomarkers of clear cell renal cell carcinoma by bioinformatics analysis. Medicine (United States), 2020, 99, e20470.	0.4	4
338	Use of hemostatic agents for surgical bleeding in laparoscopic partial nephrectomy: Biomaterials perspective. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2020, 108, 3099-3123.	1.6	10
339	Efficacy of Savolitinib vs Sunitinib in Patients WithMET-Driven Papillary Renal Cell Carcinoma. JAMA Oncology, 2020, 6, 1247.	3.4	105
340	Assessing Genomic Copy Number Alterations as Best Practice for Renal Cell Neoplasia: An Evidence-Based Review from the Cancer Genomics Consortium Workgroup. Cancer Genetics, 2020, 244, 40-54.	0.2	12
341	PD1/PD-L1 therapy in metastatic renal cell carcinoma. Current Opinion in Urology, 2020, 30, 534-541.	0.9	8
342	The Pan-Omics Landscape of Renal Cell Carcinoma and Its Implication on Future Clinical Practice. Kidney Cancer, 2020, 4, 121-129.	0.2	2
343	miR-363 suppresses the proliferation, migration and invasion of clear cell renal cell carcinoma by downregulating S1PR1. Cancer Cell International, 2020, 20, 227.	1.8	10
344	JAK3 is a potential biomarker and associated with immune infiltration in kidney renal clear cell carcinoma. International Immunopharmacology, 2020, 86, 106706.	1.7	26
345	MicroRNA-30a-5pme: a novel diagnostic and prognostic biomarker for clear cell renal cell carcinoma in tissue and urine samples. Journal of Experimental and Clinical Cancer Research, 2020, 39, 98.	3.5	34
346	Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane. Journal of Visualized Experiments, 2020, , .	0.2	5
347	VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling. Journal of Experimental and Clinical Cancer Research, 2020, 39, 104.	3.5	15
348	Beyond glycolysis: Hypoxia signaling as a master regulator of alternative metabolic pathways and the implications in clear cell renal cell carcinoma. Cancer Letters, 2020, 489, 19-28.	3.2	23
350	Polycystin-1 induces activation of the PI3K/AKT/mTOR pathway and promotes angiogenesis in renal cell carcinoma. Cancer Letters, 2020, 489, 135-143.	3.2	18

#	Article	IF	Citations
351	Microtubule-associated protein tau (MAPT) is a promising independent prognostic marker and tumor suppressive protein in clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 605.e9-605.e17.	0.8	16
352	Molecular Components of the RCC Grade. Seminars in Nephrology, 2020, 40, 14-27.	0.6	1
353	Quantification of contrast-uptake as imaging biomarker for disease progression of renal cell carcinoma after tumor ablation. Acta Radiologica, 2020, 61, 1708-1716.	0.5	0
354	Structure and function of the co-chaperone protein phosphatase 5 in cancer. Cell Stress and Chaperones, 2020, 25, 383-394.	1.2	28
355	Ubiquitin-specific protease-44 inhibits the proliferation and migration of cells via inhibition of JNK pathway in clear cell renal cell carcinoma. BMC Cancer, 2020, 20, 214.	1.1	15
356	Thymoquinone induces apoptosis of human renal carcinoma Caki-1Âcells by inhibiting JAK2/STAT3 through pro-oxidant effect. Food and Chemical Toxicology, 2020, 139, 111253.	1.8	26
357	Di-Ras2 promotes renal cell carcinoma formation by activating the mitogen-activated protein kinase pathway in the absence of von Hippelâ€“Lindau protein. Oncogene, 2020, 39, 3853-3866.	2.6	7
358	Telomere Length in Renal Cell Carcinoma: The Jekyll and Hyde Biomarker of Ageing of the Kidney . Cancer Management and Research, 2020, Volume 12, 1669-1679.	0.9	11
359	Deletion of Von Hippelâ€“Lindau Interferes with Hyper Osmolality Induced Gene Expression and Induces an Unfavorable Gene Expression Pattern. Cancers, 2020, 12, 420.	1.7	4
360	The Therapeutic Landscape of Renal Cell Carcinoma: From the Dark Age to the Golden Age. Seminars in Nephrology, 2020, 40, 28-41.	0.6	42
361	Pro-Angiogenic and Pro-Inflammatory Regulation by lncRNA MCM3AP-AS1-Mediated Upregulation of DPP4 in Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2020, 10, 705.	1.3	12
362	The oncogenic role of MUC12 in RCC progression depends on câ€Jun/TGFâ€Î² signalling. Journal of Cellular and Molecular Medicine, 2020, 24, 8789-8802.	1.6	24
363	CircHIPK3 Promotes Clear Cell Renal Cell Carcinoma (ccRCC) Cells Proliferation and Metastasis via Altering of miR-508-3p/CXCL13 Signal . OncoTargets and Therapy, 2020, Volume 13, 6051-6062.	1.0	23
365	The NADPH Oxidase Isoform 1 Contributes to Angiotensin II-Mediated DNA Damage in the Kidney. Antioxidants, 2020, 9, 586.	2.2	6
366	Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer. Cells, 2020, 9, 1495.	1.8	8
367	Anterior gradient 2 promotes tumorigenesis through upregulation of CCAATâ€enhancer binding protein beta and hypoxiaâ€inducible factorâ€2Î± and subsequent secretion of interleukinâ€6, interleukinâ€8, and vascular endothelial growth factor in the Cakiâ€1 clear cell renal cell carcinoma cell line. IUBMB Life, 2020, 72, 1807-1818.	1.5	7
368	Knockdown of PLOD3 suppresses the malignant progression of renal cell carcinoma via reducing TWIST1 expression. Molecular and Cellular Probes, 2020, 53, 101608.	0.9	9
369	Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma. BioMed Research International, 2020, 2020, 1-9.	0.9	13

#	Article	IF	Citations
370	Comprehensive analysis of copy number variance and sensitivity to common targeted therapy in clear cell renal cell carcinoma: In silico analysis with in vitro validation. Cancer Medicine, 2020, 9, 6020-6029.	1.3	8
371	Identification of gene signature for treatment response to guide precision oncology in clear-cell renal cell carcinoma. Scientific Reports, 2020, 10, 2026.	1.6	16
372	Integrative genomic study of Chinese clear cell renal cell carcinoma reveals features associated with thrombus. Nature Communications, 2020, 11, 739.	5.8	39
373	A novel EZH2 inhibitor induces synthetic lethality and apoptosis in PBRM1-deficient cancer cells. Cell Cycle, 2020, 19, 758-771.	1.3	20
374	DUSP9 Suppresses Proliferation and Migration of Clear Cell Renal Cell Carcinoma via the mTOR Pathway . OncoTargets and Therapy, 2020, Volume 13, 1321-1330.	1.0	10
375	Modeling clear cell renal cell carcinoma and therapeutic implications. Oncogene, 2020, 39, 3413-3426.	2.6	86
377	Potential New Therapeutic Approaches for Renal Cell Carcinoma. Seminars in Nephrology, 2020, 40, 86-97.	0.6	30
378	Claspin overexpression is associated with highâ€grade histology and poor prognosis in renal cell carcinoma. Cancer Science, 2020, 111, 1020-1027.	1.7	19
379	Alteration of CYP4A11 expression in renal cell carcinoma: diagnostic and prognostic implications. Journal of Cancer, 2020, 11, 1478-1485.	1.2	11
380	Recent advances in nanotechnology-based drug delivery systems for the kidney. Journal of Controlled Release, 2020, 321, 442-462.	4.8	110
381	Development and validation of an immune prognostic classifier for clear cell renal cell carcinoma. Cancer Biomarkers, 2020, 27, 265-275.	0.8	7
382	SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12. Cell Death and Disease, 2020, 11, 69.	2.7	32
383	Identification of microenvironmentâ€related genes with prognostic value in clear cell renal cell carcinoma. Journal of Cellular Biochemistry, 2020, 121, 3606-3615.	1.2	8
384	Machine learning with autophagy-related proteins for discriminating renal cell carcinoma subtypes. Scientific Reports, 2020, 10, 720.	1.6	15
385	An effective seven-CpG-based signature to predict survival in renal clear cell carcinoma by integrating DNA methylation and gene expression. Life Sciences, 2020, 243, 117289.	2.0	6
386	Germline polymorphisms in the Von Hippel-Lindau and Hypoxia-inducible factor 1-alpha genes, gene-environment and gene-gene interactions and renal cell cancer. Scientific Reports, 2020, 10, 137.	1.6	5
387	Early life body size in relation to risk of renal cell carcinoma in adulthood: a Danish observational cohort study. European Journal of Epidemiology, 2020, 35, 251-258.	2.5	10
388	Lactate Increases Renal Cell Carcinoma Aggressiveness through Sirtuin 1-Dependent Epithelial Mesenchymal Transition Axis Regulation. Cells, 2020, 9, 1053.	1.8	26

#	Article	IF	Citations
389	Lactotransferrin Downregulation Drives the Metastatic Progression in Clear Cell Renal Cell Carcinoma. Cancers, 2020, 12, 847.	1.7	10
390	Long Non-Coding RNA CASC19 Sponges microRNA-532 and Promotes Oncogenicity of Clear Cell Renal Cell Carcinoma by Increasing ETS1 Expression . Cancer Management and Research, 2020, Volume 12, 2195-2207.	0.9	17
391	MiR-144: A New Possible Therapeutic Target and Diagnostic/Prognostic Tool in Cancers. International Journal of Molecular Sciences, 2020, 21, 2578.	1.8	35
392	Cellular immunotherapy: a clinical state-of-the-art of a new paradigm for cancer treatment. Clinical and Translational Oncology, 2020, 22, 1923-1937.	1.2	14
393	Transcriptomics in RCC. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 742-754.	0.8	6
394	Renal carcinoma CD105â^'/CD44â^' cells display stem-like properties in vitro and form aggressive tumors in vivo. Scientific Reports, 2020, 10, 5379.	1.6	17
395	FOXM1-Activated LINC01094 Promotes Clear Cell Renal Cell Carcinoma Development via MicroRNA 224-5p/CHSY1. Molecular and Cellular Biology, 2020, 40, .	1.1	48
396	The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy. Clinical Genitourinary Cancer, 2020, 18, 252-257.e2.	0.9	17
397	Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy. Expert Review of Anticancer Therapy, 2020, 20, 343-354.	1.1	0
398	Long non-coding RNA PCAT1 drives clear cell renal cell carcinoma by upregulating YAP via sponging miR-656 and miR-539. Cell Cycle, 2020, 19, 1122-1131.	1.3	14
399	Integration of intratumoral RASSF10 expression and tumor-associated macrophages into the established clinical indicators better predicts the prognosis of clear cell renal cell carcinoma patients. OncoImmunology, 2020, 9, 1736793.	2.1	6
400	Challenges and opportunities in the management of metastatic renal cell carcinoma: combination therapy and the role of cytoreductive surgery. Current Opinion in Oncology, 2020, 32, 240-249.	1.1	15
401	RUNX1 Is a Driver of Renal Cell Carcinoma Correlating with Clinical Outcome. Cancer Research, 2020, 80, 2325-2339.	0.4	21
402	Modulator-Dependent RBPs Changes Alternative Splicing Outcomes in Kidney Cancer. Frontiers in Genetics, 2020, 11, 265.	1.1	22
403	Patientsâ€™ Perspective on Digital Technologies in Advanced Genitourinary Cancers. Clinical Genitourinary Cancer, 2021, 19, 76-82.e6.	0.9	12
404	Current updates and future perspectives on the management of renal cell carcinoma. Life Sciences, 2021, 264, 118632.	2.0	48
405	Long noncoding RNA SNHG6 promotes carcinogenesis by enhancing YBX1â€mediated translation of HIF1Î± in clear cell renal cell carcinoma. FASEB Journal, 2021, 35, e21160.	0.2	16
406	Integrated analysis of the functions of RNA binding proteins in clear cell renal cell carcinoma. Genomics, 2021, 113, 850-860.	1.3	5

#	Article	IF	Citations
407	Impact of antiangiogenic treatment on the erectile function in patients with advanced renal cell carcinoma. Andrologia, 2021, 53, e13881.	1.0	1
408	DNA methylation of Huglâ€2 is a prognostic biomarker in kidney renal clear cell carcinoma. Clinical and Experimental Pharmacology and Physiology, 2021, 48, 44-53.	0.9	3
409	p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma. Journal of Hepatology, 2021, 74, 96-108.	1.8	54
410	Targeting a positive regulatory loop in the tumor-macrophage interaction impairs the progression of clear cell renal cell carcinoma. Cell Death and Differentiation, 2021, 28, 932-951.	5.0	21
411	Surgical Management and Outcomes of Renal Tumors Arising from Horseshoe Kidneys: Results from an International Multicenter Collaboration. European Urology, 2021, 79, 133-140.	0.9	23
412	Transmembrane protein ADAM29 facilitates cell proliferation, invasion and migration in clear cell renal cell carcinoma. Journal of Chemotherapy, 2021, 33, 40-50.	0.7	2
413	miRâ€30bâ€5p upâ€regulation related to the dismal prognosis for patients with renal cell cancer. Journal of Clinical Laboratory Analysis, 2021, 35, e23599.	0.9	10
414	Cadmium induces epithelialâ€“mesenchymal transition and migration of renal cancer cells by increasing PGE2 through a cAMP/PKA-COX2 dependent mechanism. Ecotoxicology and Environmental Safety, 2021, 207, 111480.	2.9	24
415	CLDN10 associated with immune infiltration is a novel prognostic biomarker for clear cell renal cell carcinoma. Epigenomics, 2021, 13, 31-45.	1.0	13
416	Coupled Mass-Spectrometry-Based Lipidomics Machine Learning Approach for Early Detection of Clear Cell Renal Cell Carcinoma. Journal of Proteome Research, 2021, 20, 841-857.	1.8	13
417	DMDRMR-Mediated Regulation of m6A-Modified CDK4 by m6A Reader IGF2BP3 Drives ccRCC Progression. Cancer Research, 2021, 81, 923-934.	0.4	93
418	SUV39H1 deficiency suppresses clear cell renal cell carcinoma growth by inducing ferroptosis. Acta Pharmaceutica Sinica B, 2021, 11, 406-419.	5.7	56
419	MiR-125b promotes migration and invasion by targeting the vitamin D receptor in renal cell carcinoma. International Journal of Medical Sciences, 2021, 18, 150-156.	1.1	5
420	Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data. Japanese Journal of Clinical Oncology, 2021, 51, 793-801.	0.6	7
421	Biomimetic codelivery overcomes osimertinib-resistant NSCLC and brain metastasis via macrophage-mediated innate immunity. Journal of Controlled Release, 2021, 329, 1249-1261.	4.8	27
422	Mass Spectrometry-Based Metabolic Fingerprinting Contributes to Unveil the Role of RSUME in Renal Cell Carcinoma Cell Metabolism. Journal of Proteome Research, 2021, 20, 786-803.	1.8	2
423	B-MYBâ€”p53-related relevant regulator for the progression of clear cell renal cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2021, 147, 129-138.	1.2	4
424	Avelumab: search for combinations of immune checkpoint inhibition with chemotherapy. Expert Opinion on Biological Therapy, 2021, 21, 311-322.	1.4	10

#	Article	IF	Citations
425	Tracing Clonal Dynamics Reveals that Two- and Three-dimensional Patient-derived Cell Models Capture Tumor Heterogeneity of Clear Cell Renal Cell Carcinoma. European Urology Focus, 2021, 7, 152-162.	1.6	34
426	Establishment of a Risk Signature Based on m6A RNA Methylation Regulators That Predicts Poor Prognosis in Renal Cell Carcinoma. OncoTargets and Therapy, 2021, Volume 14, 413-426.	1.0	5
427	Clinical analysis of everolimus in the treatment of metastatic renal cell carcinoma. Annals of Palliative Medicine, 2021, 10, 584-589.	0.5	2
428	Automated segmentation of kidney and renal mass and automated detection of renal mass in CT urography using 3D U-Net-based deep convolutional neural network. European Radiology, 2021, 31, 5021-5031.	2.3	35
429	Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma. Journal of Experimental and Clinical Cancer Research, 2021, 40, 33.	3.5	11
430	Identification of biomarkers and construction of a microRNAâ€'mRNA regulatory network for clear cell renal cell carcinoma using integrated bioinformatics analysis. PLoS ONE, 2021, 16, e0244394.	1.1	8
431	Roles of the BAP1 Tumor Suppressor in Cell Metabolism. Cancer Research, 2021, 81, 2807-2814.	0.4	24
432	Identification of HIPK3 as a potential biomarker and an inhibitor of clear cell renal cell carcinoma. Aging, 2021, 13, 3536-3553.	1.4	5
433	An unusual outcome of papillary renal cell carcinoma with lung metastases: a case report and review of literature. African Journal of Urology, 2021, 27, .	0.1	4
434	TRIP13 is identified as a prognosis biomarker for renal clear cell carcinoma and promotes renal cell carcinoma cell proliferation, migration and invasion. Biocell, 2021, 45, 577-588.	0.4	2
435	Validation of CT radiomics for prediction of distant metastasis after surgical resection in patients with clear cell renal cell carcinoma: exploring the underlying signaling pathways. European Radiology, 2021, 31, 5032-5040.	2.3	14
436	Identification of DNA methylation signatures associated with poor outcome in lower-risk Stage, Size, Grade and Necrosis (SSIGN) score clear cell renal cell cancer. Clinical Epigenetics, 2021, 13, 12.	1.8	8
437	A nitric oxide-releasing prodrug promotes apoptosis in human renal carcinoma cells: Involvement of reactive oxygen species. Open Chemistry, 2021, 19, 635-645.	1.0	1
438	The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma. Expert Review of Anticancer Therapy, 2021, 21, 365-372.	1.1	5
439	SMARCC1 expression is positively correlated with pathological grade and good prognosis in renal cell carcinoma. Translational Andrology and Urology, 2021, 10, 236-242.	0.6	3
440	Identification and validation of the clinical roles of the VHL-related LncRNAs in clear cell renal cell carcinoma. Journal of Cancer, 2021, 12, 2702-2714.	1.2	22
441	Human circular RNA hsa_circRNA_101705 (circTXNDC11) regulates renal cancer progression by regulating MAPK/ERK pathway. Bioengineered, 2021, 12, 4432-4441.	1.4	22
442	Engineered nanomedicines for tumor vasculature blockade therapy. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2021, 13, e1691.	3.3	10

#	Article	IF	Citations
443	CARMA3 Transcriptional Regulation of STMN1 by NF-Î²B Promotes Renal Cell Carcinoma Proliferation and Invasion. Technology in Cancer Research and Treatment, 2021, 20, 153303382110279.	0.8	5
444	Update on the most promising biomarkers of response to immune checkpoint inhibitors in clear cell renal cell carcinoma. World Journal of Urology, 2021, 39, 1377-1385.	1.2	15
446	CT-based peritumoral radiomics signatures for malignancy grading of clear cell renal cell carcinoma. Abdominal Radiology, 2021, 46, 2690-2698.	1.0	9
447	Prognostic Impact of MITD1 and Associates With Immune Infiltration in Kidney Renal Clear Cell Carcinoma. Technology in Cancer Research and Treatment, 2021, 20, 153303382110362.	0.8	6
448	Circ_0035483 Functions as a Tumor Promoter in Renal Cell Carcinoma via the miR-31-5p-Mediated HMGA1 Upregulation. Cancer Management and Research, 2021, Volume 13, 693-706.	0.9	15
449	A genomic instability-derived risk index predicts clinical outcome and immunotherapy response for clear cell renal cell carcinoma. Bioengineered, 2021, 12, 1642-1662.	1.4	6
450	Clear Cell Renal Carcinoma: MicroRNAs With Efficacy in PreclinicalIn VivoModels. Cancer Genomics and Proteomics, 2021, 18, 349-368.	1.0	4
451	Wild-type IDH1 inhibits the tumor growth through degrading HIF-Î± in renal cell carcinoma. International Journal of Biological Sciences, 2021, 17, 1250-1262.	2.6	6
452	Long Non-Coding RNA PCED1B-AS1 Promotes the Progression of Clear Cell Renal Cell Carcinoma Through miR-484/ZEB1 Axis. OncoTargets and Therapy, 2021, Volume 14, 393-402.	1.0	19
453	Identification of hsa_circ_0002024 as a prognostic competing endogenous RNA (ceRNA) through the hsa_miR_129-5p/Anti-Silencing Function 1B Histone Chaperone (ASF1B) axis in renal cell carcinoma. Bioengineered, 2021, 12, 6579-6593.	1.4	8
454	Long non-coding RNA ARAP1-AS1 contributes to cell proliferation and migration in clear cell renal cell carcinoma via the miR-361-3p/placental growth factor axis. Bioengineered, 2021, 12, 6629-6642.	1.4	10
455	Radiotherapy and Renal Cell Carcinoma: A Continuing Saga. In Vivo, 2021, 35, 1365-1377.	0.6	3
456	Novel insights into clear cell renal cell carcinoma prognosis by comprehensive characterization of aberrant alternative splicing signature: a study based on large-scale sequencing data. Bioengineered, 2021, 12, 1091-1110.	1.4	3
457	Stem Cells and Kidney Regeneration. , 2021, , 1-27.		0
458	Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective. Journal of Medical Economics, 2021, 24, 291-298.	1.0	4
459	circTLK1 facilitates the proliferation and metastasis of renal cell carcinoma by regulating miR-495-3p/CBL axis. Open Life Sciences, 2021, 16, 362-374.	0.6	10
460	A Novel miRNA-Based Model Can Predict the Prognosis of Clear Cell Renal Cell Carcinoma. Technology in Cancer Research and Treatment, 2021, 20, 153303382110279.	0.8	3
461	Development of a novel gene signature to predict prognosis and response to PD-1 blockade in clear cell renal cell carcinoma. OncoImmunology, 2021, 10, 1933332.	2.1	26

#	Article	IF	Citations
462	Metabolic regulation in urological tumors: Interplay with epigenetics and epitranscriptomics. , 2021, , 107-145.		0
463	Long noncoding RNAs as tumorigenic factors and therapeutic targets for renal cell carcinoma. Cancer Cell International, 2021, 21, 110.	1.8	9
464	IFI16 Can Be Used as a Biomarker for Diagnosis of Renal Cell Carcinoma and Prediction of Patient Survival. Frontiers in Genetics, 2021, 12, 599952.	1.1	6
465	ENAM gene associated with T classification and inhibits proliferation in renal clear cell carcinoma. Aging, 2021, 13, 7035-7051.	1.4	8
467	The immuneâ€related biomarker TEK inhibits the development of clear cell renal cell carcinoma (ccRCC) by regulating AKT phosphorylation. Cancer Cell International, 2021, 21, 119.	1.8	12
468	Safety and Efficacy of Robotic Radiosurgery for Visceral and Lymph Node Metastases of Renal Cell Carcinoma: A Retrospective, Single Center Analysis. Cancers, 2021, 13, 680.	1.7	2
469	Immune Infiltration Landscape in Clear Cell Renal Cell Carcinoma Implications. Frontiers in Oncology, 2020, 10, 491621.	1.3	15
470	An Effective Hypoxia-Related Long Non-Coding RNAs Assessment Model for Prognosis of Clear Cell Renal Carcinoma. Frontiers in Oncology, 2021, 11, 616722.	1.3	13
471	The Impact of Oxidoreductases-Related MicroRNAs in Glucose Metabolism of Renal Cell Carcinoma and Prostate Cancer. , 0, , .		1
473	Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of renal cell carcinoma. Expert Opinion on Biological Therapy, 2021, 21, 1215-1226.	1.4	10
474	CTHRC1 Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Kidney Renal Papillary Cell Carcinoma and Kidney Renal Clear Cell Carcinoma. Frontiers in Oncology, 2020, 10, 570819.	1.3	13
475	SirtuinÂ6 regulates the proliferation and survival of clear cell renal cell carcinoma cells via Bâ€˜cell lymphomaÂ2. Oncology Letters, 2021, 21, 293.	0.8	2
476	Identification of RCC Subtype-Specific microRNAsâ€“Meta-Analysis of High-Throughput RCC Tumor microRNA Expression Data. Cancers, 2021, 13, 548.	1.7	18
478	Overexpression of MAX dimerization protein 3 (MXD3) predicts poor prognosis in clear cell renal cell carcinoma. Translational Andrology and Urology, 2021, 10, 785-796.	0.6	9
479	Macrophage M2 Co-expression Factors Correlate With the Immune Microenvironment and Predict Outcome of Renal Clear Cell Carcinoma. Frontiers in Genetics, 2021, 12, 615655.	1.1	31
480	Potential of enhancer of zeste homolog 2 inhibitors for the treatment of SWI/SNF mutant cancers and tumor microenvironment modulation. Drug Development Research, 2021, 82, 730-753.	1.4	5
481	Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?. Translational Andrology and Urology, 2021, 10, 1581-1587.	0.6	3
482	Let-7i-5p enhances cell proliferation, migration and invasion of ccRCC by targeting HABP4. BMC Urology, 2021, 21, 49.	0.6	11

#	Article	IF	Citations
484	Metabolomic and elemental profiling of human tissue in kidney cancer. Metabolomics, 2021, 17, 30.	1.4	15
485	ATF3 Suppresses Growth and Metastasis of Clear Cell Renal Cell Carcinoma by Deactivating EGFR/AKT/GSK3Î²/Î²-Catenin Signaling Pathway. Frontiers in Cell and Developmental Biology, 2021, 9, 618987.	1.8	11
486	18Fluorodeoxyglucose-positron emission tomography/computed tomography for differentiation of renal tumors in hereditary kidney cancer syndromes. Abdominal Radiology, 2021, 46, 3301-3308.	1.0	4
487	Exploration of an Integrative Prognostic Model of Radiogenomics Features With Underlying Gene Expression Patterns in Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 640881.	1.3	10
488	Tumor microenvironment immune subtypes for classification of novel clear cell renal cell carcinoma profiles with prognostic and therapeutic implications. Medicine (United States), 2021, 100, e24949.	0.4	5
489	Mucosal Associated Invariant T Cells in Cancer-Friend or Foe?. Cancers, 2021, 13, 1582.	1.7	11
490	Development and evaluation of a deep neural network for histologic classification of renal cell carcinoma on biopsy and surgical resection slides. Scientific Reports, 2021, 11, 7080.	1.6	27
491	MicroRNA related prognosis biomarkers from high throughput sequencing data of kidney renal clear cell carcinoma. BMC Medical Genomics, 2021, 14, 72.	0.7	14
492	SLC39A8/Zinc Suppresses the Progression of Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 651921.	1.3	5
493	MicroRNAs MiR-15a and MiR-26a cooperatively regulate O-GlcNAc-transferase to control proliferation in clear cell renal cell carcinoma. Cancer Biomarkers, 2021, 30, 343-351.	0.8	7
494	Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives. Frontiers in Cell and Developmental Biology, 2021, 9, 636037.	1.8	16
495	Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials. European Urology Focus, 2022, 8, 514-521.	1.6	64
496	Prolyl Hydroxylase 3 Knockdown Accelerates VHL-Mutant Kidney Cancer Growth In Vivo. International Journal of Molecular Sciences, 2021, 22, 2849.	1.8	5
497	Construction of Competitive Endogenous RNA Network and Verification of 3-Key LncRNA Signature Associated With Distant Metastasis and Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 640150.	1.3	21
498	Role of Circular RNA in Kidney-Related Diseases. Frontiers in Pharmacology, 2021, 12, 615882.	1.6	8
499	Construction of a prognostic value model in papillary renal cell carcinoma by immune-related genes. Medicine (United States), 2021, 100, e24903.	0.4	4
500	Identification of TYROBP and FCER1G as Key Genes with Prognostic Value in Clear Cell Renal Cell Carcinoma by Bioinformatics Analysis. Biochemical Genetics, 2021, 59, 1278-1294.	0.8	8
501	Urinary Extracellular Vesicles as Potential Biomarkers for Urologic Cancers: An Overview of Current Methods and Advances. Cancers, 2021, 13, 1529.	1.7	21

#	Article	IF	Citations
502	Identification of a Novel Protein-Based Signature to Improve Prognosis Prediction in Renal Clear Cell Carcinoma. Frontiers in Molecular Biosciences, 2021, 8, 623120.	1.6	10
503	Imaging features and clinic value of mri and ct in diagnosis of clear cell renal cell carcinoma. Food Science and Technology, 0, , .	0.8	0
504	Expression levels of VEGFâ€'C and VEGFRâ€'3 in renal cell carcinoma and their association with lymph node metastasis. Experimental and Therapeutic Medicine, 2021, 21, 554.	0.8	5
505	Artificial intelligence prediction model for overall survival of clear cell renal cell carcinoma based on a 21-gene molecular prognostic score system. Aging, 2021, 13, 7361-7381.	1.4	7
506	Functional Assessment of Four Novel Immune-Related Biomarkers in the Pathogenesis of Clear Cell Renal Cell Carcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 621618.	1.8	7
507	Orbit and sinonasal metastasis as presenting sign of renal cell carcinoma. BMJ Case Reports, 2021, 14, e240588.	0.2	1
508	The added value of contrast-enhanced ultrasound in evaluation of indeterminate small solid renal masses and risk stratification of cystic renal lesions. European Radiology, 2021, 31, 8468-8477.	2.3	12
509	Absent in melanoma 2-mediating M1 macrophages facilitate tumor rejection in renal carcinoma. Translational Oncology, 2021, 14, 101018.	1.7	9
510	Modeling Neoplastic Growth in Renal Cell Carcinoma and Polycystic Kidney Disease. International Journal of Molecular Sciences, 2021, 22, 3918.	1.8	9
511	Landscape of immune cell infiltration in clear cell renal cell carcinoma to aid immunotherapy. Cancer Science, 2021, 112, 2126-2139.	1.7	23
512	Molecular interactions of miR-338 during tumor progression and metastasis. Cellular and Molecular Biology Letters, 2021, 26, 13.	2.7	23
513	Effects of long non-coding RNAs on androgen signaling pathways in genitourinary malignancies. Molecular and Cellular Endocrinology, 2021, 526, 111197.	1.6	0
514	Axitinib Induces and Aggravates Hypertension Regardless of Prior Treatment With Tyrosine Kinase Inhibitors. Circulation Reports, 2021, 3, 234-240.	0.4	5
515	NFIB promotes the migration and progression of kidney renal clear cell carcinoma by regulating PINK1 transcription. PeerJ, 2021, 9, e10848.	0.9	5
516	The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma. Turkish Journal of Medical Sciences, 2021, 51, 757-765.	0.4	8
517	Initial Presentation of Renal Cell Carcinoma as Heart Failure Secondary to Tumor-Thrombus Extension to the Right Atrium. Cureus, 2021, 13, e14537.	0.2	0
518	IL13RÎ±2 Is Involved in the Progress of Renal Cell Carcinoma through the JAK2/FOXO3 Pathway. Journal of Personalized Medicine, 2021, 11, 284.	1.1	4
519	Sonic Hedgehog signaling pathway in gynecological and genitourinary cancer (Review). International Journal of Molecular Medicine, 2021, 47, .	1.8	16

#	Article	IF	Citations
520	Long noncoding RNA LINC00641 promotes renal cell carcinoma progression via sponging microRNA-340-5p. Cancer Cell International, 2021, 21, 210.	1.8	12
521	Multilevel Regulation of Î²-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma. Cancer Research, 2021, 81, 3554-3567.	0.4	14
522	miR-5701 promoted apoptosis of clear cell renal cell carcinoma cells by targeting phosphodiesterase-1B. Anti-Cancer Drugs, 2021, 32, 855-863.	0.7	5
523	RUNX1/miR-582-5p Pathway Regulates the Tumor Progression in Clear Cell Renal Cell Carcinoma by Targeting COL5A1. Frontiers in Oncology, 2021, 11, 610992.	1.3	9
524	Long Non-Coding PROX1-AS1 Expression Correlates with Renal Cell Carcinoma Metastasis and Aggressiveness. Non-coding RNA, 2021, 7, 25.	1.3	4
525	Cancer Cellsâ€™ Metabolism Dynamics in Renal Cell Carcinoma Patientsâ€™ Outcome: Influence of GLUT-1-Related hsa-miR-144 and hsa-miR-186. Cancers, 2021, 13, 1733.	1.7	12
526	Tuftelin 1 (TUFT1) Promotes the Proliferation and Migration of Renal Cell Carcinoma via PI3K/AKT Signaling Pathway. Pathology and Oncology Research, 2021, 27, 640936.	0.9	12
527	C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 239.e17-239.e25.	0.8	13
528	A psychometric evaluation of the Functional assessment of cancer therapyâ€"kidney symptom index (FKSI-19) among renal cell carcinoma patients suggesting an alternative two-factor structure. Quality of Life Research, 2021, 30, 2663-2670.	1.5	5
529	Curcumin suppresses renal carcinoma tumorigenesis by regulating circ-FNDC3B/miR-138-5p/IGF2 axis. Anti-Cancer Drugs, 2021, 32, 734-744.	0.7	17
530	Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell, 2021, 39, 649-661.e5.	7.7	263
531	Cabozantinib and dasatinib synergize to induce tumor regression in non-clear cell renal cell carcinoma. Cell Reports Medicine, 2021, 2, 100267.	3.3	4
532	Development and Interpretation of a Genomic Instability Derived lncRNAs Based Risk Signature as a Predictor of Prognosis for Clear Cell Renal Cell Carcinoma Patients. Frontiers in Oncology, 2021, 11, 678253.	1.3	14
533	Ubiquitinâ€specific peptidase 53 inhibits the occurrence and development of clear cell renal cell carcinoma through NFâ€ºB pathway inactivation. Cancer Medicine, 2021, 10, 3674-3688.	1.3	11
534	A brand-new CAR for macrophages: is it time to fire up the engines of a new era for the treatment of renal cell carcinoma?. Future Oncology, 2021, 17, 1839-1841.	1.1	3
535	Expression of functional E-selectin ligands on the plasma membrane of carcinoma cells correlates with poor prognosis in clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 302.e9-302.e18.	0.8	4
536	Relevance of CYP3A5 Expression on the Clinical Outcome of Patients With Renal Cell Carcinoma. Anticancer Research, 2021, 41, 2511-2521.	0.5	1
537	Collagen prolyl 4-hydroxylases modify tumor progression. Acta Biochimica Et Biophysica Sinica, 2021, 53, 805-814.	0.9	25

#	Article	IF	Citations
538	The prognostic value of galactosylceramide-sulfotransferase (Gal3ST1) in human renal cell carcinoma. Scientific Reports, 2021, 11, 10926.	1.6	7
539	Increased CDC6 Expression Associates With Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 666418.	1.3	7
541	Mechanism of gypenosides of Gynostemma pentaphyllum inducing apoptosis of renal cell carcinoma by PI3K/AKT/mTOR pathway. Journal of Ethnopharmacology, 2021, 271, 113907.	2.0	31
542	Immunological Effects of Histotripsy for Cancer Therapy. Frontiers in Oncology, 2021, 11, 681629.	1.3	32
543	Occurrence of Amyotrophic Lateral Sclerosis in Type 1 Gaucher Disease. Neurology: Genetics, 2021, 7, e600.	0.9	3
544	Delivery of miR-224-5p by Exosomes from Cancer-Associated Fibroblasts Potentiates Progression of Clear Cell Renal Cell Carcinoma. Computational and Mathematical Methods in Medicine, 2021, 2021, 1-9.	0.7	10
545	APOBEC1 complementation factor facilitates cell migration by promoting nucleus translocation of SMAD3 in renal cell carcinoma cells. In Vitro Cellular and Developmental Biology - Animal, 2021, 57, 501-509.	0.7	2
546	Photothermal therapy enhance the anti-mitochondrial metabolism effect of lonidamine to renal cell carcinoma in homologous-targeted nanosystem. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 34, 102370.	1.7	6
547	Single-Cell RNA-seq Identification of the Cellular Molecular Characteristics of Sporadic Bilateral Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 659251.	1.3	12
548	Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDCÂrisk groups in metastatic renal cell carcinoma: a meta-analysis. Immunotherapy, 2021, 13, 783-793.	1.0	3
550	Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence. Immunotherapy, 2021, 13, 685-692.	1.0	7
552	Characterization of Hypoxia-Related Molecular Subtypes in Clear Cell Renal Cell Carcinoma to Aid Immunotherapy and Targeted Therapy via Multi-Omics Analysis. Frontiers in Molecular Biosciences, 2021, 8, 684050.	1.6	10
553	The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: Whatâ€™s the Story Morning Glory?. International Journal of Molecular Sciences, 2021, 22, 6237.	1.8	15
554	Resource-efficient pooled sequencing expands translational impact in solid tumors. Kidney Cancer Journal: Official Journal of the Kidney Cancer Association, 2021, 19, 18-23.	0.1	1
555	Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 367.e1-367.e5.	0.8	11
556	Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells. International Journal of Molecular Sciences, 2021, 22, 6467.	1.8	12
557	Myc-associated zinc-finger protein promotes clear cell renal cell carcinoma progression through transcriptional activation of the MAP2K2-dependent ERK pathway. Cancer Cell International, 2021, 21, 323.	1.8	20
558	CYP2J2 Is a Diagnostic and Prognostic Biomarker Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma. BioMed Research International, 2021, 2021, 1-15.	0.9	11

#	Article	IF	Citations
559	Red Phosphorus Decorated TiO₂ Nanorod Mediated Photodynamic and Photothermal Therapy for Renal Cell Carcinoma. Small, 2021, 17, e2101837.	5.2	26
560	MicroRNAs Targeting HIF-2Î±, VEGFR1 and/or VEGFR2 as Potential Predictive Biomarkers for VEGFR Tyrosine Kinase and HIF-2Î± Inhibitors in Metastatic Clear-Cell Renal Cell Carcinoma. Cancers, 2021, 13, 3099.	1.7	16
561	Multidiscipline Immunotherapy-Based Rational Combinations for Robust and Durable Efficacy in Brain Metastases from Renal Cell Carcinoma. International Journal of Molecular Sciences, 2021, 22, 6290.	1.8	4
562	A deep-learning based artificial intelligence (AI) approach for differentiation of clear cell renal cell carcinoma from oncocytoma on multi-phasic MRI. Clinical Imaging, 2021, 77, 291-298.	0.8	25
563	Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 45-51.	0.7	6
564	Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data. Cancer Treatment Reviews, 2021, 97, 102191.	3.4	17
565	Alternative splicing associated with cancer stemness in kidney renal clear cell carcinoma. BMC Cancer, 2021, 21, 703.	1.1	15
566	KDELC1 and TRMT1 Serve as Prognosis-Related SARS-CoV-2 Proteins Binding Human mRNAs and Promising Biomarkers in Clear Cell Renal Cell Carcinoma. International Journal of General Medicine, 2021, Volume 14, 2475-2490.	0.8	6
567	Quality of life assessment in renal cell carcinomaÂPhase II and III clinical trials published between 2010 and 2020: a systematic review. Future Oncology, 2021, 17, 2671-2681.	1.1	17
568	pVHL promotes lysosomal degradation of YAP in lung adenocarcinoma. Cellular Signalling, 2021, 83, 110002.	1.7	2
569	Upregulation of ARNTL2 is associated with poor survival and immune infiltration in clear cell renal cell carcinoma. Cancer Cell International, 2021, 21, 341.	1.8	11
570	Loss of RANBP3L leads to transformation of renal epithelial cells towards a renal clear cell carcinoma like phenotype. Journal of Experimental and Clinical Cancer Research, 2021, 40, 226.	3.5	7
571	A Brief Overview and Update on Major Molecular Genomic Alterations in Solid, Bone and Soft Tissue Tumors, and Hematopoietic As Well As Lymphoid Malignancies. Archives of Pathology and Laboratory Medicine, 2021, 145, 1358-1366.	1.2	2
572	Immune Checkpoint Inhibition in Advanced Non-Clear Cell Renal Cell Carcinoma: Leveraging Success from Clear Cell Histology into New Opportunities. Cancers, 2021, 13, 3652.	1.7	13
573	Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncology, The, 2021, 22, 946-958.	5.1	100
574	A microRNAâ€clinical prognosis model to predict the overall survival for kidney renal clear cell carcinoma. Cancer Medicine, 2021, 10, 6128-6139.	1.3	4
575	IQGAP3 May Serve as a Promising Biomarker in Clear Cell Renal Cell Carcinoma. International Journal of General Medicine, 2021, Volume 14, 3469-3484.	0.8	2
576	Circulating microRNAs from the Molecular Mechanisms to Clinical Biomarkers: A Focus on the Clear Cell Renal Cell Carcinoma. Genes, 2021, 12, 1154.	1.0	13

#	Article	IF	Citations
577	LRRK2 is a candidate prognostic biomarker for clear cell renal cell carcinoma. Cancer Cell International, 2021, 21, 343.	1.8	3
578	Molecular Subtypes and Gene Expression Signatures as Prognostic Features in Fully Resected Clear Cell Renal Cell Carcinoma: A Tailored Approach to Adjuvant Trials. Clinical Genitourinary Cancer, 2021, 19, e382-e394.	0.9	9
579	MiR-532-3p suppresses cell viability, migration and invasion of clear cell renal cell carcinoma through targeting TROAP. Cell Cycle, 2021, 20, 1578-1588.	1.3	13
580	Diagnostic Utility of RNA-Seq for Evaluation of PD-L1 Expression in Clear Cell Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2021, , .	0.9	1
581	Lactucin induces apoptosis through reactive oxygen species-mediated BCL-2 and CFLARL downregulation in Caki-1 cells. Genes and Genomics, 2021, 43, 1199-1207.	0.5	5
582	Renal cell carcinoma therapy: Current and new drug candidates. Drug Discovery Today, 2022, 27, 304-314.	3.2	29
583	The prognostic value of circulating tumour cells (CTCs) and CTC white blood cell clusters in patients with renal cell carcinoma. BMC Cancer, 2021, 21, 826.	1.1	19
585	Hub Long Noncoding RNAs with m6A Modification for Signatures and Prognostic Values in Kidney Renal Clear Cell Carcinoma. Frontiers in Molecular Biosciences, 2021, 8, 682471.	1.6	11
586	A new and practical surgical technique of transvaginal natural orifice specimen extraction surgery (NOSES) in laparoscopic nephroureterectomyâ€”an initial clinical experience. Journal of Surgical Oncology, 2021, 124, 1200-1206.	0.8	5
587	Radiomic profiling of clear cell renal cell carcinoma reveals subtypes with distinct prognoses and molecular pathways. Translational Oncology, 2021, 14, 101078.	1.7	6
588	Spatial immunoprofiling of the intratumoral and peritumoral tissue of renal cell carcinoma patients. Modern Pathology, 2021, 34, 2229-2241.	2.9	25
589	Nuclear expression of NHERF1/EBP50 in Clear Cell Renal Cell Carcinoma. Acta Histochemica, 2021, 123, 151717.	0.9	2
590	Radiomics models based on enhanced computed tomography to distinguish clear cell from non-clear cell renal cell carcinomas. Scientific Reports, 2021, 11, 13729.	1.6	19
591	Development of a mechanically matched silk scaffolded 3D clear cell renal cell carcinoma model. Materials Science and Engineering C, 2021, 126, 112141.	3.8	8
592	Feasibility Study on Using Dynamic Contrast Enhanced MRI to Assess the Effect of Tyrosine Kinase Inhibitor Therapy within the STAR Trial of Metastatic Renal Cell Cancer. Diagnostics, 2021, 11, 1302.	1.3	3
593	Current Imaging Evaluation of Tumor Response to Advanced Medical Treatment in Metastatic Renal-Cell Carcinoma: Clinical Implications. Applied Sciences (Switzerland), 2021, 11, 6930.	1.3	4
594	Sunitinib increases the cancer stem cells and vasculogenic mimicry formation via modulating the lncRNA-ECVSR/ERÎ²/Hif2-Î± signaling. Cancer Letters, 2022, 524, 15-28.	3.2	20
595	Key sunitinibâ€related biomarkers for renal cell carcinoma. Cancer Medicine, 2021, 10, 6917-6930.	1.3	11

#	Article	IF	Citations
596	A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma. European Urology, 2021, 80, 162-170.	0.9	41
597	Preclinical activity of cobimetinib alone or in combination with chemotherapy and targeted therapies in renal cell carcinoma. Future Oncology, 2021, 17, 3051-3060.	1.1	3
598	MiR-224-5p Targeting OCLN Promotes the Proliferation, Migration, and Invasion of Clear Cell Renal Cell Carcinoma Cells. Urologia Internationalis, 2021, , 1-10.	0.6	2
599	The Significance of INHBE Expression in the Cancer Cells of Clear-Cell Renal Cell Carcinoma. Urologia Internationalis, 2022, 106, 376-386.	0.6	3
600	Prognostic factors for overall survival in patients with clear cell metastatic renal cell carcinoma. Medicine (United States), 2021, 100, e26826.	0.4	2
601	Metabolic reprogramming in renal cancer: Events of a metabolic disease. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188559.	3.3	57
602	SHARPIN regulates the development of clear cell renal cell carcinoma by promoting von Hippelâ€Lindau protein ubiquitination and degradation. Cancer Science, 2021, 112, 4100-4111.	1.7	8
603	SNHG16 promotes cell proliferation and inhibits cell apoptosis via regulation of the miR-1303-p/STARD9 axis in clear cell renal cell carcinoma. Cellular Signalling, 2021, 84, 110013.	1.7	10
604	Overall Survival of Biopsy-confirmed T1B and T2A Kidney Cancers Managed With Observation: Prognostic Value of Tumor Histology. Clinical Genitourinary Cancer, 2021, 19, 280-287.	0.9	0
605	Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study. Clinical Genitourinary Cancer, 2021, 19, 354-361.	0.9	5
606	Selective analysis of interferon-alpha in human serum with boronate affinity oriented imprinting based plastic antibody. Talanta, 2021, 230, 122338.	2.9	6
608	Epigenetic Biomarkers of Renal Cell Carcinoma for Liquid Biopsy Tests. International Journal of Molecular Sciences, 2021, 22, 8846.	1.8	16
609	A novel Apigenin derivative suppresses renal cell carcinoma via directly inhibiting wild-type and mutant MET. Biochemical Pharmacology, 2021, 190, 114620.	2.0	6
610	Immune Checkpoint Inhibitor in First-Line Treatment of Metastatic Renal Cell Carcinoma: A Review of Current Evidence and Future Directions. Frontiers in Oncology, 2021, 11, 707214.	1.3	26
611	LncRNA POU3F3 Promotes Cancer Cell Proliferation, Migration, and Invasion in Renal Cell Carcinoma by Downregulating LncRNA GAS5. Kidney and Blood Pressure Research, 2021, 46, 1-7.	0.9	1
612	Six RNA binding proteins (RBPs) related prognostic model predicts overall survival for clear cell renal cell carcinoma and it is associated with immune infiltration. Bosnian Journal of Basic Medical Sciences, 2021, , .	0.6	5
614	Bioinformatics analysis reveals biomarkers with cancer stem cell characteristics in kidney renal clear cell carcinoma. Translational Andrology and Urology, 2021, 10, 3501-3514.	0.6	0
615	Integrating HECW1 expression into the clinical indicators exhibits high accuracy in assessing the prognosis of patients with clear cell renal cell carcinoma. BMC Cancer, 2021, 21, 890.	1.1	7

#	Article	IF	Citations
616	A robust ferroptosis-related gene signature predicts overall survival in clear cell renal cell carcinoma. Future Oncology, 2021, 17, 4321-4341.	1.1	1
617	KPNA2 promotes renal cell carcinoma proliferation and metastasis via NPM. Journal of Cellular and Molecular Medicine, 2021, 25, 9255-9267.	1.6	2
618	Chromophobe Renal Cell Carcinoma of a Renal Allograft. American Journal of Case Reports, 2021, 22, e933168.	0.3	2
619	Combined Angio-CT Systems: A Roadmap Tool for Precision Therapy in Interventional Oncology. Radiology Imaging Cancer, 2021, 3, e210039.	0.7	8
621	Up-regulation expression and prognostic significance of Syntaxin4 in kidney renal clear cell carcinoma. BMC Cancer, 2021, 21, 992.	1.1	2
622	Induction of mitochondrial-dependent apoptosis by essential oil of Toona sinensis root through Akt, mTOR and NF-Î¹B signalling pathways in human renal cell carcinoma cells. Journal of Food and Drug Analysis, 2021, 29, 433-447.	0.9	2
623	Resolution-based distillation for efficient histology image classification. Artificial Intelligence in Medicine, 2021, 119, 102136.	3.8	19
624	PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance. Journal of Experimental and Clinical Cancer Research, 2021, 40, 308.	3.5	23
625	CD44 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma. Anticancer Research, 2021, 41, 4875-4883.	0.5	9
626	Deregulation of N6-Methyladenosine RNA Modification and Its Erasers FTO/ALKBH5 among the Main Renal Cell Tumor Subtypes. Journal of Personalized Medicine, 2021, 11, 996.	1.1	20
627	Downregulation of PPA2 expression correlates with poor prognosis of kidney renal clear cell carcinoma. PeerJ, 2021, 9, e12086.	0.9	2
628	Transvaginal natural orifice specimen extraction surgery (NOSES) in 3D laparoscopic partial or radical nephrectomy: a preliminary study. BMC Urology, 2021, 21, 123.	0.6	5
629	Development and Validation of Prognostic Nomogram for Young Patients with Kidney Cancer. International Journal of General Medicine, 2021, Volume 14, 5091-5103.	0.8	4
630	A costimulatory molecule-related signature in regard to evaluation of prognosis and immune features for clear cell renal cell carcinoma. Cell Death Discovery, 2021, 7, 252.	2.0	11
631	Loss of Von Hippelâ€“Lindau (VHL) Tumor Suppressor Gene Function: VHLâ€“HIF Pathway and Advances in Treatments for Metastatic Renal Cell Carcinoma (RCC). International Journal of Molecular Sciences, 2021, 22, 9795.	1.8	32
632	Overexpression of IRF3 Predicts Poor Prognosis in Clear Cell Renal Cell Carcinoma. International Journal of General Medicine, 2021, Volume 14, 5675-5692.	0.8	10
633	Construction of a Novel Immune-Related lncRNA Pair Signature with Prognostic Significance for Kidney Clear Cell Renal Cell Carcinoma. Disease Markers, 2021, 2021, 1-17.	0.6	10
634	Identification of Hub Genes Associated With Clear Cell Renal Cell Carcinoma by Integrated Bioinformatics Analysis. Frontiers in Oncology, 2021, 11, 726655.	1.3	15

#	Article	IF	Citations
635	Influence of Histologic Types and Subtypes on Survival Outcomes of Intermediate-High and High-Risk Renal Cell Carcinoma Following Nephrectomy: Findings From the SEER Database. Urology, 2022, 159, 146-151.	0.5	1
636	Biomarker Screening and Prognostic Significance Analysis for Renal Cell Carcinoma. International Journal of General Medicine, 2021, Volume 14, 5255-5267.	0.8	11
637	Renal Lipid Metabolism Abnormalities in Obesity and Clear Cell Renal Cell Carcinoma. Metabolites, 2021, 11, 608.	1.3	13
638	Heterogeneous miRNA-mRNA Regulatory Networks of Visceral and Subcutaneous Adipose Tissue in the Relationship Between Obesity and Renal Clear Cell Carcinoma. Frontiers in Endocrinology, 2021, 12, 713357.	1.5	1
639	Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 837.e9-837.e17.	0.8	3
640	Genetic Analysis Reveals the Important Role of the APC Gene in Clear Cell Renal Cell Carcinoma. Anticancer Research, 2021, 41, 4295-4304.	0.5	1
641	Morphological and hemodynamic analysis of the patient-specific renal cell carcinoma models. Journal of Biomechanics, 2021, 126, 110636.	0.9	0
642	Genomic analysis uncovers prognostic and immunogenic characteristics of ferroptosis for clear cell renal cell carcinoma. Molecular Therapy - Nucleic Acids, 2021, 25, 186-197.	2.3	29
643	The RNA N6-Methyladenosine Methyltransferase METTL3 Promotes the Progression of Kidney Cancer via N6-Methyladenosine-Dependent Translational Enhancement of ABCD1. Frontiers in Cell and Developmental Biology, 2021, 9, 737498.	1.8	22
644	Ferroptosis is involved in the antiâ€tumor effect of lycorine in renal cell carcinoma cells. Oncology Letters, 2021, 22, 781.	0.8	15
645	Development and Validation of an IL6/JAK/STAT3-Related Gene Signature to Predict Overall Survival in Clear Cell Renal Cell Carcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 686907.	1.8	11
646	Redoxâ€sensitive signaling pathways in renal cell carcinoma. BioFactors, 2022, 48, 342-358.	2.6	8
647	The Uniqueness of Clear Cell Renal Cell Carcinoma: Summary of the Process and Abnormality of Glucose Metabolism and Lipid Metabolism in ccRCC. Frontiers in Oncology, 2021, 11, 727778.	1.3	31
648	USP39 promotes malignant proliferation and angiogenesis of renal cell carcinoma by inhibiting VEGF-A165b alternative splicing via regulating SRSF1 and SRPK1. Cancer Cell International, 2021, 21, 486.	1.8	15
649	Effect of MAP3K8 on Prognosis and Tumor-Related Inflammation in Renal Clear Cell Carcinoma. Frontiers in Genetics, 2021, 12, 674613.	1.1	6
650	The Clinical Relevance and Tumor Promoting Function of C19orf10 in Kidney Renal Clear Cell Carcinoma. Frontiers in Oncology, 2021, 11, 725959.	1.3	3
651	Anti-neoplastic and demethylating activity of a newly synthetized flavanone-derived compound in Renal Cell Carcinoma cell lines. Biomedicine and Pharmacotherapy, 2021, 141, 111681.	2.5	2
652	MMP25-AS1/hsa-miR-10a-5p/SERPINE1 axis as a novel prognostic biomarker associated with immune cell infiltration in KIRC. Molecular Therapy - Oncolytics, 2021, 22, 307-325.	2.0	24

#	Article	IF	Citations
653	P53 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma. Anticancer Research, 2021, 41, 4287-4294.	0.5	6
654	Aberrant activation of m6A demethylase FTO renders HIF2Î± ^{low/â^'} clear cell renal cell carcinoma sensitive to BRD9 inhibitors. Science Translational Medicine, 2021, 13, eabf6045.	5.8	28
655	Identification of a Novel Epigenetic Signature CHFR as a Potential Prognostic Gene Involved in Metastatic Clear Cell Renal Cell Carcinoma. Frontiers in Genetics, 2021, 12, 720979.	1.1	1
656	Serum markers change for intraocular metastasis in renal cell carcinoma. Bioscience Reports, 2021, 41, .	1.1	3
657	The Construction and Analysis of ceRNA Network and Immune Infiltration in Kidney Renal Clear Cell Carcinoma. Frontiers in Genetics, 2021, 12, 667610.	1.1	14
658	Novel Molecular Subtypes and Related Score Based on Histone Acetylation Modification in Renal Clear Cell Carcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 668810.	1.8	3
659	Dietary therapeutic treatment of renal carcinoma cell lines by down-regulating cFlip, Mcl-1, Bcl-XL and STAT3 gene expression under the influence of up-regulated Bax and intrinsic apoptotic pathway. Food Bioscience, 2021, 43, 101319.	2.0	3
660	The MicroRNA Prediction Models as Ancillary Diagnosis Biomarkers for Urothelial Carcinoma in Patients With Chronic Kidney Disease. Frontiers in Medicine, 2021, 8, 726214.	1.2	1
661	Prognostic significance of hemoglobin-to-red cell distribution width ratio in patients with metastatic renal cancer. Future Oncology, 2021, 17, 3853-3864.	1.1	17
662	Prognostic relevance of ABO blood group system in non-metastatic renal cell carcinoma: An analysis of two independent European cohorts with long-term follow-up. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 736.e9-736.e16.	0.8	2
663	Nuclear and stromal expression of Manic fringe in renal cell carcinoma. Experimental and Molecular Pathology, 2021, 122, 104667.	0.9	4
664	Treatment strategy for myocarditis in patients using immune checkpoint inhibitors or combined anti-vascular endothelial growth factor therapy by clinical severity. European Journal of Cancer, 2021, 157, 10-20.	1.3	4
665	Analgesic use and the risk of renal cell carcinoma â€“ Findings from the Consortium for the Investigation of Renal Malignancies (CONFIRM) study. Cancer Epidemiology, 2021, 75, 102036.	0.8	1
666	Mitochondrial dysfunction in kidney diseases. , 2021, , 119-154.		0
668	Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report. Medicines (Basel, Switzerland), 2021, 8, 5.	0.7	2
669	A Risk Score Model Based on Nine Differentially Methylated mRNAs for Predicting Prognosis of Patients with Clear Cell Renal Cell Carcinoma. Disease Markers, 2021, 2021, 1-11.	0.6	3
670	T cells expanded from renal cell carcinoma display tumor-specific CD137 expression but lack significant IFN-Î³, TNF-Î± or IL-2 production. OncoImmunology, 2021, 10, 1860482.	2.1	16
672	Renal Cell Carcinoma Detection and Subtyping with Minimal Point-Based Annotation in Whole-Slide Images. Lecture Notes in Computer Science, 2020, , 439-448.	1.0	19

#	Article	IF	Citations
673	The Roles of Cullin-2 E3 Ubiquitin Ligase Complex in Cancer. Advances in Experimental Medicine and Biology, 2020, 1217, 173-186.	0.8	12
674	Clinical use of vascular endothelial growth factor receptor inhibitors for the treatment of renal cell carcinoma. European Journal of Medicinal Chemistry, 2020, 200, 112482.	2.6	14
675	Long non-conding RNA LOXL1-AS1 sponges miR-589-5p to up-regulate CBX5 expression in renal cell carcinoma. Bioscience Reports, 2020, 40, .	1.1	16
676	Prognostic significance of proteomics and multi-omics studies in renal carcinoma. Expert Review of Proteomics, 2020, 17, 323-334.	1.3	3
677	Contemporary Characterization and Recategorization of Adult Unclassified Renal Cell Carcinoma. American Journal of Surgical Pathology, 2021, 45, 450-462.	2.1	7
679	Role of AMPK/mTOR-independent autophagy in clear cell renal cell carcinoma. Journal of Investigative Medicine, 2020, 68, 1386-1393.	0.7	6
680	Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma. JCI Insight, 2017, 2, .	2.3	89
681	Construction of a novel gene-based model for prognosis prediction of clear cell renal cell carcinoma. Cancer Cell International, 2020, 20, 27.	1.8	103
682	Integrated Analysis of Three Publicly Available Gene Expression Profiles Identified Genes and Pathways Associated with Clear Cell Renal Cell Carcinoma. Medical Science Monitor, 2020, 26, e919965.	0.5	2
683	Expression and Prognostic Significance of Cadherin 4 (CDH4) in Renal Cell Carcinoma. Medical Science Monitor, 2020, 26, e922836.	0.5	7
684	Overexpression of PKMYT1 Facilitates Tumor Development and Is Correlated with Poor Prognosis in Clear Cell Renal Cell Carcinoma. Medical Science Monitor, 2020, 26, e926755.	0.5	10
685	Exploiting the circuit breaker cancer evolution model in human clear cell renal cell carcinoma. Cell Stress, 2020, 4, 191-198.	1.4	3
686	To Be or â€œNodeâ€•to Be: Nodal Disease and the Role of Lymphadenectomy in the Treatment of Renal Cell Carcinoma. Medical Research Archives, 2020, 8, .	0.1	4
687	MiR-223-3p promotes cell proliferation and metastasis by downregulating SLC4A4 in clear cell renal cell carcinoma. Aging, 2019, 11, 615-633.	1.4	64
688	LINC00511 promotes the malignant phenotype of clear cell renal cell carcinoma by sponging microRNA-625 and thereby increasing cyclin D1 expression. Aging, 2019, 11, 5975-5991.	1.4	25
689	A cluster of long non-coding RNAs exhibit diagnostic and prognostic values in renal cell carcinoma. Aging, 2019, 11, 9597-9615.	1.4	31
690	Identification of an immune-related risk signature for predicting prognosis in clear cell renal cell carcinoma. Aging, 2020, 12, 2302-2332.	1.4	48
691	Identification of biomarkers related to CD8+ T cell infiltration with gene co-expression network in clear cell renal cell carcinoma. Aging, 2020, 12, 3694-3712.	1.4	51

#	Article	IF	Citations
692	Discovery and validation of the prognostic value of the lncRNAs encoding snoRNAs in patients with clear cell renal cell carcinoma. Aging, 2020, 12, 4424-4444.	1.4	31
693	PTX3 modulates the immunoflogosis in tumor microenvironment and is a prognostic factor for patients with clear cell renal cell carcinoma. Aging, 2020, 12, 7585-7602.	1.4	78
694	Circular RNA DHX33 promotes malignant behavior in ccRCC by targeting miR-489-3p/MEK1 axis. Aging, 2020, 12, 14885-14896.	1.4	17
695	SYNE1 mutation may enhance the response to immune checkpoint blockade therapy in clear cell renal cell carcinoma patients. Aging, 2020, 12, 19316-19324.	1.4	19
696	Identification of novel prognostic biomarkers in renal cell carcinoma. Aging, 2020, 12, 25304-25318.	1.4	10
697	The prognostic significance of nuclear expression of PHF2 and C/EBPÎ± in clear cell renal cell carcinoma with consideration of adipogenic metabolic evolution. Oncotarget, 2018, 9, 142-151.	0.8	8
698	Low neighbor of Brca1 gene expression predicts poor clinical outcome and resistance of sunitinib in clear cell renal cell carcinoma. Oncotarget, 2017, 8, 94819-94833.	0.8	8
699	Survival prediction of kidney renal papillary cell carcinoma by comprehensive LncRNA characterization. Oncotarget, 2017, 8, 110811-110829.	0.8	21
700	The glucose and lipid metabolism reprogramming is grade-dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation. Oncotarget, 2017, 8, 113502-113515.	0.8	95
701	Discovery of lipid biomarkers correlated with disease progression in clear cell renal cell carcinoma using desorption electrospray ionization imaging mass spectrometry. Oncotarget, 2019, 10, 1688-1703.	0.8	37
702	Is active surveillance an option for metachronous metastatic renal cell carcinoma?. Annals of Translational Medicine, 2019, 7, 84-84.	0.7	3
703	C3, C3AR1, HLA-DRA, and HLA-E as potential prognostic biomarkers for renal clear cell carcinoma. Translational Andrology and Urology, 2020, 9, 2640-2656.	0.6	9
704	Targeting Strategies for Renal Cancer Stem Cell Therapy. Current Pharmaceutical Design, 2020, 26, 1964-1978.	0.9	10
705	Targeted Delivery of Therapeutics to Urological Cancer Stem Cells. Current Pharmaceutical Design, 2020, 26, 2038-2056.	0.9	6
706	Association of ATG7 Polymorphisms and Clear Cell Renal Cell Carcinoma Risk. Current Molecular Medicine, 2019, 19, 40-47.	0.6	6
707	Increased Nicotinamide Phosphoribosyltransferase and Cystathionine-Î²-Synthase in Renal Oncocytomas, Renal Urothelial Carcinoma, and Renal Clear Cell Carcinoma. Anticancer Research, 2017, 37, 3423-3427.	0.5	26
708	Integrative Analysis of lncRNAs in Kidney Cancer to Discover A New lncRNA () as A Therapeutic Target for Staphylococcal Enterotoxin Gene. Cell Journal, 2020, 22, 101-109.	0.2	9
709	Clinically relevant GSKâ€'3Î² inhibitor 9â€'INGâ€'41 is active as a single agent and in combination with other antitumor therapies in human renal cancer. International Journal of Molecular Medicine, 2020, 45, 315-323.	1.8	12

#	Article	IF	Citations
710	Different immunological effects of the molecular targeted agents sunitinib, everolimus and temsirolimus in patients with renal cell carcinoma. International Journal of Oncology, 2020, 56, 999-1013.	1.4	5
711	MicroRNAâ€'663 inhibits the proliferation and invasion of clear cell renal cell carcinoma cells by directly targeting PAK4. Molecular Medicine Reports, 2019, 19, 711-718.	1.1	3
712	Knockdown of long noncoding RNA DLEU1 suppresses the progression of renal cell carcinoma by downregulating the Akt pathway. Molecular Medicine Reports, 2019, 20, 4551-4557.	1.1	10
713	Expression of the Sonic Hedgehog pathway components in clear cell renal cell carcinoma. Oncology Letters, 2019, 18, 5801-5810.	0.8	11
714	Cell proliferation is induced in renal cell carcinoma through miRâ€'92aâ€'3p upregulation by targeting FBXW7. Oncology Letters, 2020, 19, 3258-3268.	0.8	12
715	Upregulation of lncRNA AGAP2â€'AS1 is an independent predictor of poor survival in patients with clear cell renal carcinoma. Oncology Letters, 2020, 19, 3993-4001.	0.8	14
716	Integrated bioinformatics analysis for the identification of potential key genes affecting the pathogenesis of clear cell renal cell carcinoma. Oncology Letters, 2020, 20, 1573-1584.	0.8	6
717	Impact of inflammation and immunotherapy in renal cell carcinoma (Review). Oncology Letters, 2020, 20, 1-1.	0.8	19
718	miRâ€'142â€'5p promotes renal cell tumorigenesis by targeting TFAP2B. Oncology Letters, 2020, 20, 324.	0.8	8
719	Renal cell carcinoma drug and cell therapy: today and tomorrow. Research Results in Pharmacology, 2018, 4, 17-25.	0.3	1
720	Powerful quantifiers for cancer transcriptomics. World Journal of Clinical Oncology, 2020, 11, 679-704.	0.9	6
721	Bioinformatic analysis identifies potentially key differentially expressed genes in oncogenesis and progression of clear cell renal cell carcinoma. PeerJ, 2019, 7, e8096.	0.9	14
722	Microenvironment-related gene TNFSF13B predicts poor prognosis in kidney renal clear cell carcinoma. PeerJ, 2020, 8, e9453.	0.9	7
723	Identification of DNA methylation patterns and biomarkers for clear-cell renal cell carcinoma by multi-omics data analysis. PeerJ, 2020, 8, e9654.	0.9	7
724	Expression and Clinical Significance of TOP2A in Clear Renal Cell Carcinoma Based on Bioinformatics Database. Advances in Clinical Medicine, 2021, 11, 4470-4479.	0.0	1
725	ISPRF: a machine learning model to predict the immune subtype of kidney cancer samples by four genes. Translational Andrology and Urology, 2021, 10, 3773-3786.	0.6	6
726	Renal Cancer. UNIPA Springer Series, 2021, , 755-774.	0.1	1
727	A new prognostic risk model based on autophagy-related genes in kidney renal clear cell carcinoma. Bioengineered, 2021, 12, 7805-7819.	1.4	9

#	Article	IF	Citations
728	Pan-cancer analysis and experiments with cell lines reveal that the slightly elevated expression of DLGAP5 is involved in clear cell renal cell carcinoma progression. Life Sciences, 2021, 287, 120056.	2.0	55
729	Prognostic Value of Metabolism-Related Genes and Immune Infiltration in Clear Cell Renal Cell Carcinoma. International Journal of General Medicine, 2021, Volume 14, 6885-6898.	0.8	1
730	Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma: Is There Still a Debate?. Current Urology Reports, 2021, 22, 54.	1.0	6
731	Single-Cell RNA Sequencing in Multiple Pathologic Types of Renal Cell Carcinoma Revealed Novel Potential Tumor-Specific Markers. Frontiers in Oncology, 2021, 11, 719564.	1.3	47
732	Selfâ€reported quality of life as a predictor of mortality in renal cell carcinoma. Cancer, 2022, 128, 479-486.	2.0	3
733	A novel prognostic cancer-related lncRNA signature in papillary renal cell carcinoma. Cancer Cell International, 2021, 21, 545.	1.8	9
734	Emerging Role of Neuropilin-1 and Angiotensin-Converting Enzyme-2 in Renal Carcinoma-Associated COVID-19 Pathogenesis. Infectious Disease Reports, 2021, 13, 902-909.	1.5	6
735	Coffee consumption and risk of renal cancer: a meta-analysis of cohort evidence. Cancer Causes and Control, 2021, , 1.	0.8	7
736	Clinical significance of novel DNA methylation biomarkers for renal clear cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2022, 148, 361-375.	1.2	12
737	Histone deacetylase 3 (HDAC3) as an important epigenetic regulator of kidney diseases. Journal of Molecular Medicine, 2022, 100, 43-51.	1.7	12
738	The long non-coding RNA NNT-AS1 promotes clear cell renal cell carcinoma progression via regulation of the miR-137/ Y-box binding protein 1 axis. Bioengineered, 2021, 12, 8994-9005.	1.4	9
739	Histone demethylase KDM4D inhibition suppresses renal cancer progression and angiogenesis through JAG1 signaling. Cell Death Discovery, 2021, 7, 284.	2.0	6
740	Immune Signatures Combined With BRCA1-Associated Protein 1 Mutations Predict Prognosis and Immunotherapy Efficacy in Clear Cell Renal Cell Carcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 747985.	1.8	2
741	Common Diagnostic Challenges and Pitfalls in Genitourinary Organs, With Emphasis on Immunohistochemical and Molecular Updates. Archives of Pathology and Laboratory Medicine, 2021, 145, 1387-1404.	1.2	2
742	Computational study of effective matrix metalloproteinase 9 (MMP9) targeting natural inhibitors. Aging, 2021, 13, 22867-22882.	1.4	9
743	A Novel ZNF304/miR-183-5p/FOXO4 Pathway Regulates Cell Proliferation in Clear Cell Renal Carcinoma. Frontiers in Oncology, 2021, 11, 710525.	1.3	9
744	Risk Scores Based on Six Survival-Related RNAs in a Competing Endogenous Network Composed of Differentially Expressed RNAs Between Clear Cell Renal Cell Carcinoma Patients Carrying Wild-Type or Mutant Von Hippelâ€“Lindau Serve Well to Predict Malignancy and Prognosis. Frontiers in Oncology, 2021, 11, 726671.	1.3	0
745	MiRNA-424-5p Suppresses Proliferation, Migration, and Invasion of Clear Cell Renal Cell Carcinoma and Attenuates Expression of O-GlcNAc-Transferase. Cancers, 2021, 13, 5160.	1.7	10

#	Article	IF	Citations
746	The Downregulation of Prognosis- and Immune Infiltration-Related Gene CYFIP2 Serves as a Novel Target in ccRCC. International Journal of General Medicine, 2021, Volume 14, 6587-6599.	0.8	11
747	Screening Novel Drug Candidates for Kidney Renal Clear Cell Carcinoma Treatment: A Study on Differentially Expressed Genes through the Connectivity Map Database. Kidney and Blood Pressure Research, 2021, 46, 702-713.	0.9	0
748	Histological (Sub)Classifications and Their Prognostic Impact in Renal Cell Carcinoma. , 2017, , 1-17.		0
751	Renal Cell Carcinoma Presenting as an Ampullary Mass: A Case Report and Review of Literature. Gastroenterology Research, 2018, 11, 231-234.	0.4	2
752	Quelle stratÃ©gie thÃ©rapeutique pour les stades mÃ©tastatiques ?. Oncologie, 2018, 20, 211-219.	0.2	0
753	The path to Â« the Golden Age Â» for the treatment of metastatic renal cell carcinoma. Oncotarget, 2018, 9, 31564-31565.	0.8	0
755	Kidney Cancer: From Basics to Immunotherapy. , 2019, , 625-657.		0
756	Histological (Sub)Classifications and Their Prognostic Impact in Renal Cell Carcinoma. , 2019, , 537-553.		0
757	The Hippo Pathway Effector TAZ Regulates Ferroptosis in Renal Cell Carcinoma. SSRN Electronic Journal, 0, , .	0.4	3
758	Incidental Renal Cell Carcinoma in Pelvic Malignancies. Cureus, 2019, 11, e3829.	0.2	1
759	Neoplastic Pathogenesis Associated with Cigarette Carcinogens. Cureus, 2019, 11, e3955.	0.2	9
761	Noncoding RNAs and Its Implication as Biomarkers in Renal Cell Carcinoma: A Systematic Analysis. Annals of Urologic Oncology, 2019, , 1-11.	0.0	1
763	Clinical Profile of Renal Cell CarcinomaA Retrospective Descriptive Study. Journal of Evolution of Medical and Dental Sciences, 2019, 8, 2500-2503.	0.1	0
766	Real-world evidence on first-line treatment for metastatic renal cell carcinoma with non-clear cell and sarcomatoid histologies: are sunitinib and pazopanib interchangeable?. Ecancermedicalscience, 2019, 13, 973.	0.6	1
772	Downregulation of CIP2A inhibits cancer cell proliferation and vascularization in renal clear cell carcinoma. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2020, 164, 196-202.	0.2	4
773	Von Hippel-Lindau syndrome and renal tumours: radiological diagnostic and treatment options. AÂcase report and literature review. Acta Medica Lituanica, 2020, 27, 25-32.	0.2	0
774	Leukocyte telomere length and hTERT genetic polymorphism rs2735940 influence the renal cell carcinoma clinical outcome. Future Oncology, 2020, 16, 1245-1255.	1.1	2
776	Synchronous sporadic bilateral multiple chromophobe renal cell carcinoma accompanied by a clear cell carcinoma and a cyst: A case report. World Journal of Clinical Cases, 2020, 8, 3064-3073.	0.3	1

#	Article	IF	Citations
777	Nobiletin inhibits viability of human renal carcinoma cells via the JAK2/STAT3 and PI3K/Akt pathway. Cellular and Molecular Biology, 2020, 66, 199-203.	0.3	6
778	Xanthogranulomatous Pyelonephritis and Its Differential Diagnoses: An In-Depth Case Review. Cureus, 2021, 13, e19133.	0.2	1
779	Prognostic Significance of Membranous Carbonic Anhydrase IX Expression in Patients with Nonmetastatic Clear Cell Renal Cell Carcinoma of Different Tumor Stages. Cancer Biotherapy and Radiopharmaceuticals, 2021, , .	0.7	1
780	Natural history of Von Hippelâ€“Lindau disease-associated and sporadic clear cell renal cell carcinoma: a comparative study. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2631-2641.	1.2	5
781	Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study. Acta OncolÃ³gica, 2022, 61, 22-29.	0.8	17
782	Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis. Current Opinion in Urology, 2022, 32, 61-68.	0.9	7
783	ESMO guidelines on Renal Cell Carcinoma: the paradox of the fine line that separates scientific robustness from cost-efficiency analysis. Annals of Oncology, 2021, 32, 1466-1467.	0.6	1
784	68Ga-EMP-100 PET/CTâ€”a novel ligand for visualizing c-MET expression in metastatic renal cell carcinomaâ€”first in-human biodistribution and imaging results. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1711-1720.	3.3	15
785	Comprehensive Multi-Omics Identification of Interferon-Î³ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma. Frontiers in Immunology, 2021, 12, 734646.	2.2	13
787	The expression and prognostic value of RNA binding proteins in clear cell renal cell carcinoma. Translational Cancer Research, 2020, 9, 7415-7431.	0.4	5
788	Emerging Therapies for Advanced Clear Cell Renal Cell Carcinoma. Journal of Kidney Cancer and VHL, 2020, 7, 17-26.	0.2	7
789	Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study. Anti-Cancer Drugs, 2021, 32, 74-81.	0.7	4
790	The natural extract degalactotigonin exerts antitumor effects on renal cell carcinoma cells through repressing YAP. Translational Cancer Research, 2020, 9, 7550-7561.	0.4	3
791	Circ_101341 Deteriorates the Progression of Clear Cell Renal Cell Carcinoma Through the miR-411/EGLN3 Axis. Cancer Management and Research, 2020, Volume 12, 13513-13525.	0.9	9
792	Overexpression of chemokine receptor lymphotactin receptor 1 has prognostic value in clear cell renal cell carcinoma. Molecular Genetics & Genomic Medicine, 2021, 9, e1551.	0.6	0
793	Clinical Study of Three-Dimensional Laparoscopic Partial Nephrectomy for the Treatment of Highly Complex Renal Tumors with RENAL Nephrometry Scores of â‰¥10 Points. BioMed Research International, 2020, 2020, 1-6.	0.9	3
794	Concomitant Drug Treatment and Elimination in the RCC-affected Kidneys: Can We Kill Two Birds with One Stone?. Current Drug Metabolism, 2020, 21, 1009-1021.	0.7	1
795	Ancillary Studies Applied to Renal Masses. , 2020, , 209-243.		0

#	Article	IF	Citations
796	Renal cell carcinoma arising in an open pyelolithotomy scar: A perplexing scenario!. Journal of Current Oncology, 2020, 3, 93.	0.2	0
799	RHBDF2 gene functions are correlated to facilitated renal clear cell carcinoma progression. Cancer Cell International, 2021, 21, 590.	1.8	6
800	AQP9 Is a Prognostic Factor for Kidney Cancer and a Promising Indicator for M2 TAM Polarization and CD8+ T-Cell Recruitment. Frontiers in Oncology, 2021, 11, 770565.	1.3	12
801	Establishment of a prognosis Prediction Model Based on Pyroptosis-Related Signatures Associated With the Immune Microenvironment and Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 755212.	1.3	21
802	Lipid metabolism reprogramming in renal cell carcinoma. Cancer and Metastasis Reviews, 2022, 41, 17-31.	2.7	37
803	PIWI-interacting RNA 57125 restrains clear cell renal cell carcinoma metastasis by downregulating CCL3 expression. Cell Death Discovery, 2021, 7, 333.	2.0	6
804	Development and validation of ferroptosis-related lncRNAs prognosis signatures in kidney renal clear cell carcinoma. Cancer Cell International, 2021, 21, 591.	1.8	16
805	Immunosuppressive peculiarities of stromal cells of various kidney tumor types. Onkourologiya, 2020, 16, 29-35.	0.1	4
806	Aryl hydrocarbon receptor nuclear translocator promotes the proliferation and invasion of clear cell renal cell carcinoma cells potentially by affecting the glycolytic pathway. Oncology Letters, 2020, 20, 56.	0.8	2
808	The efficacy of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma exhibiting primary resistance to front-line targeted therapy or immunotherapy. Onkourologiya, 2020, 16, 53-61.	0.1	0
809	MiR-514a-3p inhibits cell proliferation and epithelial-mesenchymal transition by targeting EGFR in clear cell renal cell carcinoma. American Journal of Translational Research (discontinued), 2017, 9, 5332-5346.	0.0	8
810	Interferon-induced IFIT5 promotes epithelial-to-mesenchymal transition leading to renal cancer invasion. American Journal of Clinical and Experimental Urology, 2019, 7, 31-45.	0.4	11
811	miR-625-3p promotes migration and invasion and reduces apoptosis of clear cell renal cell carcinoma. American Journal of Translational Research (discontinued), 2019, 11, 6475-6486.	0.0	6
812	BAP1 maintains chromosome stability by stabilizing DIDO1 in renal cell carcinoma. American Journal of Cancer Research, 2020, 10, 1455-1466.	1.4	4
813	Transcription factor NFYA promotes G1/S cell cycle transition and cell proliferation by transactivating cyclin D1 and CDK4 in clear cell renal cell carcinoma. American Journal of Cancer Research, 2020, 10, 2446-2463.	1.4	6
814	Laparoscopic cytoreductive nephrectomy is associated with significantly improved survival compared with open cytoreductive nephrectomy or targeted therapy alone. Molecular and Clinical Oncology, 2020, 13, 71.	0.4	0
815	TRIP13 predicts poor prognosis in clear cell renal cell carcinoma. American Journal of Cancer Research, 2020, 10, 2909-2918.	1.4	0
816	MicroRNAâ€‘218 inhibits tumor angiogenesis of human renal cell carcinoma by targeting GAB2. Oncology Reports, 2020, 44, 1961-1970.	1.2	3

#	Article	IF	Citations
817	Ubiquitin ligase KLHL2 promotes the degradation and ubiquitination of ARHGEF7 protein to suppress renal cell carcinoma progression. American Journal of Cancer Research, 2020, 10, 3345-3357.	1.4	3
818	Prognostic value of leukocyte telomere length in renal cell carcinoma patients. American Journal of Cancer Research, 2020, 10, 3428-3439.	1.4	1
819	Oncogenic potential of macrophageâ€‘capping protein in clear cell renal cell carcinoma. Molecular Medicine Reports, 2021, 23, .	1.1	0
820	Identification and biological characteristics of clear cell renal cell carcinoma associated urine-derived stem cells. American Journal of Translational Research (discontinued), 2021, 13, 2143-2162.	0.0	2
821	LINC00671 inhibits renal cell cancer progression via regulating miR-221-5p/SOCS1 axis. American Journal of Translational Research (discontinued), 2021, 13, 7524-7537.	0.0	2
822	Albumin levels predict prognosis in advanced renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 12.e13-12.e22.	0.8	6
824	Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma. Cancers, 2021, 13, 5856.	1.7	39
825	Inhibition of DCLK1 with DCLK1-IN-1 Suppresses Renal Cell Carcinoma Invasion and Stemness and Promotes Cytotoxic T-Cell-Mediated Anti-Tumor Immunity. Cancers, 2021, 13, 5729.	1.7	18
826	CircESRP1 inhibits clear cell renal cell carcinoma progression through the CTCF-mediated positive feedback loop. Cell Death and Disease, 2021, 12, 1081.	2.7	14
827	Machine learning-based CT radiomics approach for predicting WHO/ISUP nuclear grade of clear cell renal cell carcinoma: an exploratory and comparative study. Insights Into Imaging, 2021, 12, 170.	1.6	24
828	Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study. International Journal of Clinical Oncology, 2022, 27, 154-164.	1.0	16
829	ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma. Oncology Reports, 2021, 47, .	1.2	17
830	Manufacturing Process Development for Belzutifan, Part 4: Nitrogen Flow Criticality for Transfer Hydrogenation Control. Organic Process Research and Development, 2022, 26, 533-542.	1.3	18
831	From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma. Cells, 2021, 10, 3231.	1.8	18
832	Construction of diagnostic and subtyping models for renal cell carcinoma by genome-wide DNA methylation profiles. Translational Andrology and Urology, 2021, 10, 4161-4172.	0.6	3
833	Patterns of first-line targeted therapy utilization and adherence among older adults diagnosed with metastatic renal cell carcinoma. Journal of Geriatric Oncology, 2021, , .	0.5	1
834	Identification of SOX6 and SOX12 as Prognostic Biomarkers for Clear Cell Renal Cell Carcinoma: A Retrospective Study Based on TCGA Database. Disease Markers, 2021, 2021, 1-17.	0.6	1
835	Pazopanib-induced severe acute liver injury. Medicine (United States), 2021, 100, e27731.	0.4	5

#	Article	IF	Citations
836	Identification TRIM46 as a Potential Biomarker and Therapeutic Target for Clear Cell Renal Cell Carcinoma Through Comprehensive Bioinformatics Analyses. Frontiers in Medicine, 2021, 8, 785331.	1.2	2
837	Methyltransferaseâ€like 14 suppresses growth and metastasis of renal cell carcinoma by decreasing long noncoding RNA NEAT1. Cancer Science, 2022, 113, 446-458.	1.7	35
838	Integrative Analysis of Immune-Related Genes in the Tumor Microenvironment of Renal Clear Cell Carcinoma and Renal Papillary Cell Carcinoma. Frontiers in Molecular Biosciences, 2021, 8, 760031.	1.6	6
839	Circular RNAs in renal cell carcinoma: Functions in tumorigenesis and diagnostic and prognostic potentials. Pathology Research and Practice, 2022, 229, 153720.	1.0	20
840	Telmisartan-Induced Cytotoxicity <i>via</i> G₂/M Phase Arrest in Renal Cell Carcinoma Cell Lines. Biological and Pharmaceutical Bulletin, 2021, 44, 1878-1885.	0.6	2
841	Gene expression and oxidative stress markers profile associated with toxic metals in patients with renal cell carcinoma. Molecular Biology Reports, 2021, , 1.	1.0	7
842	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma. ESMO Open, 2021, 6, 100304.	2.0	14
843	Promising Therapeutic Targets in Kidney Renal Clear Cell Carcinoma: PLXNA1 and PLXNB3. Cancer Biotherapy and Radiopharmaceuticals, 2021, , .	0.7	1
845	Epigenetic inactivation of ACAT1 promotes epithelial-mesenchymal transition of clear cell renal cell carcinoma. Genes and Genomics, 2022, , 1.	0.5	2
846	Abnormal Iron and Lipid Metabolism Mediated Ferroptosis in Kidney Diseases and Its Therapeutic Potential. Metabolites, 2022, 12, 58.	1.3	39
847	Laparoscopic cytoreductive nephrectomy is associated with significantly improved survival compared with open cytoreductive nephrectomy or targeted therapy alone. Molecular and Clinical Oncology, 2020, 13, 1-1.	0.4	3
848	MicroRNAâ€‘218 inhibits tumor angiogenesis of human renal cell carcinoma by targeting GAB2. Oncology Reports, 2020, 44, 1961-1970.	1.2	11
849	Oncogenic potential of macrophageâ€‘capping protein in clear cell renal cell carcinoma. Molecular Medicine Reports, 2020, 23, .	1.1	6
850	KIF4A is a promising prognostic marker and correlates with immune infiltration in clear cell renal cell carcinoma. Translational Cancer Research, 2020, 9, 7165-7173.	0.4	2
851	Novel emerging biomarkers to immunotherapy in kidney cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110593.	1.4	12
852	Prognostic Immunophenotyping Clusters of Clear Cell Renal Cell Carcinoma Defined by the Unique Tumor Immune Microenvironment. Frontiers in Cell and Developmental Biology, 2021, 9, 785410.	1.8	12
853	Effects of betulinic acid on AKT/mTOR pathway in renal cell carcinoma. , 2022, 48, 58-63.		0
854	Gene Expression Analysis of Aggressive Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical Stage T1N0M0 to Identify Potential Prognostic and Therapeutic Biomarkers. Biomedicines, 2022, 10, 321.	1.4	1

#	Article	IF	Citations
855	Utilisation of virtual non-contrast images and virtual mono-energetic images acquired from dual-layer spectral CT for renal cell carcinoma: image quality and radiation dose. Insights Into Imaging, 2022, 13, 12.	1.6	19
856	Toll-Like Receptors Serve as Biomarkers for Early Diagnosis and Prognosis Assessment of Kidney Renal Clear Cell Carcinoma by Influencing the Immune Microenvironment: Comprehensive Bioinformatics Analysis Combined With Experimental Validation. Frontiers in Molecular Biosciences, 2022, 9, 832238.	1.6	8
857	Identification of adhesion-associated extracellular matrix component thrombospondin 3 as a prognostic signature for clear cell renal cell carcinoma. Investigative and Clinical Urology, 2022, 63, 107.	1.0	1
858	<scp>PINTology</scp>: A short history of the <scp>lncRNA LINCâ€PINT</scp> in different diseases. Wiley Interdisciplinary Reviews RNA, 2022, 13, e1705.	3.2	11
859	Treatment of kidney clear cell carcinoma, lung adenocarcinoma and glioblastoma cell lines with hydrogels made of DNA nanostars. Biomaterials Science, 2022, 10, 1304-1316.	2.6	6
860	Multi-Omics Profiling to Assess Signaling Changes upon VHL Restoration and Identify Putative VHL Substrates in Clear Cell Renal Cell Carcinoma Cell Lines. Cells, 2022, 11, 472.	1.8	8
861	Inflammation-Related Gene Signature: An Individualized Risk Prediction Model for Kidney Renal Clear Cell Carcinoma. Journal of Oncology, 2022, 2022, 1-23.	0.6	4
863	Micro-RNA378a-3p Induces Apoptosis in Sarcomatoid Renal Cell Carcinoma and Regulates POLR2A and RUNX2 Expression. Anticancer Research, 2022, 42, 811-825.	0.5	1
864	T and NK cell abundance defines two distinct subgroups of renal cell carcinoma. OncoImmunology, 2022, 11, 1993042.	2.1	16
865	Investigating Urinary Circular RNA Biomarkers for Improved Detection of Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 814228.	1.3	7
866	Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I. Human Mutation, 2022, 43, 316-327.	1.1	8
867	An Integrative Analysis Framework for Identifying the Prognostic Markers from Multidimensional RNA Data of Clear Cell Renal Cell Carcinoma. American Journal of Pathology, 2022, 192, 671-686.	1.9	0
869	<scp>M2â€polarization</scp>â€related <scp>CNTNAP1</scp> gene might be a novel immunotherapeutic target and biomarker for clear cell renal cell carcinoma. IUBMB Life, 2022, 74, 391-407.	1.5	7
870	A Ferroptosis-Related Genes Model Allows for Prognosis and Treatment Stratification of Clear Cell Renal Cell Carcinoma: A Bioinformatics Analysis and Experimental Verification. Frontiers in Oncology, 2022, 12, 815223.	1.3	8
871	Contrast enhanced multiparametric ultrasound of solid kidney lesions in comparison with the computed tomography. Diagnostic Radiology and Radiotherapy, 2022, 12, 74-82.	0.0	0
872	Identification of MICALL2 as a Novel Prognostic Biomarker Correlating with Inflammation and T Cell Exhaustion of Kidney Renal Clear Cell Carcinoma. Journal of Cancer, 2022, 13, 1214-1228.	1.2	4
873	Angioprevention of Urologic Cancers by Plant-Derived Foods. Pharmaceutics, 2022, 14, 256.	2.0	11
874	Spindle pole body component 24 homolog potentiates tumor progression via regulation of SRYâ€box transcription factor 2 in clear cell renal cell carcinoma. FASEB Journal, 2022, 36, e22086.	0.2	0

#	Article	IF	Citations
876	miR-21-5p serves as a promoter in renal cell carcinoma progression through ARHGAP24 downregulation. Environmental Science and Pollution Research, 2022, 29, 39985-39993.	2.7	3
877	Deubiquitylase OTUD6B stabilizes the mutated pVHL and suppresses cell migration in clear cell renal cell carcinoma. Cell Death and Disease, 2022, 13, 97.	2.7	11
878	The Human Leukocyte Antigen G as an Immune Escape Mechanism and Novel Therapeutic Target in Urological Tumors. Frontiers in Immunology, 2022, 13, 811200.	2.2	7
879	Co-expression network analysis for renal cell carcinoma genes and in vitro confirmation of their expression in cell model in the presence of curcumin. Gene Reports, 2022, 26, 101525.	0.4	0
880	A Double-Negative Feedback Interaction between miR-21 and PPAR-Î± in Clear Renal Cell Carcinoma. Cancers, 2022, 14, 795.	1.7	8
881	Downregulation of Manic fringe impedes angiogenesis and cell migration of renal carcinoma. Microvascular Research, 2022, 142, 104341.	1.1	3
882	Decrease of Intracellular Glutamine by STF-62247 Results in the Accumulation of Lipid Droplets in von Hippel-Lindau Deficient Cells. Frontiers in Oncology, 2022, 12, 841054.	1.3	2
883	SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes. Nature Cancer, 2022, 3, 188-202.	5.7	26
884	As a prognostic biomarker of clear cell renal cell carcinoma RUFY4 predicts immunotherapy responsiveness in a PDL1-related manner. Cancer Cell International, 2022, 22, 66.	1.8	2
885	Epsteinâ€“Barr virus infection is associated with the nuclear factor-kappa B p65 signaling pathway in renal cell carcinoma. BMC Urology, 2022, 22, 17.	0.6	6
886	Circular RNAs and Drug Resistance in Genitourinary Cancers: A Literature Review. Cancers, 2022, 14, 866.	1.7	5
887	Real-World Experience with Nivolumab in Metastatic Renal Cell Carcinoma Patients Who Have Progressed on Prior Therapies: A Single-Center Study from India. South Asian Journal of Cancer, 0, , .	0.2	0
888	Risk of toxicity with immunotherapyâ€“tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials. Future Oncology, 2022, 18, 625-634.	1.1	4
889	Technical challenges of lymphadenectomy in renal carcinoma performed with a 3D laparoscopic approach at a low pressure pneumoperitoneum due to associated pulmonary pathology â€“ case report. Medicine and Pharmacy Reports, 0, , .	0.2	0
890	FCER1G positively relates to macrophage infiltration in clear cell renal cell carcinoma and contributes to unfavorable prognosis by regulating tumor immunity. BMC Cancer, 2022, 22, 140.	1.1	16
891	Claudin-10 overexpression suppresses human clear cell renal cell carcinoma growth and metastasis by regulating ATP5O and causing mitochondrial dysfunction. International Journal of Biological Sciences, 2022, 18, 2329-2344.	2.6	6
892	A Comparative Study of Data Mining Techniques Applied to Renal-Cell Carcinomas. Lecture Notes of the Institute for Computer Sciences, Social-Informatics and Telecommunications Engineering, 2022, , 53-62.	0.2	0
893	A potential impact of A Disintegrin and Metalloproteinase DomainLike Protein Decysin-1 (ADAMDEC1) on clear cell renal cell carcinoma propagation. Biocell, 2022, 46, 1-9.	0.4	1

#	Article	IF	Citations
894	The RNF26/CBX7 axis modulates the TNF pathway to promote cell proliferation and regulate sensitivity to TKIs in ccRCC. International Journal of Biological Sciences, 2022, 18, 2132-2145.	2.6	12
895	Pathophysiology roles and translational opportunities of miRNAs in renal cancer. , 2022, , 271-280.		0
896	TIMP1 Indicates Poor Prognosis of Renal Cell Carcinoma and Accelerates Tumorigenesis via EMT Signaling Pathway. Frontiers in Genetics, 2022, 13, 648134.	1.1	10
897	Gradeâ€dependent changes in sphingolipid metabolism in clear cell renal cell carcinoma. Journal of Cellular Biochemistry, 2022, , .	1.2	7
898	DLEU7-AS1 promotes renal cell cancer by silencing the miR-26a-5p/coronin-3 axis. CKJ: Clinical Kidney Journal, 0, , .	1.4	1
899	Construction of a Lactate-Related Prognostic Signature for Predicting Prognosis, Tumor Microenvironment, and Immune Response in Kidney Renal Clear Cell Carcinoma. Frontiers in Immunology, 2022, 13, 818984.	2.2	32
900	Influential Factors and Personalized Prediction Model of Acute Pain Trajectories after Surgery for Renal Cell Carcinoma. Journal of Personalized Medicine, 2022, 12, 360.	1.1	1
901	PTEN loss confers sensitivity to rapalogs in clear cell renal cell carcinoma. Acta Pharmacologica Sinica, 2022, 43, 2397-2409.	2.8	5
902	Elevated SNRPA1, as a Promising Predictor Reflecting Severe Clinical Outcome via Effecting Tumor Immunity for ccRCC, Is Related to Cell Invasion, Metastasis, and Sunitinib Sensitivity. Frontiers in Immunology, 2022, 13, 842069.	2.2	10
903	The Histone Acetyltransferase MOF Regulates SIRT1 Expression to Suppress Renal Cell Carcinoma Progression. Frontiers in Oncology, 2022, 12, 842967.	1.3	4
904	LncRNA GAS5 rs145204276 Polymorphism Reduces Renal Cell Carcinoma Susceptibility in Southern Chinese Population. Journal of Inflammation Research, 2022, Volume 15, 1147-1158.	1.6	2
905	Matrix Metalloproteinase-10 in Kidney Injury Repair and Disease. International Journal of Molecular Sciences, 2022, 23, 2131.	1.8	5
906	Application of Regulatory Cell Death in Cancer: Based on Targeted Therapy and Immunotherapy. Frontiers in Immunology, 2022, 13, 837293.	2.2	23
907	Adipogenic Transdifferentiation and Regulatory Factors Promote the Progression and the Immunotherapy Response of Renal Cell Carcinoma: Insights From Integrative Analysis. Frontiers in Oncology, 2022, 12, 781932.	1.3	4
908	Proposal of sialyl Lewis x/a as prognostic biomarkers in clear cell renal cell carcinoma: A study on a cohort of 117 patients submitted to curative surgery. Journal of Clinical Urology, 0, , 205141582210828.	0.1	0
909	LncRNA FAM13A-AS1 Promotes Renal Carcinoma Tumorigenesis Through Sponging miR-141-3p to Upregulate NEK6 Expression. Frontiers in Molecular Biosciences, 2022, 9, 738711.	1.6	7
910	Identification of a Methylation-Regulating Genes Prognostic Signature to Predict the Prognosis and Aid Immunotherapy of Clear Cell Renal Cell Carcinoma. Frontiers in Cell and Developmental Biology, 2022, 10, 832803.	1.8	2
911	Clear cell renal cell carcinoma with stage IV cavoatrial tumour thrombus extension and rapid metastatic reoccurrence postsurgical treatment with review of current treatment strategies. BMJ Case Reports, 2022, 15, e248156.	0.2	1

#	Article	IF	Citations
912	Systematic Analysis of the Expression and Prognosis of FcÎ³ Receptors in Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2022, 12, 755936.	1.3	3
913	A novel nine-microRNA-based model to improve prognosis prediction of renal cell carcinoma. BMC Cancer, 2022, 22, 264.	1.1	5
914	Whole-Exome Sequencing Identifies the VHL Mutation (c.262T > C, p.Try88Arg) in Non-Obstructive Azoospermia-Associated Cystic Renal Cell Carcinoma. Current Oncology, 2022, 29, 2376-2384.	0.9	3
915	Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer. , 2022, 10, e003883.		13
916	Identification of Novel Prognostic Signatures for Clear Cell Renal Cell Carcinoma Based on ceRNA Network Construction and Immune Infiltration Analysis. Disease Markers, 2022, 2022, 1-28.	0.6	4
917	Grainyhead-like (Grhl) Target Genes in Development and Cancer. International Journal of Molecular Sciences, 2022, 23, 2735.	1.8	8
918	Cabozantinib for Treatment of Brain Metastases in Patients With Renal Cell Carcinoma. JAMA Oncology, 2022, , .	3.4	0
919	Renal Cell Cancer and Obesity. International Journal of Molecular Sciences, 2022, 23, 3404.	1.8	13
920	SIRT7 is a Prognostic Biomarker in Kidney Renal Clear Cell Carcinoma That is Correlated with Immune Cell Infiltration. International Journal of General Medicine, 2022, Volume 15, 3167-3182.	0.8	0
921	The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma. Journal of Oncology, 2022, 2022, 1-5.	0.6	0
923	Cardiotoxicity Induced by Protein Kinase Inhibitors in Patients with Cancer. International Journal of Molecular Sciences, 2022, 23, 2815.	1.8	15
924	Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma. Cancer Research, 2022, 82, 2610-2624.	0.4	24
925	A Novel Gene Signature of Tripartite Motif Family for Predicting the Prognosis in Kidney Renal Clear Cell Carcinoma and Its Association With Immune Cell Infiltration. Frontiers in Oncology, 2022, 12, 840410.	1.3	2
926	Circ_0003146 upregulates SCARB1 expression by acting as a miR-1272 sponge to promote malignant behaviors of clear cell renal cell carcinoma. Anti-Cancer Drugs, 2022, 33, 564-574.	0.7	2
927	Zafirlukast Induces VHL- and HIF-2Î±-Dependent Oxidative Cell Death in 786-O Clear Cell Renal Carcinoma Cells. International Journal of Molecular Sciences, 2022, 23, 3567.	1.8	6
928	Impact of Circadian Rhythms on the Development and Clinical Management of Genitourinary Cancers. Frontiers in Oncology, 2022, 12, 759153.	1.3	5
929	The miRNA-21-5p Payload in Exosomes from M2 Macrophages Drives Tumor Cell Aggression via PTEN/Akt Signaling in Renal Cell Carcinoma. International Journal of Molecular Sciences, 2022, 23, 3005.	1.8	17
930	Metabolism-Related Signature Analysis Uncovers the Prognostic and Immunotherapeutic Characteristics of Renal Cell Carcinoma. Frontiers in Molecular Biosciences, 2022, 9, 837145.	1.6	0

#	Article	IF	Citations
931	Expression levels of sonic hedgehog pathway genes and their targets are upregulated in early clear cell renal cell carcinoma. International Journal of Molecular Medicine, 2022, 49, .	1.8	13
932	METTL14-mediated N6-methyladenosine modification of ITGB4 mRNA inhibits metastasis of clear cell renal cell carcinoma. Cell Communication and Signaling, 2022, 20, 36.	2.7	16
933	Tumor-Educated Platelets as a Promising Biomarker for Blood-Based Detection of Renal Cell Carcinoma. Frontiers in Oncology, 2022, 12, 844520.	1.3	9
934	A Web-Based Prediction Model for Cancer-Specific Survival of Elderly Patients With Clear Cell Renal Cell Carcinoma: A Population-Based Study. Frontiers in Public Health, 2021, 9, 833970.	1.3	7
935	Key Prognostic Value of Lysosomal Protein Transmembrane 5 in Kidney Renal Clear Cell Carcinoma. International Journal of General Medicine, 2022, Volume 15, 2515-2527.	0.8	0
936	Nanoparticles targeting at methylases with high correlation to N6-methyladenosine-related lncRNA signatures as potential therapy of kidney clear cell carcinoma. Chinese Chemical Letters, 2022, 33, 4610-4616.	4.8	13
937	Successful apatinib treatment for advanced clear cell renal carcinoma as a first-line palliative treatment: A case report. World Journal of Clinical Cases, 2022, 10, 3593-3600.	0.3	1
938	Polyphenols and Their Metabolites in Renal Diseases: An Overview. Foods, 2022, 11, 1060.	1.9	15
939	Nivolumab, nivolumabâ€“ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Lancet Oncology, The, 2022, 23, 612-624.	5.1	66
940	Epigenetic activation of RBM15 promotes clear cell renal cell carcinoma growth, metastasis and macrophage infiltration by regulating the m6A modification of CXCL11. Free Radical Biology and Medicine, 2022, 184, 135-147.	1.3	24
941	Prediction of drug candidates for clear cell renal cell carcinoma using a systems biology-based drug repositioning approach. EBioMedicine, 2022, 78, 103963.	2.7	11
942	The atypical sphingosine 1â€phosphate variant, d16:1 S1P, mediates CTGF induction via S1P2 activation in renal cell carcinoma. FEBS Journal, 2022, , .	2.2	3
943	Models of Renal Cell Carcinoma Used to Investigate Molecular Mechanisms and Develop New Therapeutics. Frontiers in Oncology, 2022, 12, 871252.	1.3	8
944	Microphysiological model of renal cell carcinoma to inform anti-angiogenic therapy. Biomaterials, 2022, 283, 121454.	5.7	9
945	LZTS2: A novel and independent prognostic biomarker for clear cell renal cell carcinoma. Pathology Research and Practice, 2022, 232, 153831.	1.0	0
946	Development and Validation of a Nomogram to Predict Cancer-Specific Survival in Elderly Patients With Papillary Renal Cell Carcinoma. Frontiers in Public Health, 2022, 10, 874427.	1.3	5
947	DRAM1 plays a tumor suppressor role in clear cell renal cell carcinoma through modulating Akt signaling. Acta Histochemica, 2022, 124, 151874.	0.9	0
948	Preparation of magnetic nanoparticles-assisted plasmonic biosensors with metal affinity for interferon-Î± detection. Materials Science and Engineering B: Solid-State Materials for Advanced Technology, 2022, 280, 115687.	1.7	11

#	Article	IF	Citations
950	AGAP2-AS1 as a prognostic biomarker in low-risk clear cell renal cell carcinoma patients with progressing disease. Cancer Cell International, 2021, 21, 690.	1.8	7
951	Circular RNA circPPP6R3 upregulates CD44 to promote the progression of clear cell renal cell carcinoma via sponging miR-1238-3p. Cell Death and Disease, 2022, 13, 22.	2.7	14
952	Identification of a Novel Defined Immune-Autophagy-Related Gene Signature Associated With Clinical and Prognostic Features of Kidney Renal Clear Cell Carcinoma. Frontiers in Molecular Biosciences, 2021, 8, 790804.	1.6	6
953	Identification of a competing endogenous RNA network related to immune signature in clear cell renal cell carcinoma. Aging, 2021, 13, 25980-26002.	1.4	4
954	Systematic Pan-Cancer Analysis of KIF23 and a Prediction Model Based on KIF23 in Clear Cell Renal Cell Carcinoma (ccRCC). Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 1717-1729.	0.4	4
955	The Role of Critical N6-Methyladenosine-Related Long Non-Coding RNAs and Their Correlations with Immune Checkpoints in Renal Clear Cell Carcinoma. International Journal of General Medicine, 2021, Volume 14, 9773-9787.	0.8	5
956	CD8+ T Cell-Based Molecular Classification With Heterogeneous Immunogenomic Landscapes and Clinical Significance of Clear Cell Renal Cell Carcinoma. Frontiers in Immunology, 2021, 12, 745945.	2.2	11
957	Characterization of Genetic Heterogeneity in Recurrent Metastases of Renal Cell Carcinoma. Cancers, 2021, 13, 6221.	1.7	1
958	MiRNAs as Anti-Angiogenic Adjuvant Therapy in Cancer: Synopsis and Potential. Frontiers in Oncology, 2021, 11, 705634.	1.3	11
959	Wavelength Independent Photoâ€Chemo Triâ€Modal Combinatorial Renal Cell Carcinoma Therapy with Biocompatible Goldâ€Titania Nanostars. Advanced Therapeutics, 2022, 5, 2100204.	1.6	0
960	MCM2-7 in Clear Cell Renal Cell Carcinoma: MCM7 Promotes Tumor Cell Proliferation. Frontiers in Oncology, 2021, 11, 782755.	1.3	13
961	Pharmacokinetic Drug Interaction Study of Sorafenib and Morphine in Rats. Pharmaceutics, 2021, 13, 2172.	2.0	6
962	External Validation of the Prognostic Value of an Immune-Associated Gene Panel for Clear Cell Renal Cell Carcinomas. Frontiers in Cell and Developmental Biology, 2021, 9, 794840.	1.8	2
963	FGL1 as a Novel Mediator and Biomarker of Malignant Progression in Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 756843.	1.3	8
965	Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: aÂmeta-analysis. Immunotherapy, 2022, 14, 617-625.	1.0	3
966	Prediction of overall survival based upon a new ferroptosis-related gene signature in patients with clear cell renal cell carcinoma. World Journal of Surgical Oncology, 2022, 20, 120.	0.8	11
967	Prognostic Significance of Pre- to Postoperative Dynamics of Sarcopenia for Patients with Renal Cell Carcinoma Undergoing Laparoscopic Nephrectomy. Frontiers in Surgery, 2022, 9, 871731.	0.6	3
968	Front-Line Therapy for Metastatic Renal Cell Carcinoma: A Perspective on the Current Algorithm and Future Directions. Cancers, 2022, 14, 2049.	1.7	7

#	Article	IF	Citations
969	A proteogenomic analysis of clear cell renal cell carcinoma in a Chinese population. Nature Communications, 2022, 13, 2052.	5.8	48
970	RNA-seq and Mitochondrial DNA Analysis of Adrenal Gland Metastatic Tissue in a Patient with Renal Cell Carcinoma. Biology, 2022, 11, 589.	1.3	1
971	Identification of HGD and GSTZ1 as Biomarkers Involved Metabolic Reprogramming in Kidney Renal Clear Cell Carcinoma. International Journal of Molecular Sciences, 2022, 23, 4583.	1.8	5
972	Prognostic and Diagnostic Values of Semaphorin 5B and Its Correlation With Tumor-Infiltrating Immune Cells in Kidney Renal Clear-Cell Carcinoma. Frontiers in Genetics, 2022, 13, 835355.	1.1	2
973	The clinical significance of epigenetic and RNAPII variabilities occurring in clear cell renal cell carcinoma as a potential prognostic marker. Translational Oncology, 2022, 20, 101420.	1.7	4
1034	68Ga-PSMA-11 PET/CT Parameter Correlates with Pathological VEGFR-2/PDGFR-Î² Expression in Renal Cell Carcinoma Patients. Molecular Imaging and Biology, 2022, 24, 759-768.	1.3	3
1035	ORP5 promotes tumor metastasis via stabilizing c-Met in renal cell carcinoma. Cell Death Discovery, 2022, 8, 219.	2.0	5
1036	A Novel Prognostic Ferroptosis-Related Long Noncoding RNA Signature in Clear Cell Renal Cell Carcinoma. Journal of Oncology, 2022, 2022, 1-16.	0.6	7
1037	Prognostic significance of circulating insulin growth-like factor 1 and insulin growth-like factor binding protein 3 in renal cell carcinoma patients.. American Journal of Cancer Research, 2022, 12, 852-860.	1.4	0
1038	Renal cell carcinoma-derived exosomes deliver lncARSR to induce macrophage polarization and promote tumor progression via STAT3 pathway. International Journal of Biological Sciences, 2022, 18, 3209-3222.	2.6	37
1039	Bioinformatic Analysis Identifying PSMB 1/2/3/4/6/8/9/10 as Prognostic Indicators in Clear Cell Renal Cell Carcinoma. International Journal of Medical Sciences, 2022, 19, 796-812.	1.1	5
1040	Transient Receptor Potential Channel 1 Potentially Serves as a Biomarker Indicating T/TNM Stages and Predicting Long-Term Prognosis in Patients With Renal Cell Carcinoma. Frontiers in Surgery, 2022, 9, 853310.	0.6	3
1041	Functional deficiency of succinate dehydrogenase promotes tumorigenesis and development of clear cell renal cell carcinoma through weakening of ferroptosis. Bioengineered, 2022, 13, 11187-11207.	1.4	15
1043	A Novel Machine Learning 13-Gene Signature: Improving Risk Analysis and Survival Prediction for Clear Cell Renal Cell Carcinoma Patients. Cancers, 2022, 14, 2111.	1.7	12
1044	Advances in the Structural and Physiological Functions of SHARPIN. Frontiers in Immunology, 2022, 13, 858505.	2.2	3
1045	DMDRMR promotes angiogenesis via antagonizing DAB2IP in clear cell renal cell carcinoma. Cell Death and Disease, 2022, 13, 456.	2.7	5
1046	Extracellular Vesiclesâ€"A New Potential Player in the Immunology of Renal Cell Carcinoma. Journal of Personalized Medicine, 2022, 12, 772.	1.1	1
1047	Multi-staged gene expression profiling reveals potential genes and the critical pathways in kidney cancer. Scientific Reports, 2022, 12, 7240.	1.6	10

#	Article	IF	Citations
1048	Selenoprotein S regulates tumorigenesis of Clear Cell Renal Cell Carcinoma through AKT/ GSK3Î²/NF-ÎºB signaling pathway. Gene, 2022, , 146559.	1.0	1
1049	Identification and Verification of m7G Modification Patterns and Characterization of Tumor Microenvironment Infiltration via Multi-Omics Analysis in Clear Cell Renal Cell Carcinoma. Frontiers in Immunology, 2022, 13, 874792.	2.2	16
1050	RNF7 inhibits apoptosis and sunitinib sensitivity and promotes glycolysis in renal cell carcinoma via the SOCS1/JAK/STAT3 feedback loop. Cellular and Molecular Biology Letters, 2022, 27, 36.	2.7	10
1051	Early reduction in spectral dual-layer detector CT parameters as favorable imaging biomarkers in patients with metastatic renal cell carcinoma. European Radiology, 2022, 32, 7323-7334.	2.3	5
1052	Comprehensive Analysis of Ferroptosis- and Immune-Related Signatures to Improve the Prognosis and Diagnosis of Kidney Renal Clear Cell Carcinoma. Frontiers in Immunology, 2022, 13, .	2.2	8
1053	Comprehensive analysis of lower mitochondrial complex I expression is associated with cell metastasis of clear cell renal cell carcinoma. Translational Cancer Research, 2022, 11, 1488-1502.	0.4	2
1054	A Defucosylated Mouse Anti-CD10 Monoclonal Antibody (31-mG_{2a}-f) Exerts Antitumor Activity in a Mouse Xenograft Model of Renal Cell Cancers. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2022, 41, 320-327.	0.8	10
1055	Circ_0000274 contributes to renal cell carcinoma progression by regulating miR-338-3p/NUCB2 axis and JAK1/STAT3 pathway. Transplant Immunology, 2022, 74, 101626.	0.6	4
1056	Long Non-Coding RNAs as Novel Biomarkers in the Clinical Management of Papillary Renal Cell Carcinoma Patients: A Promise or a Pledge?. Cells, 2022, 11, 1658.	1.8	6
1057	Special issue â€œThe advance of solid tumor research in Chinaâ€: Multiâ€omics analysis based on 1311 clear cell renal cell carcinoma samples identifies a glycolysis signature associated with prognosis and treatment response. International Journal of Cancer, 2023, 152, 66-78.	2.3	4
1058	A DNA Damage Repair Gene Signature Associated With Immunotherapy Response and Clinical Prognosis in Clear Cell Renal Cell Carcinoma. Frontiers in Genetics, 2022, 13, .	1.1	2
1059	Isolated soft tissue mass of the finger as the first presentation of oligometastatic renal cell carcinoma. BMJ Case Reports, 2022, 15, e248718.	0.2	1
1060	NUF2 Drives Clear Cell Renal Cell Carcinoma by Activating HMGA2 Transcription through KDM2A-mediated H3K36me2 Demethylation. International Journal of Biological Sciences, 2022, 18, 3621-3635.	2.6	6
1061	Expression of GOT2 Is Epigenetically Regulated by DNA Methylation and Correlates with Immune Infiltrates in Clear-Cell Renal Cell Carcinoma. Current Issues in Molecular Biology, 2022, 44, 2472-2489.	1.0	7
1062	Genetic and Epigenetic Mechanisms Deregulate the CRL2pVHL Complex in Hepatocellular Carcinoma. Frontiers in Genetics, 2022, 13, .	1.1	1
1064	Unveiling the Molecular Mechanisms Driving the Capsaicin-Induced Immunomodulatory Effects on PD-L1 Expression in Bladder and Renal Cancer Cell Lines. Cancers, 2022, 14, 2644.	1.7	6
1066	Primary Ewing's sarcoma/primitive neuroectodermal tumor of the kidney and its clinical features. IJU Case Reports, 0, , .	0.1	0
1067	Micro-RNAs Predict Response to Systemic Treatments in Metastatic Renal Cell Carcinoma Patients: Results from a Systematic Review of the Literature. Biomedicines, 2022, 10, 1287.	1.4	10

#	Article	IF	Citations
1068	No Time to Die: How Kidney Cancer Evades Cell Death. International Journal of Molecular Sciences, 2022, 23, 6198.	1.8	8
1069	PBX1, EMCN and ERG are associated with the sub-clusters and the prognosis of VHL mutant clear cell renal cell carcinoma. Scientific Reports, 2022, 12, .	1.6	4
1070	Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma. Frontiers in Immunology, 0, 13, .	2.2	10
1071	Designing optimal allocations for cancer screening using queuing network models. PLoS Computational Biology, 2022, 18, e1010179.	1.5	1
1072	Deep Learning Using CT Images to Grade Clear Cell Renal Cell Carcinoma: Development and Validation of a Prediction Model. Cancers, 2022, 14, 2574.	1.7	10
1073	HLA-I-restricted CD8+ TÂcell immunity may accelerate tumorigenesis in conjunction with VHL inactivation. IScience, 2022, 25, 104467.	1.9	1
1074	Mining database and verification of PIK3CB as a marker predicting prognosis and immune infiltration in renal clear cell carcinoma. Medicine (United States), 2022, 101, e29254.	0.4	2
1075	An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives. Therapeutics and Clinical Risk Management, 0, Volume 18, 619-632.	0.9	5
1076	Identification and Verification of Immune Subtype-Related lncRNAs in Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 0, 12, .	1.3	5
1079	Heterogeneity of Platelet Derived Growth Factor Pathway Gene Expression Profile Defines Three Distinct Subgroups of Renal Cell Carcinomas. Cancer Genomics and Proteomics, 2022, 19, 477-489.	1.0	7
1080	Future treatment options in metastatic clear cell renal cell carcinoma. Bulletin Du Cancer, 2022, 109, 2S47-2S58.	0.6	0
1081	PET/MR Imaging of a Lung Metastasis Model of Clear Cell Renal Cell Carcinoma with (2S,4R)-4-[18F]Fluoroglutamine. Molecular Imaging and Biology, 2022, 24, 959-972.	1.3	2
1083	Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma. Frontiers in Oncology, 0, 12, .	1.3	1
1084	Integrated bioinformatics analysis to identify the key gene associated with metastatic clear cell renal cell carcinoma. , 2022, 39, .		1
1085	A Novel M7G-Related MicroRNAs Risk Signature Predicts the Prognosis and Tumor Microenvironment of Kidney Renal Clear Cell Carcinoma. Frontiers in Genetics, 0, 13, .	1.1	8
1086	Precision Medicine: An Optimal Approach to Patient Care in Renal Cell Carcinoma. Frontiers in Medicine, 0, 9, .	1.2	5
1087	IFI35 Promotes Renal Cancer Progression by Inhibiting pSTAT1/pSTAT6-Dependent Autophagy. Cancers, 2022, 14, 2861.	1.7	4
1088	Circular RNAs as Prognostic Biomarkers in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Frontiers in Genetics, 0, 13, .	1.1	0

#	Article	IF	Citations
1089	Transcriptional and metabolic remodeling in clear cell renal cell carcinoma caused by ATF4 activation and the integrated stress response (ISR). Molecular Carcinogenesis, 2022, 61, 851-864.	1.3	11
1090	<scp>ELOVL5</scp>â€mediated fatty acid elongation promotes cellular proliferation and invasion in renal cell carcinoma. Cancer Science, 2022, 113, 2738-2752.	1.7	14
1091	Use of Circular RNAs in Diagnosis, Prognosis and Therapeutics of Renal Cell Carcinoma. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	5
1092	The predictive accuracy of preoperative erythrocyte count and maximum tumor diameter to maximum kidney diameter ratio in renal cell carcinoma. Translational Andrology and Urology, 2021, .	0.6	0
1093	Nicotinamideâ€Nâ€methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma. Clinical and Translational Medicine, 2022, 12, .	1.7	20
1094	PREDICTING KIDNEY TUMOR SUBTYPE FROM CT IMAGES USING RADIOMICS AND CLINICAL FEATURES. Natural and Applied Sciences Journal, 0, , .	0.2	0
1095	Mutation and tissue lineage lead to organ-specific cancer. Nature, 2022, 606, 871-872.	13.7	1
1096	A Cluster of Metabolic-Related Genes Serve as Potential Prognostic Biomarkers for Renal Cell Carcinoma. Frontiers in Genetics, 0, 13, .	1.1	5
1097	SHMT2 promotes the tumorigenesis of renal cell carcinoma by regulating the m6A modification of PPAT. Genomics, 2022, 114, 110424.	1.3	11
1099	A Novel Prognostic Signature Associated With the Tumor Microenvironment in Kidney Renal Clear Cell Carcinoma. Frontiers in Oncology, 0, 12, .	1.3	4
1100	Patientâ€derived renal cell carcinoma organoids for personalized cancer therapy. Clinical and Translational Medicine, 2022, 12, .	1.7	24
1101	Pyroptosis-Related lncRNA Prognostic Model for Renal Cancer Contributes to Immunodiagnosis and Immunotherapy. Frontiers in Oncology, 0, 12, .	1.3	5
1102	Vasopressin Receptor Type-2 Mediated Signaling in Renal Cell Carcinoma Stimulates Stromal Fibroblast Activation. International Journal of Molecular Sciences, 2022, 23, 7601.	1.8	1
1103	GRAMD1A Is a Biomarker of Kidney Renal Clear Cell Carcinoma and Is Associated with Immune Infiltration in the Tumour Microenvironment. Disease Markers, 2022, 2022, 1-25.	0.6	2
1104	A Fatty Acid Metabolism Signature Associated With Clinical Therapy in Clear Cell Renal Cell Carcinoma. Frontiers in Genetics, 0, 13, .	1.1	5
1105	Aurora-A/FOXO3A/SKP2 axis promotes tumor progression in clear cell renal cell carcinoma and dual-targeting Aurora-A/SKP2 shows synthetic lethality. Cell Death and Disease, 2022, 13, .	2.7	9
1106	Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma. European Journal of Cancer, 2022, 172, 191-198.	1.3	8
1107	Comprehensive Analysis of HMCN1 Somatic Mutation in Clear Cell Renal Cell Carcinoma. Genes, 2022, 13, 1282.	1.0	2

#	Article	IF	Citations
1108	Single-cell multiomics analysis reveals regulatory programs in clear cell renal cell carcinoma. Cell Discovery, 2022, 8, .	3.1	32
1109	FXYD3 Expression Predicts Poor Prognosis in Renal Cell Carcinoma with Immunosuppressive Tumor Microenvironment. Cancers, 2022, 14, 3596.	1.7	3
1110	Comparative Analysis for the Distinction of Chromophobe Renal Cell Carcinoma from Renal Oncocytoma in Computed Tomography Imaging Using Machine Learning Radiomics Analysis. Cancers, 2022, 14, 3609.	1.7	5
1111	Circular RNA circâ€TNPO3 inhibits clear cell renal cell carcinoma metastasis by binding to IGF2BP2 and destabilizing SERPINH1 mRNA. Clinical and Translational Medicine, 2022, 12, .	1.7	25
1112	MicroRNA Processing Pathway-Based Polygenic Score for Clear Cell Renal Cell Carcinoma in the Volga-Ural Region Populations of Eurasian Continent. Genes, 2022, 13, 1281.	1.0	2
1113	Blockade of CD47 enhances the antitumor effect of macrophages in renal cell carcinoma through trogocytosis. Scientific Reports, 2022, 12, .	1.6	1
1114	Knowledge mapping and research hotspots of immunotherapy in renal cell carcinoma: A text-mining study from 2002 to 2021. Frontiers in Immunology, 0, 13, .	2.2	15
1115	Endoplasmic Reticulum Stress-Related Signature Predicts Prognosis and Drug Response in Clear Cell Renal Cell Carcinoma. Frontiers in Pharmacology, 0, 13, .	1.6	7
1116	Vision transformer and explainable transfer learning models for auto detection of kidney cyst, stone and tumor from CT-radiography. Scientific Reports, 2022, 12, .	1.6	54
1118	A Four-MicroRNA Panel in Serum as a Potential Biomarker for Screening Renal Cell Carcinoma. Frontiers in Genetics, 0, 13, .	1.1	3
1119	Interleukin 20 receptor subunit beta (IL20RB) predicts poor prognosis and regulates immune cell infiltration in clear cell renal cell carcinoma. BMC Genomic Data, 2022, 23, .	0.7	3
1120	Management and Health Resource Use of Patients With Metastatic Renal Cell Carcinoma treated With Systemic Therapy Over 2014-2017 in France: A National Real-World Study. Clinical Genitourinary Cancer, 2022, 20, 533-542.	0.9	1
1121	75 YaÅŸ ÃœstÃ¼ Hastalarda BÃ¶brek TÃ¼mÃ¶rlerinin Histopatolojik Ã–zellikleri. MuÄŸla SÄ±tkÄ± KoÃ§man Ã¼niversitesi TÄ±p Dergisi, 0, , .	0.2	0
1122	Identification of Novel Genes and Associated Drugs in Advanced Clear Cell Renal Cell Carcinoma by Bioinformatic Methods. Tohoku Journal of Experimental Medicine, 2022, 258, 79-90.	0.5	3
1123	IL6 and CCL18 Mediate Cross-talk between VHL-Deficient Kidney Cells and Macrophages during Development of Renal Cell Carcinoma. Cancer Research, 2022, 82, 2716-2733.	0.4	7
1124	Survival Improvement in Patients with Renal Cell Carcinoma and Disparities between Different Sexes, Races, and Socioeconomic Status: 1977â€“2016. Journal of Oncology, 2022, 2022, 1-11.	0.6	2
1125	Clinical implications of epigenetics in Renal Cell Carcinoma. Archives of Renal Diseases and Management, 2022, 7, 008-013.	0.3	0
1126	Overexpressed lncRNA FTX promotes the cell viability, proliferation, migration and invasion of renal cell carcinoma via FTX/miRâ€4429/UBE2C axis. Oncology Reports, 2022, 48, .	1.2	10

#	Article	IF	Citations
1127	Molecular Subtyping Based on Cuproptosis-Related Genes and Characterization of Tumor Microenvironment Infiltration in Kidney Renal Clear Cell Carcinoma. Frontiers in Oncology, 0, 12, .	1.3	30
1128	Utilizing Computed Tomography to Analyze the Morphomic Change between Patients with Localized and Metastatic Renal Cell Carcinoma: Body Composition Varies According to Cancer Stage. Journal of Clinical Medicine, 2022, 11, 4444.	1.0	1
1129	Oncogenic Role of miR-217 During Clear Cell Renal Carcinoma Progression. Frontiers in Oncology, 0, 12, .	1.3	8
1130	Establishing a prognostic model of ferroptosis- and immune-related signatures in kidney cancer: A study based on TCGA and ICGC databases. Frontiers in Oncology, 0, 12, .	1.3	2
1131	Genomic alteration of MTAP/CDKN2A predicts sarcomatoid differentiation and poor prognosis and modulates response to immune checkpoint blockade in renal cell carcinoma. Frontiers in Immunology, 0, 13, .	2.2	7
1132	The role of LncRNA MCM3AP-AS1 in human cancer. Clinical and Translational Oncology, 0, , .	1.2	5
1133	Anti-CD40 predominates over anti-CTLA-4 to provide enhanced antitumor response of DC-CIK cells in renal cell carcinoma. Frontiers in Immunology, 0, 13, .	2.2	3
1134	Multiregional single-cell proteogenomic analysis of ccRCC reveals cytokine drivers of intratumor spatial heterogeneity. Cell Reports, 2022, 40, 111180.	2.9	7
1136	Practical identifiability analysis of a mechanistic model for the time to distant metastatic relapse and its application to renal cell carcinoma. PLoS Computational Biology, 2022, 18, e1010444.	1.5	5
1137	IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma. Frontiers in Oncology, 0, 12, .	1.3	5
1138	Delineating the role of extracellular vesicles in cancer metastasis: A comprehensive review. Frontiers in Immunology, 0, 13, .	2.2	8
1139	A Causal Framework for Making Individualized Treatment Decisions in Oncology. Cancers, 2022, 14, 3923.	1.7	9
1140	Clear-cell renal cell carcinoma and glioblastoma multiforme coexistence: Double primary malignancy, does it have a causal relationship?. , 0, 13, 361.		1
1141	Circulating exosomal mRNA signatures for the early diagnosis of clear cell renal cell carcinoma. BMC Medicine, 2022, 20, .	2.3	10
1142	Interleukin 17 and Its Involvement in Renal Cell Carcinoma. Journal of Clinical Medicine, 2022, 11, 4973.	1.0	3
1143	The tumor and plasma cytokine profiles of renal cell carcinoma patients. Scientific Reports, 2022, 12, .	1.6	5
1144	A multiomics disease progression signature of low-risk ccRCC. Scientific Reports, 2022, 12, .	1.6	3
1145	Real-world efficacy of sequential nivolumab for metastatic renal cancer after first-line molecular targeting therapy. Medicine (United States), 2022, 101, e29510.	0.4	0

#	Article	IF	Citations
1146	Transfection with Plasmid-Encoding lncRNA-SLERCC nanoparticle-mediated delivery suppressed tumor progression in renal cell carcinoma. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	16
1147	The SWI/SNF chromatin remodeling factor DPF3 regulates metastasis of ccRCC by modulating TGF-Î² signaling. Nature Communications, 2022, 13, .	5.8	9
1150	Cuproptosis status affects treatment options about immunotherapy and targeted therapy for patients with kidney renal clear cell carcinoma. Frontiers in Immunology, 0, 13, .	2.2	20
1152	Integrated multi-omics analyses reveal that BCAM is associated with epigenetic modification and tumor microenvironment subtypes of clear cell renal cell carcinoma. Clinical Epigenetics, 2022, 14, .	1.8	1
1153	Tumor-associated macrophages promote migration and invasion via modulating IL-6/STAT3 signaling in renal cell carcinoma. International Immunopharmacology, 2022, 111, 109139.	1.7	7
1154	Long Non-coding RNA DLGAP1-AS1 and DLGAP1-AS2: Two Novel Oncogenes in Multiple Cancers. Current Medicinal Chemistry, 2023, 30, 2822-2834.	1.2	0
1155	The evolving view of thermogenic fat and its implications in cancer and metabolic diseases. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	15
1156	Global research trends and foci of artificial intelligence-based tumor pathology: a scientometric study. Journal of Translational Medicine, 2022, 20, .	1.8	29
1157	The core genes of cuproptosis assists in discerning prognostic and immunological traits of clear cell renal cell carcinoma. Frontiers in Oncology, 0, 12, .	1.3	1
1158	Epidemiology of Renal Cell Carcinoma: 2022 Update. European Urology, 2022, 82, 529-542.	0.9	120
1159	A novel nomogram can predict pathological T3a upstaged from clinical T1a in localized renal cell carcinoma. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2022, 48, 784-794.	0.7	4
1160	Renal cell carcinoma management: A step to nano-chemoprevention. Life Sciences, 2022, 308, 120922.	2.0	8
1161	Comprehensive analysis to identify the RP11â€“478C19.2/ E2F7 axis as a novel biomarker for treatment decisions in clear cell renal cell carcinoma. Translational Oncology, 2022, 25, 101525.	1.7	4
1162	Stem Cells and Kidney Regeneration. , 2022, , 115-141.		0
1163	Multi-task Semi-supervised Learning forÂVascular Network Segmentation andÂRenal Cell Carcinoma Classification. Lecture Notes in Computer Science, 2022, , 1-11.	1.0	1
1164	Nierenzellkarzinom. , 2022, , 565-585.		0
1165	Gastric fundic gland metastasis of renal cell carcinoma 14 years after the primary diagnosis. Journal of Cancer Research and Therapeutics, 2022, 18, 1801.	0.3	1
1166	Sanguinarine Targets BRD4 to Suppress Cell Proliferation and Migration in ccRCC. SSRN Electronic Journal, 0, , .	0.4	0

#	Article	IF	Citations
1167	Comprehensive Analysis of Transcriptional Expression of hsa-mir-21 Predicted Target Genes and Immune Characteristics in Kidney Renal Clear Cell Carcinoma. International Journal of Medical Sciences, 2022, 19, 1482-1501.	1.1	2
1168	A Comprehensive Description of Hypoxia-inducible Factor 2Î± Inhibitors as Anticancer Agents: A Mini-review. Current Medicinal Chemistry, 2023, 30, 2835-2849.	1.2	1
1169	Identification of ACSL4 as a biomarker and contributor of ferroptosis in clear cell renal cell carcinoma. Translational Cancer Research, 2022, 11, 2688-2699.	0.4	7
1170	Definition and verification of novel metastasis and recurrence related signatures of ccRCC: A multicohort study. , 2022, 1, 146-167.		2
1171	circFOXO3 Induced by KLF16 Modulates Clear Cell Renal Cell Carcinoma Growth and Natural Killer Cell Cytotoxic Activity through Sponging miR-29a-3p and miR-122-5p. Disease Markers, 2022, 2022, 1-24.	0.6	6
1172	Expression and prognosis analysis of PAQR5 in kidney cancer. Frontiers in Oncology, 0, 12, .	1.3	2
1173	C chemokines are prognostic biomarkers correlated with diverse immune cell infiltrations in clear cell renal cell carcinoma. Translational Cancer Research, 2022, 11, 2501-2522.	0.4	2
1174	Biomarkers in Urological Cancers. , 2022, , 37-76.		0
1175	miR-21-5p/PRKCE axis implicated in immune infiltration and poor prognosis of kidney renal clear cell carcinoma. Frontiers in Genetics, 0, 13, .	1.1	3
1176	Construction and Characterization of n6-Methyladenosine-Related lncRNA Prognostic Signature and Immune Cell Infiltration in Kidney Renal Clear Cell Carcinoma. Journal of Oncology, 2022, 2022, 1-10.	0.6	2
1177	FDX1 expression predicts favourable prognosis in clear cell renal cell carcinoma identified by bioinformatics and tissue microarray analysis. Frontiers in Genetics, 0, 13, .	1.1	7
1178	Identification of key somatic oncogenic mutation based on a confounder-free causal inference model. PLoS Computational Biology, 2022, 18, e1010529.	1.5	1
1179	A cuproptosis-related lncRNA signature identified prognosis and tumour immune microenvironment in kidney renal clear cell carcinoma. Frontiers in Molecular Biosciences, 0, 9, .	1.6	4
1180	Ultrasound-guided in vivo histotripsy in rabbit kidneys using millisecond-length two-stage ultrasound pulses combined with fundamental and second harmonic superposition. Physics in Medicine and Biology, 0, , .	1.6	1
1181	Silencing circFTO inhibits malignant phenotype through modulating DUSP4 expression in clear cell renal cell carcinoma. Cell Death Discovery, 2022, 8, .	2.0	3
1182	GLUD1 suppresses renal tumorigenesis and development via inhibiting PI3K/Akt/mTOR pathway. Frontiers in Oncology, 0, 12, .	1.3	3
1183	Daphnetin: A bioactive natural coumarin with diverse therapeutic potentials. Frontiers in Pharmacology, 0, 13, .	1.6	15
1184	Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma. Expert Review of Anticancer Therapy, 2022, 22, 1049-1059.	1.1	5

#	Article	IF	Citations
1185	Construction and validation of a ferroptosis-related long noncoding RNA signature in clear cell renal cell carcinoma. Cancer Cell International, 2022, 22, .	1.8	4
1186	A new finding for the obesity paradox? Evaluation of the relationship between muscle and adipose tissue in nuclear grade prediction in patients with clear cell renal cell carcinoma. Acta Radiologica, 0, , 028418512211263.	0.5	1
1187	Comprehensive analysis of LAMC1 expression and prognostic value in kidney renal papillary cell carcinoma and clear cell carcinoma. Frontiers in Molecular Biosciences, 0, 9, .	1.6	5
1188	Cuprotosis-related signature predicts overall survival in clear cell renal cell carcinoma. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	5
1189	Multifocal synchronous renal cell carcinoma of three different histologic subtypes: unusual findings and literature review. Journal of Surgical Case Reports, 2022, 2022, .	0.2	0
1190	Development and validation of a novel necroptosis-related score to improve the outcomes of clear cell renal cell carcinoma. Frontiers in Genetics, 0, 13, .	1.1	0
1191	Identification of subtypes of clear cell renal cell carcinoma and construction of a prognostic model based on fatty acid metabolism genes. Frontiers in Genetics, 0, 13, .	1.1	1
1192	CyberKnife Stereotactic Body Radiotherapy as a treatment option for renal cell carcinoma: The complex case of a patient with unilateral renal agenesis. Journal of Onco-Nephrology, 0, , 239936932211233.	0.3	0
1193	Identification and Validation of a Novel Ferroptotic Prognostic Genes-Based Signature of Clear Cell Renal Cell Carcinoma. Cancers, 2022, 14, 4690.	1.7	10
1194	NEK2 Serves as a Novel Biomarker and Enhances the Tumorigenicity of Clear-CellRenal-Cell Carcinoma by Activating WNT/Î²-Catenin Pathway. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-9.	0.5	2
1195	m7G regulator-mediated molecular subtypes and tumor microenvironment in kidney renal clear cell carcinoma. Frontiers in Pharmacology, 0, 13, .	1.6	4
1196	Human herpesvirus 6A and 6B and polyomavirus JC and BK infections in renal cell carcinoma and their relationship with p53, p16INK4a, Kiâ€67, and nuclear factorâ€kappa B expression. Microbiology and Immunology, 0, , .	0.7	0
1197	Identification of novel mycocompounds as inhibitors of PI3K/AKT/mTOR pathway against RCC. Journal of Receptor and Signal Transduction Research, 2022, 42, 599-607.	1.3	1
1198	Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma. International Journal of Urology, 2022, 29, 1419-1428.	0.5	4
1199	A newly defined basement membrane-related gene signature for the prognosis of clear-cell renal cell carcinoma. Frontiers in Genetics, 0, 13, .	1.1	6
1201	Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. Frontiers in Immunology, 0, 13, .	2.2	6
1202	Identification of an amino acid metabolism-associated gene signature predicting the prognosis and immune therapy response of clear cell renal cell carcinoma. Frontiers in Oncology, 0, 12, .	1.3	5
1203	Isoform-resolved mRNA profiling of ribosome load defines interplay of HIF and mTOR dysregulation in kidney cancer. Nature Structural and Molecular Biology, 2022, 29, 871-880.	3.6	6

#	Article	IF	Citations
1204	Crosstalk of necroptosis and pyroptosis defines tumor microenvironment characterization and predicts prognosis in clear cell renal carcinoma. Frontiers in Immunology, 0, 13, .	2.2	6
1205	<scp>BACH1</scp> promotes clear cell renal cell carcinoma progression by upregulating oxidative stressâ€related tumorigenicity. Cancer Science, 2023, 114, 436-448.	1.7	6
1206	A transcriptional metastatic signature predicts survival in clear cell renal cell carcinoma. Nature Communications, 2022, 13, .	5.8	15
1207	Bioinformatics analysis of markers based on m⁶A related to prognosis combined with immune invasion of renal clear cell carcinoma. Cell Biology International, 2023, 47, 260-272.	1.4	6
1208	DHRS7 is an immune-related prognostic biomarker of KIRC and pan-cancer. Frontiers in Genetics, 0, 13, .	1.1	3
1209	Establishment of a ccRCC patient-derived chick chorioallantoic membrane model for drug testing. Frontiers in Medicine, 0, 9, .	1.2	3
1210	Overexpression of CYP11A1 recovers cell cycle distribution in renal cell carcinoma Caki-1. Cancer Cell International, 2022, 22, .	1.8	1
1211	A novel nomogram and risk classification system predicting the overall survival of patients with papillary renal cell carcinoma after nephrectomy: A population-based study. Frontiers in Public Health, 0, 10, .	1.3	1
1212	Energy-Stress-Mediated AMPK Activation Promotes GPX4-Dependent Ferroptosis through the JAK2/STAT3/P53 Axis in Renal Cancer. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-17.	1.9	13
1213	Comprehensive investigation into cuproptosis in the characterization of clinical features, molecular characteristics, and immune situations of clear cell renal cell carcinoma. Frontiers in Immunology, 0, 13, .	2.2	6
1214	Emerging photodynamic/sonodynamic therapies for urological cancers: progress and challenges. Journal of Nanobiotechnology, 2022, 20, .	4.2	9
1215	FTO-mediated autophagy promotes progression of clear cell renal cell carcinoma via regulating SIK2 mRNA stability. International Journal of Biological Sciences, 2022, 18, 5943-5962.	2.6	35
1216	A retrospective single-centered, comprehensive targeted genetic sequencing analysis of prognostic survival using tissues from Korean patients with metastatic renal cell carcinoma after targeted therapy. Investigative and Clinical Urology, 2022, 63, 602.	1.0	0
1217	Chemotherapeutic Protocols for the Treatment of Genitourinary Cancer. , 2022, , 201-231.		0
1219	Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma. Biomedicines, 2022, 10, 2444.	1.4	2
1221	Chlorogenic acid for cancer prevention and therapy: Current status on efficacy and mechanisms of action. Pharmacological Research, 2022, 186, 106505.	3.1	35
1222	A predictive signature based on enhancer RNA associates with immune infiltration and aids treatment decision in clear cell renal cell carcinoma. Frontiers in Oncology, 0, 12, .	1.3	0
1223	Radiomics analysis of contrast-enhanced CT scans can distinguish between clear cell and non-clear cell renal cell carcinoma in different imaging protocols. Frontiers in Medicine, 0, 9, .	1.2	3

#	Article	IF	Citations
1224	Advances in the functions of CTRP6 in the development and progression of the malignancy. Frontiers in Genetics, 0, 13, .	1.1	1
1225	Pyroptosis-Related Gene Signature Predicts the Prognosis of ccRCC Using TCGA and Single-Cell RNA Seq Database. Journal of Healthcare Engineering, 2022, 2022, 1-12.	1.1	1
1226	Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update. Journal of Personalized Medicine, 2022, 12, 1788.	1.1	9
1227	Calreticulin as a prognostic biomarker and correlated with immune infiltrate in kidney renal clear cell carcinoma. Frontiers in Genetics, 0, 13, .	1.1	3
1228	System Biology Approaches Identified Novel Biomarkers and their Signaling Pathways Involved in Renal Cell Carcinoma (RCC) with Different Human Diseases. Bioscience Reports, 0, , .	1.1	1
1230	Novel insight into the functions of N⁶â€˜methyladenosine modified lncRNAs in cancers (Review). International Journal of Oncology, 2022, 61, .	1.4	6
1232	Systematic Analysis of Immune Infiltration and Predicting Prognosis in Clear Cell Renal Cell Carcinoma Based on the Inflammation Signature. Genes, 2022, 13, 1897.	1.0	1
1233	Effects of the Targeted Regulation of CCRK by miR-335-5p on the Proliferation and Tumorigenicity of Human Renal Carcinoma Cells. Journal of Oncology, 2022, 2022, 1-14.	0.6	0
1234	HLGNN-MDA: Heuristic Learning Based on Graph Neural Networks for miRNAâ€“Disease Association Prediction. International Journal of Molecular Sciences, 2022, 23, 13155.	1.8	3
1235	IQGAP3 in clear cell renal cell carcinoma contributes to drug resistance and genome stability. PeerJ, 0, 10, e14201.	0.9	2
1236	PBRM1, SETD2 and BAP1 â€” the trinity of 3p in clear cell renal cell carcinoma. Nature Reviews Urology, 2023, 20, 96-115.	1.9	14
1237	A Potential Fatty Acid Metabolism-Related Gene Signature for Prognosis in Clear Cell Renal Cell Carcinoma. Cancers, 2022, 14, 4943.	1.7	1
1238	Chromatin regulators-related lncRNA signature predicting the prognosis of kidney renal clear cell carcinoma and its relationship with immune microenvironment: A study based on bioinformatics and experimental validation. Frontiers in Genetics, 0, 13, .	1.1	3
1239	PDCD5 inhibits progression of renal cell carcinoma by promoting T cell immunity: with the involvement of the HDAC3/microRNA-195-5p/SGK1. Clinical Epigenetics, 2022, 14, .	1.8	2
1240	Diagnosing, Typing, and Staging of Renal Cell Carcinoma by Designer Matrix-Based Urinary Metabolic Analysis. Analytical Chemistry, 2022, 94, 14846-14853.	3.2	6
1241	The crossâ€talk between Abl2 tyrosine kinase and <scp>TGFÎ²1</scp> signalling modulates the invasion of clear cell Renal Cell Carcinoma cells. FEBS Letters, 2023, 597, 1098-1113.	1.3	21
1242	Treatment of Refractory Metastatic Renal Cell Carcinoma. Cancers, 2022, 14, 5005.	1.7	10
1243	Crosstalk of renal cell carcinoma cells and tumor-associated macrophages aggravates tumor progression by modulating muscleblind-like protein 2/B-cell lymphoma 2/beclin 1-mediated autophagy. Cytotherapy, 2023, 25, 298-309.	0.3	3

#	Article	IF	Citations
1244	DNA Methylation and Epigenetic Events Underlying Renal Cell Carcinomas. Cureus, 2022, , .	0.2	2
1245	Identifying tumor antigens and immune subtypes of renal cell carcinoma for immunotherapy development. Frontiers in Immunology, 0, 13, .	2.2	2
1246	Smart Milli-capsules manipulated by nIR irradiation for controllable drug delivery in-vivo for renal cell carcinoma and neurodegenerative diseases. Materials and Design, 2022, 224, 111287.	3.3	2
1248	The Versatile Role of miR-21 in Renal Homeostasis and Diseases. Cells, 2022, 11, 3525.	1.8	7
1249	Oxidative Phosphorylation-Related Signature Participates in Cancer Development, and PTPRG Overexpression Suppresses the Cancer Progression in Clear Cell Renal Cell Carcinoma. Journal of Immunology Research, 2022, 2022, 1-18.	0.9	1
1250	HAPLN3 inhibits apoptosis and promotes EMT of clear cell renal cell carcinoma via ERK and Bcl-2 signal pathways. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	4
1251	Stereotactic Body Radiotherapy for Localized Kidney Cancer. Current Urology Reports, 2022, 23, 371-381.	1.0	3
1252	NEK2 is associated with poor prognosis of clear cell renal cell carcinoma and promotes tumor cell growth and metastasis. Gene, 2023, 851, 147040.	1.0	1
1254	Sustained release system of paclitaxel based on composite nanofibers for inhibiting renal clear cell carcinoma. Journal of Materials Science, 0, , .	1.7	0
1255	CircSCNN1A is a tumor suppressor in renal cell carcinoma via inducing the upregulation of MPP7 by the sponge effect on miR-421. Transplant Immunology, 2022, 75, 101736.	0.6	1
1256	Prostate-specific membrane antigen expression in clear-cell renal cell carcinoma: An angiogenic marker with clinicopathologic significance. Egyptian Journal of Pathology, 2022, 42, 11.	0.0	0
1257	Diagnostic and Prognostic Biomarkers in Renal Clear Cell Carcinoma. Biomedicines, 2022, 10, 2953.	1.4	10
1258	Prognostic model for clear-cell renal cell carcinoma based on natural killer cell-related genes.. Clinical Genitourinary Cancer, 2022, , .	0.9	1
1259	Computed tomographyâ€based radiomics prediction of <scp>CTLA4</scp> expression and prognosis in clear cell renal cell carcinoma. Cancer Medicine, 2023, 12, 7627-7638.	1.3	2
1260	CT radiomics for differentiating oncocytoma from renal cell carcinomas: Systematic review and meta-analysis. Clinical Imaging, 2023, 94, 9-17.	0.8	9
1261	Development and validation of a machine learning model to predict the risk of lymph node metastasis in renal carcinoma. Frontiers in Endocrinology, 0, 13, .	1.5	3
1262	TRPM2 facilitates tumor progression of clear cell renal cell carcinoma by relieving Endoplasmic Reticulum Stress. International Journal of Medical Sciences, 2023, 20, 57-69.	1.1	2
1263	Renal Cell Carcinoma in Kidney Transplant Recipients. , 2022, , 325-329.		0

#	Article	IF	Citations
1264	Interdisciplinary Approach in Genitourinary Cancers. , 2022, , .		0
1265	Prognostic Role of Long-Chain Acyl-Coenzyme A Synthetase Family Genes in Patients with Clear Cell Renal Cell Carcinoma: A Comprehensive Bioinformatics Analysis Confirmed with External Validation Cohorts. Clinical Genitourinary Cancer, 2023, 21, 91-104.	0.9	1
1266	Cell Differentiation Trajectory Predicts Prognosis and Immunotherapeutic Response in Clear Cell Renal Cell Carcinoma. Genetical Research, 2022, 2022, 1-19.	0.3	1
1267	Increased expression of HMMR in renal cell carcinoma is an independent prognostic factor. Oncology Letters, 2022, 25, .	0.8	1
1268	Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nature Reviews Urology, 2023, 20, 133-157.	1.9	46
1269	STEAP3 can predict the prognosis and shape the tumor microenvironment of clear cell renal cell carcinoma. BMC Cancer, 2022, 22, .	1.1	3
1272	Differentiation of clear cell and non-clear-cell renal cell carcinoma through CT-based Radiomics models and nomogram. Current Medical Imaging, 2022, 19, .	0.4	1
1274	Current Trends in Liquid Biopsy Technology for Early Diagnosis of Metastatic Renal Cell Carcinoma. The Korean Journal of Urological Oncology, 2022, 20, 223-234.	0.1	1
1275	Lupus Nephritis Associated With Renal Cell Carcinoma. Cureus, 2022, , .	0.2	0
1276	Bioinformatics analysis of immune-related prognostic genes and immunotherapy in renal clear cell carcinoma. PLoS ONE, 2022, 17, e0272542.	1.1	1
1277	Identification of Novel miRNAs Involved in Cancer Progression and Metastasis in Clear Cell Renal Cell Carcinoma. Mathematical Biology and Bioinformatics, 2022, 17, 338-359.	0.1	0
1278	Ganglioside analysis in body fluids by liquidâ€phase separation techniques hyphenated to mass spectrometry. Electrophoresis, 2023, 44, 501-520.	1.3	1
1279	Expression analysis of hsa_circ_0020397, hsa_circ_0005986, hsa_circ_0003028, and hsa_circ_0006990 in renal cell carcinoma. Experimental and Molecular Pathology, 2023, 129, 104848.	0.9	1
1280	Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer. Cancer Cell, 2022, 40, 1583-1599.e10.	7.7	39
1281	Prediction of World Health Organization /International Society of Urological Pathology (WHO/ISUP) Pathological Grading of Clear Cell Renal Cell Carcinoma by Dual-Layer Spectral CT. Academic Radiology, 2023, 30, 2321-2328.	1.3	2
1282	Therapeutic Management of Metastatic Clear Cell Renal Cell Carcinoma: A Revolution in Every Decade. Cancers, 2022, 14, 6230.	1.7	3
1283	Postoperative Metabolic Phenoreversion in Clear Cell Renal Cell Carcinoma. Journal of Proteome Research, 0, , .	1.8	0
1284	Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy. Cancer Cell International, 2022, 22, .	1.8	3

#	Article	IF	Citations
1285	Prognostic and immunological significance of calcium-related gene signatures in renal clear cell carcinoma. Frontiers in Pharmacology, 0, 13, .	1.6	1
1286	Case report and literature review: Small bowel intussusception due to solitary metachronous metastasis from renal cell carcinoma. Frontiers in Oncology, 0, 12, .	1.3	2
1288	Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness. Cancer Cell, 2023, 41, 139-163.e17.	7.7	43
1289	A novel biflavone from Reineckia carnea induces apoptosis of human renal cancer 786-O cells. Frontiers in Pharmacology, 0, 13, .	1.6	2
1290	Cuproptosis-Related Genes Are Associated with Cell Cycle and Serve as the Prognostic Signature for Clear Cell Renal Cell Carcinoma. Journal of Clinical Medicine, 2022, 11, 7507.	1.0	0
1291	Characterization of protein S-(2-succino)-cysteine (2SC) succination as a biomarker for fumarate hydrataseâ€“deficient renal cell carcinoma. Human Pathology, 2023, 134, 102-113.	1.1	7
1292	Immune-based treatment re-challenge in renal cell carcinoma: A systematic review and meta-analysis. Frontiers in Oncology, 0, 12, .	1.3	1
1293	Construction of a ferroptosis-related signature based on seven lncRNAs for prognosis and immune landscape in clear cell renal cell carcinoma. BMC Medical Genomics, 2022, 15, .	0.7	4
1295	circPLIN2 promotes clear cell renal cell carcinoma progression by binding IGF2BP proteins and miR-199a-3p. Cell Death and Disease, 2022, 13, .	2.7	5
1296	Etiologies, Gross Appearance, Histopathological Patterns, Prognosis, and Best Treatments for Subtypes of Renal Carcinoma: An Educational Review. Cureus, 2022, , .	0.2	2
1297	The cuproptosis related genes signature predicts the prognosis and correlates with the immune status of clear cell renal cell carcinoma. Frontiers in Genetics, 0, 13, .	1.1	0
1298	Potential Value of Visfatin, Omentin-1, Nesfatin-1 and Apelin in Renal Cell Carcinoma (RCC): A Systematic Review and Meta-Analysis. Diagnostics, 2022, 12, 3069.	1.3	2
1299	Pazopanib-Induced Liver Injury in Patients With Metastatic Renal Cell Carcinoma: A Report of Two Cases. Cureus, 2022, , .	0.2	0
1300	High Expression of DNTTIP1 Predicts Poor Prognosis in Clear Cell Renal Cell Carcinoma. Pharmacogenomics and Personalized Medicine, 0, Volume 16, 1-14.	0.4	0
1301	SF3B4 promotes Twist1 expression and clear cell renal cell carcinoma progression by facilitating the export of KLF 16 mRNA from the nucleus to the cytoplasm. Cell Death and Disease, 2023, 14, .	2.7	4
1302	Upregulation of CENPM is associated with poor clinical outcome and suppression of immune profile in clear cell renal cell carcinoma. Hereditas, 2023, 160, .	0.5	0
1303	Renal cell carcinoma T staging: Diagnostic accuracy of preoperative contrastâ€‘enhanced computed tomography. Molecular and Clinical Oncology, 2023, 18, .	0.4	1
1304	Identification of kinases activated by multiple pro-angiogenic growth factors. Frontiers in Pharmacology, 0, 13, .	1.6	0

#	Article	IF	Citations
1305	AI-Driven Robust Kidney and Renal Mass Segmentation and Classification on 3D CT Images. Bioengineering, 2023, 10, 116.	1.6	7
1306	Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers. Drug Resistance Updates, 2023, 67, 100929.	6.5	23
1307	EZH2-regulated immune risk score prognostic model predicts outcome of clear cell renal cell carcinoma. Translational Andrology and Urology, 2023, 12, 71-82.	0.6	0
1308	LINC00941 Promotes Cell Malignant Behavior and Is One of Five Costimulatory Molecule-Related lncRNAs That Predict Prognosis in Renal Clear Cell Carcinoma. Medicina (Lithuania), 2023, 59, 187.	0.8	3
1310	Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma. Cancers, 2023, 15, 348.	1.7	3
1311	The Curcuminoid EF24 in Combination with TRAIL Reduces Human Renal Cancer Cell Migration by Decreasing MMP-2/MMP-9 Activity through a Reduction in H2O2. International Journal of Molecular Sciences, 2023, 24, 1043.	1.8	6
1312	An Overview of Epigenetics in Clear Cell Renal Cell Carcinoma. In Vivo, 2023, 37, 1-10.	0.6	6
1313	The Emerging Role of PET/CT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer: An Updated Systematic Review. Cancers, 2023, 15, 355.	1.7	9
1314	Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a). International Journal of Molecular Sciences, 2023, 24, 1096.	1.8	3
1315	MR texture analysis in differentiation of small and very small renal cell carcinoma subtypes. Abdominal Radiology, 0, , .	1.0	1
1316	MECHANISM OF ACTION, SYNTHESIS, PROPERTIES AND ANALYTICAL METHODS OF CABOZANTINIB. International Journal of Applied Pharmaceutics, 0, , 57-65.	0.3	0
1317	Inhibition of Cyclin F Promotes Cellular Senescence through Cyclin-dependent Kinase 1-mediated Cell Cycle Regulation. Current Medical Science, 2023, 43, 246-254.	0.7	1
1318	MicroRNA-10a-5p targets SERPINE1 to suppress cell progression and epithelialâ€“mesenchymal transition process in clear cell renal cell carcinoma. Molecular and Cellular Toxicology, 2024, 20, 75-84.	0.8	0
1319	Genitourinary imaging. , 2023, , 289-312.		1
1320	Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences. Cancers, 2023, 15, 408.	1.7	2
1321	Coordinated reprogramming of renal cancer transcriptome, metabolome and secretome associates with immune tumor infiltration. Cancer Cell International, 2023, 23, .	1.8	4
1322	Single-cell RNA-seq integrated with multi-omics reveals SERPINE2 as a target for metastasis in advanced renal cell carcinoma. Cell Death and Disease, 2023, 14, .	2.7	8
1323	Comparative real-world survival outcomes of metastatic papillary and clear cell renal cell carcinoma treated with immunotherapy, targeted therapy, and combination therapy. Urologic Oncology: Seminars and Original Investigations, 2023, , .	0.8	2

#	Article	IF	Citations
1324	LGALS1 was related to the prognosis of clear cell renal cell carcinoma identified by weighted correlation gene network analysis combined with differential gene expression analysis. Frontiers in Genetics, 0, 13, .	1.1	1
1325	A Novel Predictive Model of Pathological Lymph Node Metastasis Constructed with Preoperative Independent Predictors in Patients with Renal Cell Carcinoma. Journal of Clinical Medicine, 2023, 12, 441.	1.0	2
1326	Renal clear cell carcinoma-derived CXCL5 drives tumor-associated fibroblast formation and facilitates cancer progression. Pathology Research and Practice, 2023, 244, 154319.	1.0	2
1327	In silico analysis reveals PRDX4 as a prognostic and oncogenic marker in renal papillary cell carcinoma. Gene, 2023, 859, 147201.	1.0	1
1328	Construction and Validation of a Novel Immune Checkpoint-Related Model in Clear Cell Renal Cell Carcinoma. Disease Markers, 2022, 2022, 1-14.	0.6	2
1329	The Role of miRNA in the Management of Localized and Advanced Renal Masses, a Narrative Review of the Literature. Applied Sciences (Switzerland), 2023, 13, 275.	1.3	5
1330	High Hepcidin expression predicts poor prognosis in patients with clear cell renal cell carcinoma. Diagnostic Pathology, 2022, 17, .	0.9	1
1331	Higher TYROBP and lower SOX6 as predictive biomarkers for poor prognosis of clear cell renal cell carcinoma: A pilot study. Medicine (United States), 2022, 101, e30658.	0.4	1
1332	RBM4 inhibits the growth of clear cell renal cell carcinoma by enhancing the stability of p53 mRNA. Molecular Carcinogenesis, 0, , .	1.3	0
1333	Modeling a Fine-Tuned Deep Convolutional Neural Network for Diagnosis of Kidney Diseases from CT Images. , 2022, , .		3
1335	Targeting hyaluronic acid synthase-3 (HAS3) for the treatment of advanced renal cell carcinoma. Cancer Cell International, 2022, 22, .	1.8	6
1336	Theranostic Applications of Glycosaminoglycans in Metastatic Renal Cell Carcinoma. Cancers, 2023, 15, 266.	1.7	4
1337	Construction of a Necroptosis-Related lncRNA Signature for Predicting Prognosis and Immune Response in Kidney Renal Clear Cell Carcinoma. Cells, 2023, 12, 66.	1.8	2
1338	PIMREG is a prognostic biomarker involved in immune microenvironment of clear cell renal cell carcinoma and associated with the transition from G1 phase to S phase. Frontiers in Oncology, 0, 13, .	1.3	2
1340	Epigenomic charting and functional annotation of risk loci in renal cell carcinoma. Nature Communications, 2023, 14, .	5.8	10
1341	Nivolumab plus cabozantinib for advanced renal cell carcinoma. Future Oncology, 0, , .	1.1	0
1342	Identification of IRF-associated molecular subtypes in clear cell renal cell carcinoma to characterize immunological characteristics and guide therapy. Frontiers in Oncology, 0, 12, .	1.3	1
1343	Polysaccharide-Based Hydrogels and Their Application as Drug Delivery Systems in Cancer Treatment: A Review. Journal of Functional Biomaterials, 2023, 14, 55.	1.8	23

#	Article	IF	Citations
1344	Clinicopathological study of sarcomatoid renal cell carcinoma in animals in East Java, Indonesia, from 2017 to 2022. Open Veterinary Journal, 2023, 13, 64.	0.3	0
1345	Impact of ischemia time during partial nephrectomy on short- and long-term renal function. Scandinavian Journal of Urology, 2023, 57, 86-89.	0.6	2
1346	Can CXCL13 be a prognostic marker in clear cell renal cell carcinoma?. Indian Journal of Pathology and Microbiology, 2023, 66, 54.	0.1	0
1347	HSP70 Expression Signature in Renal Cell Carcinoma: A Clinical and Bioinformatic Analysis Approach. Genes, 2023, 14, 355.	1.0	1
1348	Serum C-NLR score, a new inflammatory marker, predicts tumor histopathology and oncological outcomes of localized clear cell renal carcinoma after nephrectomy: A single center retrospective analysis. Journal of Surgery and Medicine, 2023, 7, 123-127.	0.0	0
1349	Comprehensive Analysis of Transcriptomic Profiles Identified the Prediction of Prognosis and Drug Sensitivity of Aminopeptidase-Like 1 (NPEPL1) for Clear Cell Renal Cell Carcinoma. Journal of Oncology, 2023, 2023, 1-19.	0.6	0
1350	FXR1 facilitates axitinib resistance in clear cell renal cell carcinoma via regulating KEAP1/Nrf2 signaling pathway. Anti-Cancer Drugs, 2023, 34, 248-256.	0.7	3
1351	<scp>HIF2Î±</scp>â€induced upregulation of RNASET2 promotes triglyceride synthesis and enhances cell migration in clear cell renal cell carcinoma. FEBS Open Bio, 2023, 13, 638-654.	1.0	4
1352	Construction and Validation of Protein Expression-related Prognostic Models in Clear Cell Renal Cell Carcinoma. Journal of Cancer, 2023, 14, 793-808.	1.2	0
1353	GPX8 regulates clear cell renal cell carcinoma tumorigenesis through promoting lipogenesis by NNMT. Journal of Experimental and Clinical Cancer Research, 2023, 42, .	3.5	7
1354	Identification and validation of DLX4 as a prognostic and diagnostic biomarker for clear cell renal cell carcinoma. Oncology Letters, 2023, 25, .	0.8	0
1355	Integrated analysis of the relation to tumor immune microenvironment and predicted value of Stonin1 gene for immune checkpoint blockage and targeted treatment in kidney renal clear cell carcinoma. BMC Cancer, 2023, 23, .	1.1	0
1356	Application of CRISPR/Cas9 Technology in Cancer Treatment: A Future Direction. Current Oncology, 2023, 30, 1954-1976.	0.9	6
1358	A novel lipid metabolism gene signature for clear cell renal cell carcinoma using integrated bioinformatics analysis. Frontiers in Cell and Developmental Biology, 0, 11, .	1.8	2
1359	Identification of fatty acid metabolism-based molecular subtypes and prognostic signature to predict immune landscape and guide clinical drug treatment in renal clear cell carcinoma. International Immunopharmacology, 2023, 116, 109735.	1.7	4
1360	Impact of Therapy Management on Axitinib-Related Adverse Events in Patients With Advanced Renal Cell Carcinoma Receiving First-Line AxitinibÂ+ÂCheckpoint Inhibitor. Clinical Genitourinary Cancer, 2023, 21, e343-e351.	0.9	1
1361	Integrated Metabolomic and Transcriptomic Analysis of Modified Nucleosides for Biomarker Discovery in Clear Cell Renal Cell Carcinoma. Cells, 2023, 12, 1102.	1.8	3
1362	Single-cell Deconvolution of a Specific Malignant Cell Population as a Poor Prognostic Biomarker in Low-risk Clear Cell Renal Cell Carcinoma Patients. European Urology, 2023, 83, 441-451.	0.9	3

#	Article	IF	Citations
1363	Scope of Bio-based nanoparticle targeted through the cancer zone to deactivate cancer affected cells. Chemical Physics Impact, 2023, 6, 100180.	1.7	3
1364	POLD1 as a Prognostic Biomarker Correlated with Cell Proliferation and Immune Infiltration in Clear Cell Renal Cell Carcinoma. International Journal of Molecular Sciences, 2023, 24, 6849.	1.8	4
1366	Decreasing expression of Prohibitin-2 lowers the oncogenicity of renal cell carcinoma cells by suppressing eIF4E-mediated oncogene translation via MNK inhibition. Toxicology and Applied Pharmacology, 2023, 466, 116458.	1.3	4
1367	Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma. Management of Urology, 2022, , 237-245.	0.0	0
1368	Low Expression of MATR3 Is Associated with Poor Survival in Clear Cell Renal Cell Carcinoma. Biomedicines, 2023, 11, 326.	1.4	4
1369	Construction and Validation of a Novel Cuproptosis-Related Seven-lncRNA Signature to Predict the Outcomes, Immunotherapeutic Responses, and Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma. Disease Markers, 2023, 2023, 1-35.	0.6	1
1370	Current status and clinical application of patient-derived tumor organoid model in kidney and prostate cancers. BMB Reports, 2023, 56, 24-31.	1.1	2
1371	NDUFA4L2 reduces mitochondrial respiration resulting in defective lysosomal trafficking in clear cell renal cell carcinoma. Cancer Biology and Therapy, 2023, 24, .	1.5	4
1372	A review on the role of long non-coding RNA and microRNA network in clear cell renal cell carcinoma and its tumor microenvironment. Cancer Cell International, 2023, 23, .	1.8	4
1373	Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial. Cancer Immunology, Immunotherapy, 2023, 72, 1903-1915.	2.0	4
1374	Prognostic biomarker NEIL3 and its association with immune infiltration in renal clear cell carcinoma. Frontiers in Oncology, 0, 13, .	1.3	0
1375	Multiparametric magnetic resonance imaging for characterizing renal tumors: A validation study of the algorithm presented by Cornelis et al.. Journal of Clinical Imaging Science, 0, 13, 7.	0.4	0
1376	Ferroptosis-associated lncRNA prognostic signature predicts prognosis and immune response in clear cell renal cell carcinoma. Scientific Reports, 2023, 13, .	1.6	7
1377	Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma: Challenges and Opportunities. Oncologist, 2023, 28, 297-308.	1.9	1
1378	<scp>EFHD1</scp>, a novel mitochondrial regulator of tumor metastasis in clear cell renal cell carcinoma. Cancer Science, 2023, 114, 2029-2040.	1.7	6
1379	A novel gene signature related to oxidative stress predicts the prognosis in clear cell renal cell carcinoma. PeerJ, 0, 11, e14784.	0.9	3
1381	Delayed Cardiac Metastasis from Renal Cell Carcinoma Caused by VHL Mutation. Journal of Kidney Cancer and VHL, 2023, 10, 15-18.	0.2	2
1382	Metastatic Renal Cell Carcinoma to the Scalp: A Case Report With Review of Literature. Cureus, 2023, , .	0.2	1

#	Article	IF	Citations
1383	LncRNA GABPB1â€IT1 inhibits the tumorigenesis of renal cancer via the miRâ€21/PTEN axis. Journal of Biochemical and Molecular Toxicology, 2023, 37, .	1.4	2
1384	Top 100 most-cited articles on renal cell carcinoma: A bibliometric analysis. Medicine (United States), 2023, 102, e32926.	0.4	1
1386	Hyponatremia and Cancer: From Bedside to Benchside. Cancers, 2023, 15, 1197.	1.7	3
1387	Development and validation of a nomogram to evaluate the therapeutic effects of second-line axitinib in patients with metastatic renal cell carcinoma. Frontiers in Oncology, 0, 13, .	1.3	0
1388	Our Current Understanding of the Heterogeneity in Prostate Cancer and Renal Cell Carcinoma. Journal of Clinical Medicine, 2023, 12, 1526.	1.0	2
1389	FBXO30 functions as a tumor suppressor and an E3 ubiquitin ligase for hZIP1â€mediated HIFâ€1Î± degradation in renal cell carcinoma. International Journal of Oncology, 2023, 62, .	1.4	1
1391	Micall2 Is Responsible for the Malignancy of Clear Cell Renal Cell Carcinoma. Yonago Acta Medica, 2023, 66, 171-179.	0.3	1
1392	Downstream Targets of VHL/HIF-Î± Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance. Cancers, 2023, 15, 1316.	1.7	11
1393	Identification of Five Tumor Antigens for Development and Two Immune Subtypes for Personalized Medicine of mRNA Vaccines in Papillary Renal Cell Carcinoma. Journal of Personalized Medicine, 2023, 13, 359.	1.1	0
1394	Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application. Molecular Cancer, 2023, 22, .	7.9	12
1395	ETNK2 Low-Expression Predicts Poor Prognosis in Renal Cell Carcinoma with Immunosuppressive Tumor Microenvironment. Journal of Oncology, 2023, 2023, 1-11.	0.6	1
1396	Preoperative serum low-density lipoprotein cholesterol is an independent prognostic factor in patients with renal cell carcinoma after nephrectomy. Lipids in Health and Disease, 2023, 22, .	1.2	0
1397	Comparing efficacy and safety of first-line treatment of metastatic renal cell carcinoma: A Bayesian network meta-regression analysis. Frontiers in Oncology, 0, 13, .	1.3	0
1398	Metabolic classifications of renal cell carcinoma reveal intrinsic connections with clinical and immune characteristics. Journal of Translational Medicine, 2023, 21, .	1.8	2
1399	Kidney Diseases Classification using Hybrid Transfer-Learning DenseNet201-Based and Random Forest Classifier. Kurdistan Journal of Applied Research, 0, , 131-144.	0.4	7
1400	Proteotranscriptomic Discrimination of Tumor and Normal Tissues in Renal Cell Carcinoma. International Journal of Molecular Sciences, 2023, 24, 4488.	1.8	0
1401	RP11â€367G18.1 ÂV2 enhances clear cell renal cell carcinoma progression via induction of epithelialâ€“mesenchymal transition. Cancer Medicine, 0, , .	1.3	1
1402	Clear Cell Renal Cell Carcinoma: A Comprehensive in silico Study in Searching for Therapeutic Targets. Kidney and Blood Pressure Research, 2023, 48, 135-150.	0.9	2

#	Article	IF	Citations
1403	Renal Cell Carcinomas. , 2023, , 337-355.		0
1404	Assessing the impact of kidney cancer-related premature mortality and productivity loss in Greece and Portugal. Expert Review of Pharmacoeconomics and Outcomes Research, 2023, 23, 391-398.	0.7	1
1405	Clinical Implication of Keratin-15 Quantification for Renal Cell Carcinoma Management: Its Dysregulation and Association with Clinicopathologic Characteristics and Prognostication. Tohoku Journal of Experimental Medicine, 2023, 260, 99-107.	0.5	3
1407	N6â€methyladenosineâ€modified DBT alleviates lipid accumulation and inhibits tumor progression in clear cell renal cell carcinoma through the ANXA2/YAP axisâ€regulated Hippo pathway. Cancer Communications, 2023, 43, 480-502.	3.7	11
1408	The role of hyaluronan in renal cell carcinoma. Frontiers in Immunology, 0, 14, .	2.2	2
1409	Identification and Validation of a Necroptosis-Related Prognostic Signature for Kidney Renal Clear Cell Carcinoma. Stem Cells International, 2023, 2023, 1-29.	1.2	1
1411	Results of surgical treatment of malignant kidney tumors based on the materials of urology departments of the Siberian State Medical University clinics. Onkourologiya, 2023, 18, 25-32.	0.1	0
1412	Low gammaâ€butyrobetaine dioxygenase (<scp>BBOX1</scp>) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma: a machine learning approach. Journal of Pathology: Clinical Research, 2023, 9, 236-248.	1.3	1
1413	Transcriptome mapping of renal clear cell carcinoma revealed by machine learning algorithm based on enhanced computed tomography images. Journal of Gene Medicine, 2023, 25, .	1.4	0
1414	The natural killer cell immunotherapy platform: An overview of the landscape of clinical trials in liquid and solid tumors. Seminars in Hematology, 2023, 60, 42-51.	1.8	2
1415	Endoplasmic Reticulum Stress in Renal Cell Carcinoma. International Journal of Molecular Sciences, 2023, 24, 4914.	1.8	3
1416	Bridging radiomics to tumor immune microenvironment assessment in clear cell renal cell carcinoma. , 2023, , .		1
1417	Synchronous Kaposi sarcoma and renal cell carcinoma in an elderly male patientÂ(aÂveryÂuncommonÂreportedÂentity): A case report. Medicine International, 2023, 3, .	0.2	0
1418	Exosomal MicroRNA Levels Associated with Immune Checkpoint Inhibitor Therapy in Clear Cell Renal Cell Carcinoma. Biomedicines, 2023, 11, 801.	1.4	2
1419	Ferredoxin 1, the key regulator of cuproptosis, was associated with prognosis and immune cell infiltration in clear cell renal cell carcinoma. , 2023, 2, .		0
1420	PDIA4 confers resistance to ferroptosis via induction of ATF4/SLC7A11 in renal cell carcinoma. Cell Death and Disease, 2023, 14, .	2.7	7
1421	A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy. International Journal of Molecular Sciences, 2023, 24, 5332.	1.8	1
1422	MKRN1/2 serve as tumor suppressors in renal clear cell carcinoma by regulating the expression of p53. Cancer Biomarkers, 2023, 36, 267-278.	0.8	1

#	Article	IF	Citations
1423	A novel immune-related model to predict prognosis and responsiveness to checkpoint and angiogenesis blockade therapy in advanced renal cancer. Frontiers in Oncology, 0, 13, .	1.3	0
1424	Carcinome rÃ©nal. , 2022, , 546-565.		0
1425	Histologic reâ€'evaluation of a populationâ€'based series of renal cell carcinomas from The Netherlands Cohort Study according to the 2022 ISUP/WHO classification. Oncology Letters, 2023, 25, .	0.8	1
1426	Comprehensive overview of the role of PBX1 in mammalian kidneys. Frontiers in Molecular Biosciences, 0, 10, .	1.6	0
1427	Discrimination between human normal renal tissue and renal cell carcinoma by dielectric properties using in-vitro BIA. Frontiers in Physiology, 0, 14, .	1.3	1
1428	A novel 7-chemokine-genes predictive signature for prognosis and therapeutic response in renal clear cell carcinoma. Frontiers in Pharmacology, 0, 14, .	1.6	1
1429	Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1). Clinical Genitourinary Cancer, 2023, 21, e309-e319.e1.	0.9	4
1430	Treatment strategies for clear cell renal cell carcinoma: Past, present and future. Frontiers in Oncology, 0, 13, .	1.3	6
1431	Identification and validation of <scp>NFIA</scp> as a novel prognostic marker in renal cell carcinoma. Journal of Pathology: Clinical Research, 2023, 9, 261-272.	1.3	0
1432	Association between dietary 3-monochloropropane-1,2-diol esters (3-MCPDE) and renal cancer in Peninsular Malaysia: exposure assessment and matched case-control study. Food Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment, 2023, 40, 475-492.	1.1	0
1433	Cadmium Disrupted ER Ca2+ Homeostasis by Inhibiting SERCA2 Expression and Activity to Induce Apoptosis in Renal Proximal Tubular Cells. International Journal of Molecular Sciences, 2023, 24, 5979.	1.8	3
1434	Identification of berberine as a potential therapeutic strategy for kidney clear cell carcinoma and COVID-19 based on analysis of large-scale datasets. Frontiers in Immunology, 0, 14, .	2.2	1
1435	Integrative analysis of transcriptomic landscape and urinary signature reveals prognostic biomarkers for clear cell renal cell carcinoma. Frontiers in Oncology, 0, 13, .	1.3	1
1436	Immunogenicity in renal cell carcinoma: shifting focus to alternative sources of tumour-specific antigens. Nature Reviews Nephrology, 2023, 19, 440-450.	4.1	4
1437	Differential Activation of NRF2 Signaling Pathway in Renal-Cell Carcinoma Caki Cell Lines. Biomedicines, 2023, 11, 1010.	1.4	0
1438	Role of renal mass biopsy for diagnosis and management: Review of current trends and future directions. Cancer Cytopathology, 2023, 131, 480-494.	1.4	2
1439	Establishment and validation of a novel anoikis-related prognostic signature of clear cell renal cell carcinoma. Frontiers in Immunology, 0, 14, .	2.2	3
1440	Low expression of SLC34A1 is associated with poor prognosis in clear cell renal cell carcinoma. BMC Urology, 2023, 23, .	0.6	0

#	Article	IF	Citations
1442	Data-Independent Acquisition Phosphoproteomics of Urinary Extracellular Vesicles Enables Renal Cell Carcinoma Grade Differentiation. Molecular and Cellular Proteomics, 2023, 22, 100536.	2.5	5
1443	Cancer Cell-Derived PDGFB Stimulates mTORC1 Activation in Renal Carcinoma. International Journal of Molecular Sciences, 2023, 24, 6447.	1.8	0
1444	PIK3C2A is a prognostic biomarker that is linked to immune infiltrates in kidney renal clear cell carcinoma. Frontiers in Immunology, 0, 14, .	2.2	2
1445	Kidney Cancer. , 2023, , 327-347.		0
1446	Total Flavone Content of Cydonia oblonga Miller Inhibits Proliferation and Migration of Renal Carcinoma Cells by Inhibiting the S1PR2/FAK Pathway. Journal of Food Biochemistry, 2023, 2023, 1-17.	1.2	0
1447	The Prognostic Role of Serum Albumin Level and Prognostic Nutritional Index in Patients With Localized Clear Cell Renal Cell Carcinoma. Haseki Tip Bulteni, 2023, 61, 135-140.	0.2	0
1448	circPTPN12 promotes the progression and sunitinib resistance of renal cancer via hnRNPM/IL-6/STAT3 pathway. Cell Death and Disease, 2023, 14, .	2.7	0
1450	LINC00493â€encoded microprotein SMIM26 exerts antiâ€metastatic activity in renal cell carcinoma. EMBO Reports, 2023, 24, .	2.0	4
1452	Endovascular management of RCC in one-kidney patient: a case report study. Annals of Medicine and Surgery, 2023, 85, 2108-2111.	0.5	0
1453	LINC00839, LINC01671, AC093673 and AC008760 are Associated with the Prognosis and Immune Infiltration of Clear-cell Renal Cell Carcinoma. Current Proteomics, 2023, 20, .	0.1	0
1454	Bioinformatics Prediction and Experimental Verification Identify CAB39L as a Diagnostic and Prognostic Biomarker of Kidney Renal Clear Cell Carcinoma. Medicina (Lithuania), 2023, 59, 716.	0.8	0
1455	LncRNA CASC19: a novel oncogene involved in human cancer. Clinical and Translational Oncology, 2023, 25, 2841-2851.	1.2	1
1456	Inflammatory Networks in Renal Cell Carcinoma. Cancers, 2023, 15, 2212.	1.7	1
1457	HIGD1A inactivated by DNA hypermethylation promotes invasion of kidney renal clear cell carcinoma. Pathology Research and Practice, 2023, 245, 154463.	1.0	0
1458	Multiparametric MRI of Solid Renal Masses: Principles and Applications of Advanced Quantitative and Functional Methods for Tumor Diagnosis and Characterization. Journal of Magnetic Resonance Imaging, 2023, 58, 342-359.	1.9	4
1459	Correlation between CXCR4 and MMP-2 Expression with T Stage in Clear Cell Renal Cell Carcinoma. Research Journal of Pharmacy and Technology, 2023, , 821-829.	0.2	1
1460	Dissecting order amidst chaos of programmed cell deaths: construction of a diagnostic model for KIRC using transcriptomic information in blood-derived exosomes and single-cell multi-omics data in tumor microenvironment. Frontiers in Immunology, 0, 14, .	2.2	4
1461	Integrated glycoproteomic characterization of clear cell renal cell carcinoma. Cell Reports, 2023, 42, 112409.	2.9	1

#	Article	IF	Citations
1463	Evaluation of the safety of retroperitoneal laparoscopic partial nephrectomy by investigating the perioperative indicators. Frontiers in Oncology, 0, 13, .	1.3	0
1464	SPAG9 Expression Predicts Good Prognosis in Patients with Clear-Cell Renal Cell Carcinoma: A Bioinformatics Analysis with Experimental Validation. Genes, 2023, 14, 944.	1.0	1
1465	Runt-related transcription factors in human carcinogenesis: a friend or foe?. Journal of Cancer Research and Clinical Oncology, 2023, 149, 9409-9423.	1.2	0
1481	Risk of urinary tract cancers following arsenic exposure and tobacco smoking: a review. Environmental Geochemistry and Health, 0, , .	1.8	0
1488	Cancers du rein et des voies urinaires. , 2023, , 207-209.		0
1572	Nephrectomy and IVC thrombectomy in renal cancer: a narrative review. Clinical and Translational Oncology, 2024, 26, 574-583.	1.2	2
1586	Perspective Chapter: An Update on Renal Cell Carcinoma. , 0, , .		0
1607	Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinoma. Frontiers in Oncology, 0, 13, .	1.3	0
1611	Adjuvant Treatment and Follow-Up of Clinically Localized Renal Cell Carcinoma. , 2023, , 53-70.		0
1640	Novel Targets in Development for Advanced Renal Cell Carcinoma. , 2023, , 309-342.		0
1647	Case report: Adjuvant therapy with toceranib for an incompletely resected renal cell carcinoma with suspected pulmonary metastasis in a dog. Frontiers in Veterinary Science, 0, 10, .	0.9	0
1679	Multi-omics Analyses Reveal Function of Apolipoprotein E in Alternative Splicing and Tumor Immune Microenvironment in Kidney Renal Clear Cell Carcinoma via Pan-cancer Analysis. Cell Biochemistry and Biophysics, 2024, 82, 1-13.	0.9	0
1688	Metabolic alterations in hereditary and sporadic renal cell carcinoma. Nature Reviews Nephrology, 2024, 20, 233-250.	4.1	0
1710	Nierenzellkarzinome. , 2024, , 387-408.		0
1711	Cascade UNets forÂKidney andÂKidney Tumor Segmentation. Lecture Notes in Computer Science, 2024, , 107-113.	1.0	0